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n der Schule haben wir gelernt, dass Lehrerwissen absolutes Wissen ist. 
Doch Wissenschaft kann niemals absolut sein. Sie ist die Kunst der 
Annäherung. Sie definiert nicht, sondern kreist ein, zieht keine Trennlinien, 
sondern schafft Übergänge, kennt keine Dogmen, sondern Entwicklungen. 
Sie kann nichts verifizieren, sondern nur durch Wegstreichen von Variablen 
ein möglichst klares Bild entwerfen. Selbst die Naturgesetze sind streng 
genommen Hypothesen. Wenn der Apfel jedes Mal zu Boden fällt, sobald 
man ihn loslässt, drängen sich absolute Aussagen regelrecht auf. Im Grunde 
resultieren die entsprechenden Gesetze aber nur aus identischen 
Versuchsreihen, die bis heute ausnahmslos das gleiche Ergebnis lieferten. 
 
- Frank Schätzing - 
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für meine lehrer 
 
Serum lipid status in European adolescents - associations with age, gender,  
maturity, body mass index, percentage body fat, and fat free mass 
 
The development of cardiovascular diseases and atherosclerosis and its relation to lipids (e.g. 
cholesterol, lipoproteins, and fatty acids [FA]) is well established and begins in childhood and 
adolescence. Beside that, an adequate lipid profile is also important for normal growth and 
development in youth. However, less is known about how factors associated with adolescence 
like age, gender, maturity, body mass index (BMI), body fat (BF), and fat free mass (FFM) 
are influencing lipid profiles in healthy European adolescents.  
Consequently, this thesis investigated the association of age, gender, maturity, BMI, BF, and 
FFM with the lipid profile of European adolescents within the Healthy Lifestyle in Europe by 
Nutrition in Adolescence (HELENA) Study. More precisely, the investigated associations of 
the factors mentioned above with clinical lipid parameters (i.e. total cholesterol (TC), high 
density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), 
triglycerides (TG), lipoprotein(a) [Lp(a)], and the apolipoproteins (apo) A-1 and B) as well as 
with several lipid and lipoprotein ratios are described in chapter 4. The relation of age, 
gender, maturity, BMI, BF, and FFM to the FA profile is presented in chapter 5. The results 
of the association of age, gender, maturity, BMI, BF, and FFM with several FA ratios are 
provided in chapter 6. Further, in chapter 7 the relationships between selected FA and TC, 
HDL, LDL, TG, Lp(a), apo A-1 and B are summarized. 
Generally, the results were as follows: the clinical lipid parameters were higher in girls than in 
boys. Furthermore, almost all absolute FA values were higher in girls than in boys whereas 
the relative FA profile showed less clear gender differences. 
Triglyceride levels were positively associated with age in boys. Further, in both boys and girls 
some FA of the absolute FA profile and the relative FA profile were related to age.  
Progression in maturity was associated with lower TC and HDL levels in boys and changes in 
TC, LDL, and apo B levels without clear direction in girls. Additionally, maturity was 
associated with fluctuations in the FA profile without clear pattern in boys and girls. 
Body mass index was hardly associated with the lipid profile of boys. By contrast, TG levels 
and several lipid and lipoprotein ratios increased and HDL levels decreased with higher BMI 
status in girls.  
Body fat was mainly associated with changes in the male subjects. In boys, TG, LDL, and 
several lipid and lipoprotein ratios increased, whereas HDL decreased with higher body fat. 
The FA profile and FA ratios showed minimal associations with body fat. 
Fat free mass was positively associated with C20:5ω3c/C18:3ω3c ratios in boys and also 
associated with some FA in both sexes.  
In chapter 7, individual serum FA (i.e. C16:0, C18:0, C18:1ω9c, C18:2ω6c, C18:3ω3c, 
C20:4ω6c, C20:5ω3c, and C22:6ω3c) were associated with clinical lipid parameters (i.e. TC, 
HDL, LDL, TG, Lp(a), apo A-1, and apo B) using multiple linear regression models. The 
effect of individual FA on several lipids and lipoproteins was minimal. The highest 
association was found between C16:0 and C18:0 with TG levels. In boys and girls, 
approximately 7% and 4% of the TG level variability could be related to C16:0 and C18:0. 
The other clinical lipid parameters showed minor associations (R² change=0.2%-3.5%) in 
both sexes. 
 
 
 
 
 
 
 
Serum-Lipidstatus in europäischen Jugendlichen – Assoziationen mit Alter, Geschlecht, 
Reife, Body-Mass-Index, prozentualem Körperfettanteil und Magermasse 
 
Das Auftreten von kardiovaskulären Erkrankungen und Atherosklerose steht in engem 
Zusammenhang mit Blutlipiden (z. Bsp. Cholesterol, Lipoproteinen, Fettsäuren [FS]), wobei 
erste Ausprägungen schon in früher Kindheit bzw. im Jugendalter diagnostiziert wurden. 
Andererseits sind adäquate Blutlipidwerte für ein normales Wachstum und eine entsprechende 
Entwicklung in diesem Alter von großer Bedeutung. Allerdings sind Faktoren, die die 
Adoleszenz beeinflussen können, wie Alter, Geschlecht, sexuelle Reife, Body-Mass-Index 
(BMI), prozentualer Körperfettanteil (BF) und die Magermasse (FFM), in gesunden 
europäischen Jugendlichen nicht hinreichend untersucht. 
Daher war das Ziel dieser Arbeit, den Zusammenhang zwischen Alter, Geschlecht, Reife, 
BMI, BF und FFM und den Blutlipiden von europäischen Jugendlichen anhand der Daten der 
Healthy Lifestyle in Europe by Nutrition in Adolescence (HELENA) Studie zu untersuchen. 
In Kapitel 4 der Arbeit wurden die Assoziationen zwischen den oben genannten Faktoren und 
den klinischen Lipidparametern Gesamtcholesterin (TC), HDL, LDL, Triglyzeriden (TG), 
Lipoprotein(a) [Lp(a)], den Apolipoproteinen (apo) A-1 und B sowie verschiedenen Lipid- 
und Lipoproteinquotienten beschrieben. Weitere Schwerpunkte wurden auf die 
Zusammenhänge zwischen Alter, Geschlecht, Reife, BMI, BF sowie FFM und dem FS-Profil 
(Kapitel 5) und den FS-Quotienten (Kapitel 6) gelegt. In Kapitel 7 wurde beschrieben, 
inwieweit ausgewählte FS einen Zusammenhang mit den klinischen Lipidparametern zeigten. 
Aus der vorliegenden Arbeit lassen sich folgenden Ergebnisse zusammenfassen: Mädchen 
wiesen höhere Werte der klinischen Lipidparameter auf als Jungen. Dasselbe wurde für die 
meisten absoluten FS-Werte beobachtet. Darüber hinaus waren die FS der prozentualen 
Verteilung nicht eindeutig geschlechtsspezifisch erhöht.  
Die TG-Werte der Jungen zeigten einen positiven Zusammenhang mit dem Alter. Weiterhin 
waren einige FS des relativen und absoluten FS-Musters bei Jungen und Mädchen mit dem 
Alter assoziiert. 
Sinkende TC- und HDL-Werte waren bei männlichen Teilnehmern mit fortschreitender 
sexueller Reife zu beobachten. Im Gegensatz dazu waren bei den weiblichen 
Studienteilnehmern die TC-, LDL- und Apo B-Werte mit der sexuellen Reife assoziiert, 
wobei jedoch ein klarer Verlauf nicht zu erkennen war. Ein eindeutiges Muster konnte auch 
nicht in Bezug auf das FS-Profil festgestellt werden, obwohl einige FS mit dem Fortschreiten 
der sexuellen Reife in Verbindung gebracht werden konnten. Dies konnte sowohl für Jungen 
als auch für Mädchen gezeigt werden. 
Die Blutlipidwerte der Jungen zeigten kaum Zusammenhänge mit dem BMI. Auf der anderen 
Seite waren die TG-Werte der Mädchen sowie die meisten Lipid- und Lipoproteinquotienten 
mit steigendem BMI erhöht und das HDL erniedrigt. 
Der Körperfettanteil war hauptsächlich mit Blutlipiden der männlichen Teilnehmer assoziiert. 
Diese zeigten erhöhte TG- und LDL-Werte sowie erhöhte Lipid- und Lipoproteinquotienten 
mit erhöhtem BF. Zusätzlich war das HDL der Jungen mit höherem BF erniedrigt. Das FS-
Profil und die FS-Quotienten zeigten nur geringe Zusammenhänge zum Körperfett. 
Die Magermasse war positiv assoziiert mit dem C20:5ω3c/C18:3ω3c-Quotienten der Jungen. 
In beiden Geschlechtern zeigten einzelne FS Zusammenhänge mit der Magermasse. 
In Kapitel 7 wurde der Zusammenhang zwischen den FS C16:0, C18:0, C18:1ω9c, C18:2ω6c, 
C18:3ω3c, C20:4ω6c, C20:5ω3c sowie C22:6ω3c und TC, HDL, LDL, TG, Lp(a), apo A-1 
und B mittels multipler, linearer Regressionsanalysen untersucht. Es zeigte sich jedoch, dass 
der Zusammenhang zwischen den Parametern minimal war. Lediglich die FS C16:0 und 
C18:0 zeigten einen wesentlichen Zusammenhang mit den TG-Werten. In Jungen und 
Mädchen war die Variabilität der TG-Werte zu 7% bzw. 4% durch diese FS zu erklären. Die 
restlichen Parameter waren mit den FS in Größenordnungen von 0.2%-3.5% assoziiert. 
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Fatty Acids 
Code Common name Scientific name 
C12:0 Lauric acid Dodecanoic acid 
C14:0 Myristic acid Tetradecanoic acid 
C14:1ω5c Myristoleic acid Cis-9-Tetradecenoic acid 
C15:0                                                              Pentadecanoic acid 
C15:1ω5c Pentadecenoic acid Cis-10-Pentadecenoic acid 
C16:0 Palmitic acid Hexadecanoic acid 
C16:1ω7c Palmitoleic acid Cis-9-Hexadecenoic acid 
C17:0                                                              Heptadecanoic acid 
C17:1ω7c Heptadecenoic acid Cis-10-Heptadecenoic acid 
C18:0 Stearic acid Octadecanoic acid 
C18:1ω7c Vaccenic acid Cis-11-Octadecenoic acid 
C18:1ω7t Trans vaccenic acid Trans-11-Octadecenoic acid 
C18:1ω9c Oleic acid Cis-9-Octadecenoic acid 
C18:2ω6c Linoleic acid (LA) All-cis-9,12-Octadecadienoic acid 
C18:2ω6t Linolelaidic acid All-trans-9,12-Octadecadienoic acid 
C18:3ω3c α-Linolenic acid (ALA) All-cis-9,12,15-Octadecatrienoic acid 
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C20:3ω6c Dihomo-γ-linolenic acid (DHGLA) All-cis-8,11,14-Eicosatrienoic acid 
C20:3ω9c Mead acid All-cis-5,8,11-Eicosatrienoic acid 
C20:4ω6c Arachidonic acid (AA) All-cis-5,8,11,14-Eicosatetraenoic acid 
The suffix “-ic acid” can be substituted for “-ate” 
Fatty acids with the suffix “c” indicate cis, whereas the suffix “t” indicates trans configurations. 
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C23:0                                                              Tricosanoic acid 
C24:0 Lignoceric acid Tetracosanoic acid 
C24:1ω9c Nervonic acid Cis-15-Tetracosenoic acid 
The suffix “-ic acid” can be substituted for “-ate” 
Fatty acids with the suffix “c” indicate cis, whereas the suffix “t” indicates trans configurations. 
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HDL High density lipoprotein cholesterol 
LDL Low density lipoprotein cholesterol 
Lp(a) Lipoprotein(a) 
nonHDLC Non high density lipoprotein cholesterol 
TC Total cholesterol 
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ANCOVA Analysis of Covariance 
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AVENA Alimentación y Valoración del Estado Nutricional 
en Adolescentes (=Food and Assessment of the 
Nutritional Status of Adolescents) 
BEFO Behavioural and food choice study 
BF Body fat 
BIA Bioelectrical impedance analysis 
BMI Body mass index 
bp Boiling point 
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CDS Chromatography data system 
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Every human being is the author of his own health or disease. 
 
- Siddharta Gautama Shakyamuni - 
560-480 B.C. 
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1 General Introduction 
 
The importance of reliable lipid data in adolescence 
Adolescence is a life span characterized by rapid growth and development. Prerequisite for 
normal growth and development in this phase is an adequate provision of energy, macro- and 
micronutrients. A rapidly growing body is more sensitive to under- and/ or malnutrition than 
an adult. Moreover, an imbalanced nutrition in adolescence can already contribute to develop 
early signs and/ or risks for chronic diseases like atherosclerosis [1-7].  
A balanced lipid profile is an important factor to maintain health in young age and to avoid 
early morbidity in later life. Therefore, blood lipid profiles in adolescents should be screened 
as early as possible to detect imbalances. A lipid profile screening should include the blood 
parameters mentioned below, which are suitable biomarkers and can be easily measured. 
An objective evaluation of analytical data from cross-sectional studies in adolescents is, 
however, hampered by the fact that reliable reference data considering communicable and 
non-communicable determinants is not available. Consequently, the evaluation of blood lipid 
profiles in adolescence uses reference data of the American National Cholesterol Education 
Program (NCEP) for children and adolescents [8], which might lead to wrong conclusions for 
further reasons. First of all, the data is based on examinations of children and adolescents 
from families with hypercholesterolemia or premature cardiovascular disease, thus the 
subjects might not be healthy because of the familial predisposition. Secondly, the lipid 
values were defined in the 1980s and are addressed to the American adolescent population. 
Thus, reference data for Europe should include data based on examinations of apparently 
healthy European adolescents, considering communicable and non-communicable factors as 
well as being up-to-date.  
With respect to fatty acid (FA) profiles, Decsi and Koletzko mentioned the importance of 
available and adequate reference data from a healthy population for the paediatric age group 
as prerequisite for the diagnosis of an altered FA status and the monitoring of a therapeutic 
intervention, but their proposed FA reference data was based on a Hungarian study group 
with a quite large age range (0-26 years) and a relatively small sample size (n=115). Even 
though, the authors categorized the study population into more specific age groups, the age 
range of the adolescent group (10 to 15 years) misrepresent adolescence and the study size 
became even smaller (n=25) [9]. Therefore, reference data should be based on a larger study 
group with a more appropriate age range.  
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Within adolescence, sexual hormones play an increasing role in controlling physiological 
processes and body composition, especially body fat distribution. Body mass index (BMI), 
percentage body fat (BF), and fat free mass (FFM) can be used to judge body composition. 
Moreover, sexual hormones affect lipid levels and other blood parameters. Thus, gender-
specific differences in these parameters become more obvious in adolescence [10, 11]. 
Consequently, gender should be taken into account when investigating and interpreting data 
from cross-sectional studies in adolescence. 
By contrast, age describes mainly the chronological development of individuals and is 
generally used as the main category to group adolescent subjects. As a consequence, 
significant findings are often related to age, even though the results might reflect changes due 
to sexual maturation [12]. Because of the particular role of sexual hormones in adolescence, 
as noted above, puberty has a main influence on lipid levels [12-14], thus maturity should be 
favoured over age for categorizations. 
 
Blood lipid profiles in adolescents – descriptions and present knowledge 
Blood lipids can be easily measured in plasma/ serum samples and are used as risk markers 
for chronic diseases like atherosclerosis [15-20]. Total cholesterol (TC), high density 
lipoprotein cholesterol (HDL), and low density lipoprotein cholesterol (LDL) indicate the 
cholesterol content of different blood lipoproteins. These lipoproteins act in specific ways as 
lipid transport system in the bloodstream. High levels of TC and LDL correlate with a higher 
risk for developing cardiovascular diseases, whereas high levels of HDL have a protective 
effect. Furthermore, the main apolipoprotein (apo) of the LDL particle, termed apo B, is 
associated with cardiovascular morbidity because of its essentiality for the binding of the 
LDL particle to the LDL receptor. Thus, an excessive number of apo B-containing particles 
promote the atherogenic process [21]. By contrast, apo A-1 is the major protein compound of 
HDL particles and supports the process of reverse cholesterol transport [21]. Triglyceride-rich 
lipoproteins are a major component of non-HDL particles and thus high triglyceride (TG) 
levels can be associated with atherogenic processes [22]. Lipoprotein(a) [Lp(a)] has no clear 
function in the human body, but is an independent risk marker for atherosclerosis [23]. The 
Lp(a) particle is strongly determined by genetics, and thus blood levels are quite constant 
during life [24]. Furthermore, lipid and lipoprotein ratios based on the already mentioned lipid 
and lipoprotein parameters can be used to assess atherogenic risks [25-27], because they 
reflect the particular relation of those lipid and lipoproteins.  
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A complete blood lipid profile should also include the measurement of FA. Generally, FA are 
important for optimal growth and development [28] including fetal and perinatal periods [29-
31]. Fatty acids perform a variety of different tasks including the modification of cell 
membrane fluidity, and thus influencing pinocytosis, ion channel modulation, and membrane-
associated receptor activities. Furthermore, FA can regulate gene expression due to the 
interaction with transcription factors as specific and non-specific ligands [32] and modulate 
inflammatory and immunological processes due to the provision of precursors for eicosanoids 
[33]. Fatty acids are proposed to have cholesterolemic effects on several lipoprotein classes, 
suggesting saturated FA (SFA) as hypercholesterolemic and polyunsaturated FA (PUFA) as 
hypocholesterolemic compared to SFA [34, 35]. 
Serum FA reflect the dietary FA intake as well as the endogenous FA metabolism and are 
mainly transported by lipoproteins as TG, cholesteryl esters, and phospholipids (PL). The 
metabolic situation of the last few days is reflected best by the FA pattern of serum PL [36, 
37], because of the slower metabolic turnover of PL compared to other blood lipid classes 
(e.g. cholesteryl esters, TG or free FA) [38]. Thus, serum FA of the PL fraction are suitable in 
documenting the short-term FA status in humans [39]. To document the FA status according 
to the long-term situation, month to years, PL of the red blood cells, or FA of adipose and 
liver tissues are more suitable. However, these cells/ tissues were not available from the 
adolescent participants of the present project. Furthermore, FA can be used to calculate FA 
ratios. These FA ratios can indicate the relationship between FA families, for instance ω6/ω3 
FA or C18:2ω6/C18:3ω3, because these FA families compete against the same enzymes for 
elongation and desaturation. Fatty acid ratios are also estimated, when the FA of the ratio are 
connected through enzymatic steps within the same FA family, for example 
C20:5ω3/C22:6ω3 or C18:2ω6/C20:4ω6. Thus, the obtained indices can help to identify the 
relation between several FA, which is important for the fulfilling of the physiologic functions 
within the human body. 
 
Present studies highlight only the influence of single factors like BMI as communicable factor 
and/ or age and gender as non-communicable factors [40-45]. Studies covering a more 
complete spectrum including communicable determinants like BMI, BF, and FFM as well as 
the non-communicable factors age, sexual maturity, and gender are missing. Thus, the 
continued effect of these variables on blood lipids (e.g. lipoproteins, cholesterol, FA) is not 
known.  
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Furthermore, our knowledge of lipid profiles of children and adolescents is mostly based on 
studies in already diseased subjects, e.g. children with obesity and diabetes [43, 46-54]. Data 
available for healthy adolescents is mainly coming from surveys in America [41, 55, 56]. In 
Europe, only one known study examined healthy adolescents to present a reference lipid 
profile based on five representative Spanish cities [45]. The AVENA Study presented age- 
and sex-specific lipid and lipoprotein profiles of 581 adolescents aged 13 to 18.5 years. The 
90th percentile for TC was 191 mg/dL for males and 200 mg/dL for females. Females had 
higher HDL levels than boys and LDL levels ranged from 90 to 98 mg/dL in males and from 
92 to 101 mg/dL in females. Triglyceride levels tended to increase gradually and to peak at 17 
years of age for both sexes. Apolipoprotein A-1 and B-100 levels paralleled those of HDL and 
LDL values [45].  
In general, comparisons of current studies are quite difficult because of the following reasons. 
First of all, comparing European countries is not possible, because there is only one known 
survey presenting reference data. The use of American data as European guideline may not be 
transferable due to discrepancies between European and American lifestyles and blood lipid 
profiles. Secondly, different methodological and analytical approaches have been used, which 
complicate comparisons on a global level. Thirdly, reliable reference data should consider 
gender and the impact of growth and development assessed as grade of puberty. 
Consequently, former trials evaluating an early atherogenic risk of children and adolescents 
could only be made by using cut-offs based on incorrect data, because of the already 
mentioned reasons. It cannot be excluded that this approach might under- or overestimate 
individual risks.  
Presently, the FA profiles of healthy adolescents are not investigated sufficiently with respect 
to communicable and non-communicable factors and reliable reference data is missing. 
Similar to the before-mentioned difficulties in lipid research, FA research in adolescence is 
also focusing on subjects with diseases (e.g. diabetes, obesity, metabolic syndrome) [57-63]. 
Furthermore, methodological and analytical approaches differ and study comparisons are 
complicated due to the use of different blood lipid fractions (e.g. TG, cholesteryl esters, PL, 
red blood cell PL). As already pointed out, maturity and gender may also influence FA 
profiles of adolescents, but study results are still presented by age categories with and without 
consideration of gender. Summarized, the problems in lipid research mentioned before like 
transferability of study results, methodological differences and neglecting communicable and 
non-communicable factors apply to FA research as well. 
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2 Purpose of the Thesis 
 
As a consequence of the limited availability of European data, this thesis will investigate the 
lipid status of healthy European adolescents associated with communicable and non-
communicable factors.  
The data for this thesis is based on results of the cross-sectional part of the Healthy Lifestyle 
in Europe by Nutrition in Adolescence (HELENA) Study designed and performed in Europe. 
This project will be introduced in detail in the following chapter.  
 
 
The outline of this work is presented in chapters to achieve a clear overview. The following 
questions are tried to be answered within these chapters: 
 
 What is the current lipid and lipoprotein status of European adolescents? 
 Are maturity, age, gender, body mass index and body fat associated with lipid and 
lipoprotein levels in European adolescents? 
 (Chapter 4) 
 What is the fatty acid status of European adolescents? 
 Are maturity, age, gender, body mass index, body fat, and fat free mass associated 
with fatty acid levels in European adolescents? 
 (Chapter 5) 
 What is the current status of fatty acid ratios? 
 Are maturity, age, gender, body mass index, body fat, and fat free mass associated 
with fatty acid ratios? 
 (Chapter 6) 
 
 Are the fatty acids C16:0, C18:0, C18:1ω9c, C18:2ω6c, C18:3ω3c, C20:4ω6c, 
C20:5ω3c, and C22:6ω3c associated with triglycerides, total cholesterol, cholesterol 
subclasses, lipoprotein(a), and apolipoproteins? 
 (Chapter 7) 
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3 General Methodology 
 
3.1 The HELENA Study - Study design and objectives 
 
The Healthy Lifestyle in Europe by Nutrition in Adolescence (Acronym: HELENA; contract 
number: 007034) Study is a European multi-centre study supported within the frame of the 6th 
framework program (FP6-2003-Food-2-A, FOOD-CT-2005-007034) under the coordination 
of Prof. Luis A. Moreno Aznar (Universidad de Zaragoza). The study was performed in 
cooperation with ten cities all over Europe [1]. 
 
 Ghent University; Ghent (Belgium) 
 Harokopio University; Athens (Greece) 
 Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione; Rome (Italy) 
 Karolinska Institutet; Stockholm (Sweden) 
 Medical University of Vienna; Vienna (Austria) 
 Research Institute of Child Nutrition Dortmund; Dortmund (Germany) 
 Universidad de Zaragoza; Saragossa (Spain) 
 Université de Lille 2; Lille (France) 
 University of Crete School of Medicine; Heraklion (Greece) 
 University of Pécs; Pécs (Hungary) 
 
The general goals of the study were: 
 
 To develop and harmonize innovative methods for the assessment of lifestyle habits of 
adolescents across Europe with special focus on diet, nutrition and physical activity. 
 To assess dietary and physical activity patterns as well as nutritional status among 
European adolescents. 
 To investigate knowledge and attitudes towards nutrition and physical activity among 
adolescents and to establish the main determinants of their food choice and preference. 
 To describe biological parameters and give reference data of European adolescents for 
future studies. 
 To describe social, genetic, pubertal, weight-dependent and gender differences and 
similarities across Europe. 
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 To identify adolescents at risk of eating disorders, dyslipidemia, obesity and/or type 2 
diabetes. 
 To develop a number of healthy foods and identify marketing strategies for 
consumers, in order to improve the diet of adolescents. 
 To develop a Lifestyle Education Programme and test its efficacy for improving 
adolescents’ health. 
 
In order to organize the work efficiently, 14 Work Packages (WP) were introduced dealing 
with specific topics and research fields. Accordingly, the HELENA project was split in four 
experimental parts: (I) a crossover multi-centre study (COMS); (II) a lifestyle education 
intervention (LSEI); (III) a behavioural and food choice study (BEFO); (IV) a cross-sectional 
study (CSS). All work presented in this thesis was part of the CSS, specifically of WP 9 
(Haematological, biochemical, and immunologic data) and WP 8 (Body composition and 
obesity).  
 
 
The HELENA-CSS 
Within the CSS, an adolescent group was assessed for food and nutrient intake, nutrition 
knowledge, physical activity and fitness, body composition, vitamin and mineral status, lipid 
and blood profile, and genetic variability. Therefore, methods were developed and 
harmonized in cooperation with all partners in order to obtain comparable data within the 
study centres. Subject recruitment was done by one research group or institute within the ten 
participating centres.  
 
Study design and subject recruitment  
Subjects with an age range of 12.5-17.49 years were recruited in ten cities across Europe. 
Selection of cities was based on two criteria: regional distribution and presence of an active 
research group assuring sufficient expertise and resources to successfully perform 
epidemiological studies. Within the study, Stockholm (Sweden) represented Northern Europe, 
Athens, Heraklion (Greece), Rome (Italy), Saragossa (Spain) Southern Europe, Pécs 
(Hungary) Eastern Europe, Ghent (Belgium), Lille (France) Western Europe, and Dortmund 
(Germany), Vienna (Austria) Central Europe. The sample size of 3,000 adolescents has been 
estimated using BMI (confidence level of 95%, and a ±0.3 error). Each partner was asked to 
include 150 male and female subjects per protocol, respectively. 
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Reliable and objective data concerning age and gender were obtained by analysing complete 
school classes. On the city level, diversity of the sample with respect to cultural and socio-
economic aspects was achieved by performing a random proportional distribution of all 
schools taking into account the site of the school (district/ zone of the city) and the type of 
school (public or private). Blood sampling was performed in one third of the adolescents 
recruited (choice of whole classes representing the desired age of the subjects). The school 
and class random selection procedure, including the subset of classes for blood sampling, has 
been done centrally by one partner (i.e. Ghent) for all study centres. In case a selected school 
denied its participation, a school with comparable characteristics from a reserve list was 
taken.  
Individual exclusion criteria were not being able to speak the local language and the 
simultaneous participation in another clinical trial. All protocols and informed consents for 
this study were reviewed and approved by an Ethics Review Committee in each country 
according to the Declaration of Helsinki and International Conferences on Harmonization for 
Good Clinical Practice. Quality control was assured throughout the whole project as described 
by Beghin et al. [2]. 
Prior to the start of the HELENA-CSS all methods have been tested in a pilot study to assure 
optimal sampling and to optimize transport logistics and analytics. These results have been 
described and published elsewhere more in detail [3]. 
 
Medical examination, blood sampling and anthropometric measurements  
Prior to the study day of blood donation, body composition assessment and bioelectrical 
impedance analysis (BIA), participants were asked to abstain from eating and drinking later 
than 8 p.m. At the study day a medical doctor visited the school classes and asked all 
participants for medical history and acute diseases. A blood sampling questionnaire was used 
to assess fasting status, acute infections, allergies, vitamin and mineral supplements, and 
medication (see Appendix A). Maturity was assessed by means of Tanner stage [4]. Medical 
data and all information were recorded in a case report form for each participant (see 
Appendix B).  
Blood sampling generally took place between 8-10 a.m. Approximately 30 mL of blood were 
collected from an antecubital vein in serum, heparin, and ethylene diamine tetraacetic acid 
monovettes® (Sarstedt AG & Co., Nümbrecht, Germany). These blood samples were used to 
assess the different biomarkers and blood parameters, including lipids and lipoproteins for the 
present thesis. After blood sampling a breakfast was offered for all participants.  
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Various anthropometric measures were performed using validated methods as published in 
detail previously [5]. Briefly, body weight was measured after blood sampling in underwear 
and without shoes with an electronic scale (Type SECA 861) to the nearest 0.1 kg, and height 
was measured barefoot in the Frankfort plane with a telescopic height measuring instrument 
(Type SECA 225) to the nearest 0.1 cm. A set of skinfold thicknesses (biceps, triceps, 
subscapular, suprailiac, thigh) were measured several times on the left side of the body, with a 
Holtain caliper (nearest 0.2 mm). For BIA measurements a classical tetrapolar technique was 
used by means of BIA 101 AKERN SRL. Standard instructions for BIA measurements were 
followed.  
The intraobserver technical errors of measurement (TEMs) were between 0.12 and 2.9 mm for 
skinfold thicknesses. Intraobserver reliability for skinfold thicknesses was >69%. The 
intraobserver TEMs for skinfold thicknesses were <1; for BIA resistance TEMs were <0.1 Ώ 
and <0.2 Ώ for reactance. Intraobserver reliability values were >95%, 99% and 97% for 
skinfold thicknesses, BIA resistance and reactance. Interobserver TEMs for skinfold 
thicknesses ranged from 1 to 2 mm; for BIA they were 1.16 and 1.26 Ώ for resistance and 
reactance. Interobserver reliability for skinfold thicknesses, BIA resistance and reactance 
were >90% [5]. 
 
Sample treatment and transport 
Sample treatment and transport were tested in a pilot study to assure optimal sampling as 
described in detail previously [3]. After blood donation, serum samples were clotted at room 
temperature for at least 30 minutes followed by a centrifugation (2,500 x g, 10 minutes). 
Aliquots for FA analysis were stored locally at -20/ -80°C as soon as possible. After field 
work was done, all samples of one city were shipped on dry ice to the central laboratory (IEL) 
at the University of Bonn (Germany) and stored at -80°C until analysis. Aliquots for routine 
lipid parameters were sent to the IEL, stored in a refrigerator at 4-7°C overnight and analysed 
within 24 hours after blood collection in the University Hospital in Bonn. Aliquots for leptin 
analyses were also shipped to the IEL and stored locally at -80°C within 24 hours after blood 
donation. Leptin samples were shipped on dry ice to the laboratory of the Universidad 
Politécnica de Madrid (Spain) after all field work was done.  
Heparin samples for insulin analyses were put directly on ice until centrifugation (2,500 x g, 
10 minutes). Afterwards, samples were shipped under cooled conditions (4-7°C) to the IEL 
and stored at -80°C within 24 hours after blood drawing.  
For all samples freeze-thaw cycles were avoided until analysis.  
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3.2 Materials 
 
The following tables summarize all laboratory materials, equipments and FA standards used 
for FA analytics within the HELENA-CSS.  
 
Table 3.1a: Used chemicals and gases 
Name Company Order number 
2’,7’Dichlorofluorescein Fluka, Deisenhofen, Germany 35848 
Acetone Carl Roth, Karlsruhe, Germany 7328.2 
Air Praxair GmbH, Düsseldorf, Germany - 
Ethanol Carl Roth, Karlsruhe, Germany P076.2 
Hydrochloric acid fuming 37% Carl Roth, Karlsruhe, Germany X942.1 
Helium 4.6 Praxair GmbH, Düsseldorf, Germany - 
Hydrogen 5.0 Praxair GmbH, Düsseldorf, Germany - 
Methanol Carl Roth, Karlsruhe, Germany HN41.1 
n-Heptane Carl Roth, Karlsruhe, Germany CP78.1 
Nitrogen 5.0 Praxair GmbH, Düsseldorf, Germany - 
Petroleum benzine 63-80°C Carl Roth, Karlsruhe, Germany 5649.1 
Petroleum ether 40-60°C Carl Roth, Karlsruhe, Germany T173.1 
Trichloromethane/chloroform Carl Roth, Karlsruhe, Germany 3313.2 
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Table 3.1b: Used authentic fatty acid standards* 
Name Company Order number 
1,2-Dipentadecanoyl-sn-glycero-3-
phosphocholine Sigma-Aldrich, Deisenhofen, Germany P7285 
Docosadienoic acid methyl ester Sigma-Aldrich, Deisenhofen, Germany D4034 
Docosahexaenoic acid methyl ester Sigma-Aldrich, Deisenhofen, Germany D2659 
F.A.M.E. Mix, C4-C24 Sigma-Aldrich, Deisenhofen, Germany 18919-1 AMP 
Methyl 11,14,17-eicosatrienoate Sigma-Aldrich, Deisenhofen, Germany E6001 
Methyl 5,8,11-eicosatrienoate Sigma-Aldrich, Deisenhofen, Germany E6013 
Methyl 8,11,14-eicosatrienoate Fluka, Deisenhofen, Germany 00813 
Methyl arachidate Fluka, Deisenhofen, Germany 10941 
Methyl arachidonate Sigma-Aldrich, Deisenhofen, Germany A9298 
Methyl behenate Fluka, Deisenhofen, Germany 11940 
Methyl butyrate Fluka, Deisenhofen, Germany 19358 
Methyl decanoate Fluka, Deisenhofen, Germany 21479 
Methyl docosapentaenoate Fluka, Deisenhofen, Germany 17269 
Methyl eicosadienoate Fluka, Deisenhofen, Germany 17272 
Methyl eicosapentaenoate Fluka, Deisenhofen, Germany 17266 
Methyl eicosenoate Fluka, Deisenhofen, Germany 17263 
Methyl erucate Fluka, Deisenhofen, Germany 45659 
Methyl heneicosanoate Fluka, Deisenhofen, Germany 51535 
Methyl heptadecanoate Fluka, Deisenhofen, Germany 51633 
Methyl heptadecenoate Sigma-Aldrich, Deisenhofen, Germany H9021 
Methyl hexanoate Fluka, Deisenhofen, Germany 21599 
Methyl laurate Fluka, Deisenhofen, Germany 234591 
Methyl linoleate Fluka, Deisenhofen, Germany 62280 
Methyl linolelaidate Fluka, Deisenhofen, Germany 62155 
Methyl linolenate Fluka, Deisenhofen, Germany 62200 
Methyl myristate Fluka, Deisenhofen, Germany 70129 
Methyl myristoleate Fluka, Deisenhofen, Germany 70121 
Methyl octadecenoate Fluka, Deisenhofen, Germany 46904 
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Name Company Order number 
Methyl octanoate Fluka, Deisenhofen, Germany 21790 
Methyl oleate Fluka, Deisenhofen, Germany 75160 
Methyl palmitate Fluka, Deisenhofen, Germany 76159 
Methyl palmitoleate Fluka, Deisenhofen, Germany 76176 
Methyl pentacosanoate Fluka, Deisenhofen, Germany 76497 
Methyl pentadecanoate Fluka, Deisenhofen, Germany 76560 
Methyl pentadecenoate Sigma-Aldrich, Deisenhofen, Germany P0315 
Methyl stearate Fluka, Deisenhofen, Germany 85769 
Methyl stearidonate Fluka, Deisenhofen, Germany 43959 
Methyl tetracosanoate Fluka, Deisenhofen, Germany 87115 
Methyl tetracosenoate Fluka, Deisenhofen, Germany 17265 
Methyl trans-vaccenate Sigma-Aldrich, Deisenhofen, Germany V1381 
Methyl tricosanoate Fluka, Deisenhofen, Germany 91478 
Methyl tridecanoate Fluka, Deisenhofen, Germany 91558 
Methyl undecanoate Fluka, Deisenhofen, Germany 94118 
Methyl γ-linolenate Fluka, Deisenhofen, Germany 00238 
   
* the precise nomenclature is shown in the list of abbreviations  
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Table 3.1c: Used laboratory equipment and materials 
Name Specification Company 
Analysis funnels Lime-soda glass, 55 mm Carl Roth, Karlsruhe, Germany 
Centrifuge tubes With thread and screw-cap, conical, 112x17 mm 
Hecht-Assistant, Sondheim, 
Germany 
Culture tubes Schott DURAN, with screw-cap,  12x100 mm Carl Roth, Karlsruhe, Germany 
Eppendorf pipettes Eppendorf Research®, 10-100µL,  100-1,000µL Eppendorf, Hamburg, Germany 
Filter papers MN616 WA, 90 mm, hydrophobic phase 
separation papers Macherey-Nagel, Düren, Germany 
Medical gloves Flexam, Latex, size M, REF 88471 Cardinalhealth, Illinois, USA 
Micro-vials conic CS-Chromatographie Service GmbH, Langerwehe, Germany 
Monovettes® 
Serum, heparin, and ethylene diamine 
tetraacetic acid monovettes for different 
volumes 
Sarstedt AG & Co., Nümbrecht, 
Germany 
Pasteur pipettes Lime-soda clear glass, uniform Carl Roth, Karlsruhe, Germany 
Pipette filler - Carl Roth, Karlsruhe, Germany 
Pipette tips For 10-100 µL, 100-1,000 µL pipettes Eppendorf, Hamburg, Germany 
Reaction tubes Safe-lock tubes, 1.5 mL Eppendorf, Hamburg, Germany 
Reaction tubes Tubes with screw-cap, 1.5 mL Eppendorf, Hamburg, Germany 
Syringes Syringe Perfection, 10µL, 250 µL SGE GmbH, Griesheim, Germany 
Test tubes With thread and plastic screw-cap, 98x16 mm 
Schütt Labortechnik, Göttingen, 
Germany 
TLC plates SIL G-25, 20x20 cm Macherey-Nagel, Düren, Germany 
TLC-seperating chamber glass Carl Roth, Karlsruhe, Germany 
Volumetric flasks 25, 50, 100, 200 mL Carl Roth, Karlsruhe, Germany 
Volumetric pipettes 1 mL, 2 mL, AR-glass Hierschmann Laborgeräte, Eberstadt, Germany 
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Table 3.1d: Used machines and devices 
Name Specification Company 
Gas chromatograph Varian CP-3900 Varian GmbH, Darmstadt, Germany 
Autoinjector Injector 1177 Varian GmbH, Darmstadt, Germany 
Autosampler Autosampler 8410 Varian GmbH, Darmstadt, Germany 
Column 
Zebron ZB-WAXplus, 
polyethylene glycol,  
30 m x 0.25 mm x 0.25 µm 
Phenomenex LTD, 
Aschaffenburg, Germany 
   
Centrifuge Heraeus Megafuge 1.0R Thermo-Electron.Corporation, Waltham, USA 
Thermostat Reacti-Therm III, Heating/Stirring 
module Pierce, Rockford, USA 
Thermostat (additional equipment) Reacti-Vap III Pierce, Rockford, USA 
Thin-layer fluorescent sprayer Thin-layer fluorescent sprayer E. Merck, Darmstadt, Germany 
Ultrapure water-preparation system Nanopure D 1797 Barstead, Bergisch-Galdbach, Germany 
UV-System Fluotest universal Gerhardt, Bonn, Germany 
Vacuum pump Eppendorf 4151 Eppendorf, Hamburg, Germany 
Vortex Vortex-Genie® Zimmermann Laborausrüster, Cologne, Germany 
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3.3 Analytical Methods 
 
A Fatty acid determination of serum phospholipids 
 
Figure 3.1 gives an overview of the complete analysis scheme. Serum samples were defrosted 
at room temperature. One mL of serum or if not available, the maximal sample volume, was 
transferred into culture tubes with Teflon caps. The precise sample volume was considered in 
the formula when calculating the FA concentration. Afterwards, 50 µL of internal standard 
(IS: 1,2-Dipentadecanoyl-sn-glycero-3-phosphocholine) were added. Throughout the 
procedure, samples were repeatedly flushed with nitrogen (N2) and mixed with a Vortex®. 
 
 
 
 
Figure 3.1: Flow chart of blood handling, sample preparation, and analysis of fatty acids.  
          TLC:Thin-layer chromatography 
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Lipid extraction, thin-layer chromatography and methylation 
 
I. Lipid extraction 
The FA extraction is based on a modified method by Folch [6] and Sperry and Brand [7]. For 
protein precipitation, one mL of methanol was added to the sample, and the samples were 
rested for 10 minutes. Next, two mL of chloroform were added. Ten minutes later, samples 
were centrifuged at 836 x g and 4°C for 10 minutes. After centrifugation, three phases were 
obtained and the upper methanol-containing phase was aspirated. The remaining protein band 
and the lipophil phase were mixed and filtrated through hydrophobic phase separation paper 
filters. The proteins and remaining aqueous solutions retained in the paper filters. The lipid 
phase, which contained the total amount of the extracted serum lipids, was collected in 
conical centrifugation tubes. Afterwards, the lipid phase was evaporated to dryness under 
constant N2 flow. Dried samples were frozen overnight at -80°C.  
 
II. Thin-layer chromatography 
The TLC method including methylation and extraction was performed as described by 
Christophe and Matthijs [8]. The dried sample was dissolved in 150 mL of chloroform and 
spotted with a syringe on a TLC plate. Separation in PL, monoglyceride, non-esterified FA, 
cholesterol, diglycerid, TG, and cholesterol ester fractions took place in a TLC-separating 
chamber containing 100 mL of running solution (15% acetone + 85% petroleum benzine [bp 
63-80°C]) (see figure 3.2). Thin-layer chromatography was completed when the solution front 
reached nearly 0.5 cm from the border (approximately after 45 minutes to 1 hour). Thin-layer 
chromatography plates were sprayed with a fluorescent solution, to visualize PL under UV 
light, containing 200 mg of 2’,7’-dichlorofluorescein solved in 100 mL ethanol. The PL band 
was scraped off and transferred into culture tubes to be used for methylation.  
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Figure 3.2: Illustration  of  the  separation  of  serum  lipid  fractions  by  thin-layer  
                    chromatography  (running  solution:  15%  acetone  and 85% petroleum 
                    benzine [bp 63-80°C]; duration: approx. 1 hour). 
 
 
III. Methylation and Extraction 
Phospholipids were dissolved in two mL of methylating solution (mixture of four mL 37% 
hydrochloric acid and 100 mL methanol) and incubated (95°C, 4 h). The solution containing 
fatty acid methyl esters (FAME) was cooled at -20°C for 10 minutes. Two mL of petroleum 
ether (bp 40-60°C) and two mL of distilled water were then added for methyl ester extraction. 
Afterwards, the samples were centrifugated (836 x g, 4°C, 10 minutes). The top layer was 
transferred to conical centrifuge tubes and evaporated to dryness under constant N2 flow. One 
hundred µL n-heptane were added to redissolve the dried FAME. Samples were transferred 
into micro-vials and one µL was injected in the gas chromatograph. 
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B Gas chromatography 
 
Fatty acid methyl esters were analysed using gas chromatography. Equipment and analytical 
conditions are given in table 3.2.  
 
Table 3.2: Gas chromatography – equipment and analytical conditions. 
 
 
Gas chromatograph CP-3900 (Varian GmbH) 
Autosampler 8410 (Varian GmbH) 
Injector 1177 (Varian GmbH) 
Detector Flame ionisation detector (FID) 
Column Zebron ZB-WAXplus, Polyethylene glycol,  30 m x 0.25 mm x 0.25 µm 
Injection mode Split/ splitless; split ratio 20 
Injector temperature 200°C 
Column pneumatics Constant flow (4 mL/min) 
Carrier gas Helium 
Detector temperature 250°C 
Detector characteristics 
Helium flow (makeup):         30 mL/min 
Hydrogen flow (reference):   30 mL/min 
Air flow:                              300 mL/min 
Injection volume 1 µL 
Column oven program 
 
Rate (°C/min)     Step (°C)     Time step (min)     Total time (min) 
Initial                    100                        2.0                           2.0 
   25.0                    180                        0.0                           5.2 
     0.5                    190                        0.0                         25.2 
     1.0                    200                        0.0                         35.2 
     5.0                    210                        0.0                         37.2 
   10.0                    240                        3.0                         43.2 
  
 
Typical chromatograms of a F.A.M.E. C4-C24 standard and a serum sample are presented in 
figures 3.3, 3.4 and 3.5, respectively. 
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Single authentic FAME reference standards were used to identify FA peaks of the sample. 
The retention times of the single FAME were measured and compared with the analysed 
peaks of the sample.  
Valid identification during routine analysis was assured by analysing a F.A.M.E. C4-C24 
standard every tenth sample. It was only feasible to calculate the absolute FA concentrations 
of those FA in the sample that were also included in the standard. The concentrations of those 
ten consecutive FA samples were calculated by using the mean concentrations of two 
F.A.M.E. C4-C24 standards, measured before and after those ten samples. 
As mentioned earlier, 1,2-Dipentadecanoyl-sn-glycero-3-phosphocholine was chosen as IS. 
This was due to two reasons: (a) IS consists of two pentadecanoates (C15:0), which are also 
included in the FA composition of the F.A.M.E. C4-C24 standard; (b) pentadecanoate can be 
neglected in the evaluation of serum FA because it is only a minor component of blood FA 
profiles. 
 
Preparation of the internal standard 
One hundred mg IS (molecular mass [MM] 705.99) were solved in 40 mL of a 
methanol:chloroform solution. The methanol:chloroform solution consisted of 20 mL 
methanol and 40 mL chloroform (dilution factor 1:3). Thus, an IS concentration of 2.5 mg per 
one mL methanol:chloroform solution was obtained. 
 
Concentration of IS each 1,000 mL = 
MM 705.99
mg 2,500
 
              = 3.5411 mmol 
 
A concentration of 3.54 nmol IS per µL methanol:chloroform solution was obtained. Adding 
50 µL of this solution to one mL serum sample resulted in an end concentration of 354.1 
µmol pentadecanoates per L serum. 
 
Calculation of the single fatty acids methyl esters of the F.A.M.E. C4-C24 standard 
The following formula was used to calculate the concentration of the FAME of the standard. 
All important information to calculate the single FAME concentrations can be found in table 
3.3 as well as the referring results (right column). 
 
FAME concentration (µmol/L) = 
ester methyl acidfatty   theof massMolecular 
mg/dLin ester  methyl acidFatty 
*10*1,000 
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Table 3.3: Details of the single fatty acid methyl esters of the F.A.M.E. C4-C24. 
Fatty acid methyl ester  
(FAME) 
Weight% 
in the 
standard 
Concentration in 
the diluted 
standard (mg/dL) 
Molecular mass 
of the FAME 
Concentration 
(µmol) per L 
standard 
Butyric acid (C4:0) 4% 39.90 102.13 3906.79 
Caproic acid (C6:0) 4% 39.80 130.18 3057.31 
Caprylic acid (C8:0) 4% 39.90 158.24 2521.49 
Capric acid (C10:0) 4% 39.90 186.3 2141.71 
Undecanoic acid (C11:0) 2% 20.00 214.34 933.10 
Dodecanoic acid (C12:0) 4% 39.90 214.34 1861.53 
Tridecanoic acid (C13:0) 2% 20.00 228.37 875.77 
Tetradecanoic acid (C14:0) 4% 39.90 242.4 1646.04 
Cis-9-Tetradecenoic acid (C14:1) 2% 20.00 240.38 832.02 
Pentadecanoic acid (C15:0) 2% 20.00 256.42 779.97 
Cis-10-Pentadecenoic acid (C15:1) 2% 19.90 254.41 782.20 
Hexadecanoic acid (C16:0) 6% 59.80 270.45 2211.13 
Cis-9-Hexadecenoic acid (C16:1) 2% 20.00 268.43 745.07 
Heptadecanoic acid (C17:0) 2% 20.30 284.48 713.58 
Cis-10-Heptadecenoic acid 
(C17:1) 
2% 20.00 282.46 708.06 
Octadecanoic acid (C18:0) 4% 40.60 298.5 1360.13 
Trans-9-Elaidic acid (C18:1) 2% 20.60 296.49 694.80 
Cis-9-Octadecenoic acid (C18:1) 4% 39.90 296.49 1345.75 
All-trans-9,12-Octadecadienoic 
acid (C18:2) 
2% 20.00 294.47 679.19 
All-cis-9,12-Octadecadienoic acid 
(C18:2) 
2% 19.90 294.47 675.79 
All-cis-6,9,12-Octadecatrienoic 
acid (C18:3) 
2% 19.90 292.46 680.43 
Eicosanoic acid (C20:0) 4% 39.90 326.56 1221.83 
Cis-11-Eicosenoic acid (C20:1) 2% 20.00 324.54 616.26 
All-cis-9,12,15-Octadecatrienoic 
acid (C18:3) 
2% 20.00 292.46 683.85 
Heneicosanoic acid (C21:0) 2% 20.00 340.58 587.23 
 
continued 
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Fatty acid methyl ester  
(FAME) 
Weight% 
in the 
standard 
Concentration in 
the diluted 
standard (mg/dL) 
Molecular mass 
of the FAME 
Concentration 
(µmol) per L 
standard 
All-cis-11,14-Eicosadienoic acid 
(C20:2) 
2% 20.00 322.53 620.10 
Docosapentanoic acid (C22:0) 4% 39.90 354.61 1125.18 
All-cis-8,11,14-Eicosatrienoic acid 
(C20:3) 
2% 19.90 320.51 620.89 
Cis-13-Docosenoic acid (C22:1) 2% 19.90 352.59 564.39 
All-cis-11,14,17-Eicosatrienoic 
acid (C20:3) 
2% 20.40 320.51 636.49 
All-cis-5,8,11,14-Eicosatetraenoic 
acid (C20:4) 
2% 20.00 318.49 627.96 
Tricosanoic acid (C23:0) 2% 19.90 368.64 570.48 
All-cis-13,16-Docosadienoic acid 
(C22:2) 
2% 20.00 350.58 570.48 
Tetracosanoic acid (C24:0) 4% 39.90 382.66 1042.70 
All-cis-5,8,11,14,17-
Eicosapentaenoic acid (C20:5) 
2% 20.20 316.48 638.27 
Cis-15-Tetracosenoic acid (C24:1) 2% 20.00 380.65 525.42 
All-cis-4,7,10,13,16,19-
Docosahexaenoic acid (C22:6) 
2% 19.90 342.51 581.00 
      
 
 
Calculations - absolute fatty acid concentrations 
This formula was used to obtain the fatty acid concentration in µmol per L serum: 
 
Concentration (µmol/L) = 
standard]in  acid[Fatty PA 
sample]in  acid[Fatty PA 
*
sample]in  0:[C15PA 
standard]in  0:[C15PA 
*Factor 
 
Factor = 
standard]in  0:[C15ion Concentrat
sample]in  0:[C15ion Concentrat
*Concentration(FAME in standard)*Dilution factor 
 
Dilution factor = 
µLin   volumeSample
µL 1,000
 
PA:Peak area (µV/min) 
  Table 3.3 continued 
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Calculations – absolute fatty acid concentrations as percentage distribution  
The percentage distribution of the absolute concentrations of the FA profile was obtained 
using the calculated absolute concentrations of a single FA divided by the sum (∑) of all 
calculated FA, multiplied by the factor 100 (see example). The results are expressed as 
percentage of concentration (conc%).  
 
Example: 
Oleic acid (conc%) = (µmol/L) acidsfatty  all of
(µmol/L) acid Oleic
∑
*100 
 
Calculations - relative fatty acid profile 
The relative FA profile, based on the peak area (PA), was obtained using two factors. Firstly, 
the PA of each FA of interest was calculated by integration, expressed in µV/min, with 
standard software (Galaxie CDS, version 1.8.4.1.) provided by Varian GmbH (Darmstadt, 
Germany). Secondly, the sum of all measured FA of interest was calculated. The calculation 
to obtain the individual relative FA in area% is shown in the example below. Within this 
calculations it was feasible to enlarge the FA profile with selected FA (C18:1ω7c, C18:1ω7t, 
C18:4ω3c, C20:3ω9c, and C22:5ω3c), which were not present in the F.A.M.E. C4-C24 
standard. 
 
Example: 
Oleic acid (area%) = (µV/min) ] acidsfatty  calculated all of[PA 
(µV/min) Acid] [OleicPA 
∑
*100 
 
 
C Validation of fatty acid measurements 
 
Precision 
The precision of the used gas chromatography method was assured by measuring the same 
single FAME reference standard within three runs. Afterwards, means and standard deviations 
were used to calculate the coefficient of variation (CV) as shown below. 
 
Coefficient of variation (%) = 
mean
deviation standard
*100 
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Table 3.4a summarizes the CV of the intra-assay precision of each single FAME standard.  
To obtain an overview about the variation within the different runs, the CV of the F.A.M.E. 
C4-C24 measurements were calculated for the complete sequence of each city (see table 
3.4b). The CV includes day-by-day fluctuations and variations because of freshly prepared 
F.A.M.E. standards due to the time-consuming analysis of several days.  
 
Table 3.4a: Intra-assay precision (n=3) of  single  fatty acid  methyl ester  standards measured   
  by gas chromatography. 
Single fatty acid methyl ester standard* Coefficient of variation (%) 
Docosadienoic acid methyl ester 2.8 
Docosahexaenoic acid methyl ester 2.9 
Methyl 11,14,17-eicosatrienoate 1.4 
Methyl 5,8,11-eicosatrienoate 3.2 
Methyl 8,11,14-eicosatrienoate 3.6 
Methyl arachidate 1.6 
Methyl arachidonate 1.5 
Methyl behenate 4.4 
Methyl butyrate 2.9 
Methyl decanoate 3.0 
Methyl docosapentaenoate 0.4 
Methyl eicosadienoate 2.2 
Methyl eicosapentaenoate 1.5 
Methyl eicosenoate 3.2 
Methyl erucate 2.9 
Methyl heneicosanoate 2.7 
Methyl heptadecanoate 3.4 
Methyl heptadecenoate 1.3 
Methyl hexanoate 3.2 
Methyl laurate 2.4 
Methyl linoleate 2.4 
Methyl linolelaidate 0.7 
continued 
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Single fatty acid methyl ester standard* Coefficient of variation (%) 
Methyl linolenate 2.4 
Methyl myristate 2.3 
Methyl myristoleate 1.7 
Methyl octadecenoate 0.1 
Methyl octanoate 1.4 
Methyl oleate 1.5 
Methyl palmitate 1.0 
Methyl palmitoleate 1.8 
Methyl pentacosanoate 2.9 
Methyl pentadecanoate 3.0 
Methyl pentadecenoate 1.2 
Methyl stearate 3.5 
Methyl stearidonate 1.7 
Methyl tetracosanoate 0.9 
Methyl tetracosenoate 1.2 
Methyl trans-vaccenate 2.5 
Methyl tricosanoate 1.8 
Methyl tridecanoate 2.1 
Methyl undecanoate 2.7 
Methyl γ-linolenate 2.8 
    
* the precise nomenclature is shown in the list of abbreviations  
 
 
 
 
 
 
 
 
 
  Table 3.4a continued 
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Table 3.4b: Coefficients of variation of the fatty acid methyl ester standard (F.A.M.E. C4- 
  C24) for each study centre analysed by gas chromatography. 
Fatty acid methyl ester* Coefficient of variation (%) 
 A D G H L P R S V Z 
Docosadienoic acid methyl ester 10.7 6.5 6.6 3.5 14.5 8.1 11.0 9.8 11.5 8.0 
Docosahexaenoic acid methyl ester 11.8 7.3 6.3 5.2 14.6 7.3 10.7 8.8 11.9 7.5 
Methyl 8,11,14-eicosatrienoate 10.4 6.0 6.0 3.9 13.1 6.9 9.9 9.1 11.6 7.7 
Methyl arachidate 11.3 5.3 5.4 3.7 11.4 4.9 10.9 9.0 7.9 10.2 
Methyl arachidonate 11.1 6.3 5.7 3.9 12.2 6.9 10.7 8.0 11.9 7.6 
Methyl behenate 11.1 5.9 6.6 4.2 11.2 6.4 10.2 9.7 9.0 15.7 
Methyl eicosadienoate 11.2 6.0 5.9 4.0 13.4 7.1 10.8 8.6 12.0 8.4 
Methyl eicosapentaenoate 11.0 5.6 5.8 4.0 12.6 6.6 10.5 8.8 11.8 8.0 
Methyl eicosenoate 11.3 5.9 5.8 3.9 13.7 6.8 10.9 8.2 13.1 7.9 
Methyl erucate 11.2 6.2 5.8 4.5 15.0 7.9 10.9 9.8 13.1 7.8 
Methyl heneicosanoate 10.7 5.7 6.1 4.1 11.6 6.0 10.3 9.0 8.7 13.9 
Methyl heptadecanoate 9.4 9.7 3.8 3.6 6.9 5.5 11.8 5.3 9.9 8.1 
Methyl heptadecenoate 9.0 4.2 3.7 3.7 6.6 5.9 8.7 5.3 10.2 7.8 
Methyl laurate 2.2 4.8 4.9 4.4 4.5 6.4 4.0 4.5 9.2 7.6 
Methyl linoleate 10.7 5.7 5.2 3.2 8.4 8.4 9.3 8.7 8.7 6.5 
Methyl linolelaidate 9.6 4.9 4.4 5.2 9.4 6.5 10.7 5.9 12.4 8.2 
Methyl linolenate 9.8 4.7 4.3 3.7 9.1 6.0 9.9 6.3 10.9 10.2 
Methyl myristate 4.2 4.3 4.3 4.1 3.7 6.0 4.6 4.1 9.6 7.8 
Methyl myristoleate 3.9 4.3 4.2 4.1 3.7 6.0 4.6 4.1 9.5 7.6 
Methyl oleate 10.2 4.8 4.3 3.6 9.1 6.2 9.9 6.4 10.9 7.5 
Methyl palmitate 7.9 4.4 3.7 3.8 4.7 6.0 7.7 4.5 9.9 7.6 
Methyl palmitoleate 7.4 4.0 3.6 3.7 4.6 5.9 7.8 4.4 10.1 7.5 
Methyl pentadecanoate 6.0 4.3 3.9 4.0 3.6 6.1 6.6 4.2 9.9 7.7 
Methyl pentadecenoate 5.7 4.0 3.8 3.9 3.6 5.9 6.0 4.0 9.7 7.7 
Methyl stearate 10.5 5.0 4.7 3.7 9.1 5.4 10.0 6.7 8.7 7.1 
Methyl tetracosanoate 10.4 7.2 9.1 4.2 11.8 6.4 10.8 8.4 9.6 19.1 
Methyl tetracosenoate 10.1 7.0 6.3 4.5 14.7 7.8 10.7 8.9 12.7 7.4 
continued 
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Fatty acid methyl ester* Coefficient of variation (%) 
 A D G H L P R S V Z 
Methyl tricosanoate 10.8 7.0 8.1 5.5 12.3 6.9 9.8 8.9 10.2 17.3 
Methyl γ-linolenate 9.8 4.5 4.2 3.8 8.5 6.1 9.5 6.1 10.8 7.8 
              
 
* the precise nomenclature is shown in the list of abbreviations  
A:Athens (analysed F.A.M.E.: n=13), D:Dortmund (n=14), G:Ghent (n=13), H:Heraklion (n=13), L:Lille 
(n=12), P:Pecs (n=15), R:Rome (n=12), S:Stockholm (n=13), V:Vienna (n=13), Z:Saragossa (n=13). 
 
 
Stability of fatty acids 
Prior to the study, the stability of the FA was tested. Blood samples were collected in ethylene 
diamine tetraacetic acid monovettes from six volunteers (mean age 29±3 years, 5 females), 
immediately centrifuged (2,500 x g, 10 minutes) and aliquoted. Aliquots were stored at room 
temperature or at approximately 7°C (refrigerator) over 24 hours. Samples were analyzed 
after eight and 24 hours in the IEL. Samples showed no stability over time at room 
temperature as well as at 7°C. Thus, for logistical and analytical reasons, serum blood was 
used instead of plasma and the samples had to be stored at -20/ -80°C in the local centre as 
soon as possible. No antioxidant or stabilizer was used to avoid FA oxidation because of the 
direct storage of the samples at -20/ -80°C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Table 3.4b continued 
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D Routine lipid and lipoprotein determination 
 
Serum TG, TC, HDL, and LDL were measured enzymatically on the Dimension RxL clinical 
chemistry system (Dade Behring, Schwalbach, Germany) using the manufacturer’s reagents 
and instructions. Apolipoprotein A-1 and B concentrations were measured in an 
immunochemical reaction with a BN II analyzer (Dade Behring, Schwalbach, Germany) 
according to the manufacturer’s instructions. The proteins contained in the serum sample form 
immune complexes with specific antibodies. These complexes scatter a light beam when 
passed through the sample. The intensity of the scattered light is proportional to the 
concentration of the relevant protein in the sample. The result is evaluated by comparison 
with a standard of known concentration. Serum Lp(a) was measured by means of particle-
enhanced immunonephelometry using the BN II analyzer (Dade Behring).  
 
 
E Validation of routine lipid measurements 
 
Precision 
The intraassay coefficient of variation of the TG, TC, HDL, LDL, apo A-1, apo B, and Lp(a) 
assay was 1.9%, 1.3%, 3.3%, 2.7%, 2.7%, 2.1%, and 3.9%, while the interassay coefficient 
was 2.2%, 1.8%, 3.9%, 3.6%, 3.4%, 3.2%, and 4.3%.  
 
 
Stability of routine lipid parameters 
To guarantee the stability of routine biochemistry analyses in fresh serum samples three 
samples with high – mean – low baseline values were tested over different time points during 
24 hours after blood extraction. These stability tests were performed in the University 
Hospital in Bonn. The results are shown in table 3.5. 
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Table 3.5: Results from stability tests for lipids and lipoproteins.  
Time after blood 
extraction (hours) 
0 2 4 6 8 12 24 Median of 
deviation to 
time 0 (%)  
Mean of 
deviation to 
time 0 (%) 
 
Sample 
         
Triglycerides  1 148 149 148 150 151 150 149 1.0 1.0 
(mg/dL) 2 48 48 50 50 49 51 50 4.2 3.5 
  
3 105 103 107 107 108 108 106 1.9 2.1 
TC  1 165 167 166 166 166 168 166 0.6 0.9 
(mg/dL) 2 125 124 124 127 126 126 127 0.8 1.1 
  
3 63 62 62 62 63 63 63 0.8 0.8 
HDL  1 31 32 31 32 31 31 33 1.6 2.2 
(mg/dL) 2 33 33 32 34 33 34 34 3.0 2.0 
  
3 12 12 12 11 12 11 11 4.2 4.2 
LDL  1 101 100 103 99 103 102 103 2.0 1.7 
(mg/dL) 2 77 75 75 74 77 76 77 1.9 1.7 
  
3 29 29 30 29 30 30 30 3.4 2.3 
Lp(a)  1 62 58 64 59 60 60 61 3.2 3.8 
(mg/L) 2 62 58 60 59 63 60 62 3.2 3.2 
  
3 459 480 461 486 474 468 459 2.6 2.7 
Apo A-1 1 1.37 1.4 1.39 1.39 1.38 1.39 1.4 1.5 1.6 
(g/L) 2 0.82 0.86 0.85 0.8 0.79 0.85 0.84 3.7 3.5 
 
3 2 2.03 1.99 2.03 1.98 1.99 2.03 1.3 1.1 
Apo B 1 0.35 0.34 0.35 0.37 0.35 0.35 0.36 1.4 1.9 
(g/L) 2 0.95 0.98 0.97 0.97 0.97 0.96 0.95 2.1 1.8 
 
3 0.88 0.9 0.89 0.91 0.88 0.87 0.87 1.1 1.5 
 
          
Apo:Apolipoprotein, HDL:High density lipoprotein cholesterol, LDL:Low density lipoprotein cholesterol, 
Lp(a):Lipoprotein(a), TC:Total cholesterol. 
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F Leptin and insulin determination 
 
Leptin 
Leptin concentrations were measured with an enzyme-linked immunosorbent assay kit 
(RayBio® Human Leptin ELISA Kit, RayBiotech Inc., Norcross, GA, USA) according to the 
manufacturer´s instructions and reagents using a sample volume of 100 µL serum. A Thermo 
Scientic Multiskan® EX (Hucoa Erlöss S.A., Madrid, Spain) was used as microplate 
photometer at a wave length of 450 nm. The sensitivity of the leptin assay was 6 pg/mL. The 
intraassay CV was <10% and the interassay CV <12%.  
 
Insulin 
Insulin concentrations were measured by a solid-phase two-site chemiluminescent 
immunometric assay with an Immulite 2000 analyzer (DPC Biermann GmbH, Bad Nauheim, 
Germany) using the manufacturer’s reagents and instructions. A total amount of 100 µL 
heparin plasma was needed for analysis. The sensitivity of the insulin assay was 2 mLU/L. 
The interassay CV was 5.2%. 
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3.4 Statistics, Evaluation Procedures and Lipid Calculations 
 
A Statistics 
 
Generally, data analysis was performed using Statistical Package for Social Sciences (SPSS) 
version 17.0 for Windows (SPSS Inc., Chicago, Illinois, USA) and p values <0.05 were 
considered as statistically significant. 
However, for the different topics of the chapters specific statistical methods were applied. 
Thus, in terms of simplification these specific methods are described within each chapter. 
 
 
B Evaluation procedures 
 
Within each chapter several non-communicable (i.e. age and maturity) and communicable 
(i.e. BMI, BF, and FFM) factors were determined and grouped. The specific classifications 
are listed below. 
 
Age 
To assess the influence of age, adolescents were stratified into four gender-specific age 
groups ranging from 12.5-13.99, 14-14.99, 15-15.99, and 16-17.49 years, respectively. A 
weighting factor was calculated in order to adjust the theoretical sampling to the observed 
sample in function of age and gender. 
 
Maturity 
Graduation into five stages of maturity ranging from no development (Tanner stage I) to 
complete development (Tanner stage V) was made using the method described by Tanner and 
Whitehouse [4]. If maturity revealed different results, when assessing gonads/ breasts and 
pubic hair, the higher grade was chosen. 
 
Body mass index 
Body mass index (weight [kg] divided by height [m] squared) categories were based on age- 
and sex-specific cut-off points created by Cole et al. [9, 10]. The BMI cut-off points 
correspond to adult cut-offs for underweight (≤18.5 kg/m²), normal weight (18.5-25 kg/m²), 
overweight (25-30 kg/m²), and obesity (>30 kg/m²).  
General Methodology 
 38 
Percentage body fat 
Percentage BF was calculated using the formula of Slaughter et al. [11]. For girls, BF equals 
0.61*(triceps+calf)+5.1, and for boys BF equals 0.735*(triceps+calf)+1. Normal BF 
correspond to <25% for boys and <35% for girls. High BF was defined as ≥25% for boys and 
≥35% for girls [12].  
 
Fat free mass 
Fat free mass according to BIA measurements were expressed as quartiles for boys and girls. 
More precisely, the FFM quartiles (25th, 50th, and 75th) were 38.5, 41.0, and 44.4 kg for girls, 
and 46.0, 52.0, and 57.8 kg for boys.  
 
 
C Lipid Calculations 
 
The calculations and estimations of lipid and lipoprotein ratios, FA families and FA ratios, 
which are used in the corresponding chapters, are summarized in the tables below. 
 
Lipid and lipoprotein ratios 
 
Table 3.6: Lipid and lipoprotein ratios based on the corresponding measurements. 
Name/Abbreviation Calculation 
Apo B/Apo A-1 ratio Apo B/Apo A-1 
Apo B/LDL ratio Apo B/LDL*100 
Atherogenic Index (TC-HDL)*Apo B/(HDL*Apo A-1) 
LDL/HDL ratio LDL/HDL 
nonHDLC TC-HDL 
nonHDLC/HDL ratio nonHDLC/HDL 
TC/HDL ratio TC/HDL 
TG/HDL ratio TG/HDL 
  
Apo:Apolipoprotein, HDL:High density lipoprotein cholesterol, LDL:Low density lipoprotein cholesterol, 
nonHDLC:Non high density lipoprotein cholesterol, TC:total cholesterol, TG:Triglycerides. 
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Fatty acid ratios 
 
Table 3.7: Fatty acid ratios based on the corresponding measurements.  
Fatty acid ratio Calculation* 
AA/LA C20:4ω6c/C18:2ω6c 
(DHGLA+AA)/LA (C20:3ω6c+C20:4ω6c)/C18:2ω6c 
EPA/ALA C20:5ω3c/C18:3ω3c 
AA/EPA C20:4ω6c/C20:5ω3c 
DHA/EPA C22:6ω3c/C20:5ω3c 
LA/ALA C18:2ω6c/C18:3ω3c 
AA/(EPA+DHA) C20:4ω6c/(C20:5ω3c+C22:6ω3c) 
 
ω6/ω3  
 
cCcCcCcCc
cCcCcCcCcCtc
36:2235:2235:2034:1833:C18
62:2264:2063:2062:2063:1862:C18
ωωωωω
ωωωωωω
++++
++ +++&
 
 
Polyunsaturates/Saturates 
 
0:C240:C230:C220:C210:C200:C180:C170:C160:C14 0:C12
3:C2036:2235:2235:2034:1833:C18      
62:2264:2063:2062:2063:1862:C18
+++++++++
9+++++
+++ +++&
ccCcCcCcCc
cCcCcCcCcCtc
ωωωωωω
ωωωωωω
 
 
 
Monosaturates/Saturates 
 
0:C240:C230:C220:C210:C200:C180:C170:C160:C14 0:C12
&71:181:C14
+++++++++
1:24 + 91:22 + 91:20+91:18++71:17+71:16+51:15+5 CcCcCcCtcCcCcCcCc ωωωωωωωω
 
  
*Calculations regarding the absolute fatty acid composition and fatty acids expressed as conc% did not include 
C18:1ω7c, C18:1ω7t, C18:4ω3c, C20:3ω9c, and C22:5ω3c. 
 
AA:Arachidonic acid, ALA:α-linolenic acid, EPA:Eicosapentaenoic acid, DHA:Docosahexaneoic acid, 
DHGLA:Dihomo-γ-linolenic acid, LA:Linoleic acid. 
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Fatty acid families 
 
Table 3.8: Fatty acid families based on single fatty acid calculation. 
Name Calculation* 
Saturated fatty acids  ∑ of C12:0, C14:0, C16:0, C17:0, C18:0, C20:0, C21:0, C22:0, C23:0 and C24:0 
Monounsaturated fatty acids 
∑ of C14:1ω5c, C15:1ω5c, C16:1ω7c, C17:1ω7c, C18:1ω7c, 
C18:1ω7t, C18:1ω9c, C20:1ω9c, C20:3ω9c, C22:1ω9c, and 
C24:1ω9c 
Polyunsaturated fatty acids  
∑ of C18:2ω6c, C18:2ω6t, C18:3ω6c, C18:3ω3c, C18:4ω3c, 
C20:2ω6c, C20:3ω9c, C20:3ω6c, C20:4ω6c, C20:5ω3c, 
C22:2ω6c, C22:5ω3c and C22:6ω3c 
Long-chain polyunsaturated fatty acids ∑ of C20:3ω6c, C20:3ω9c, C20:4ω6c, C20:5ω3c, C22:5ω3c, and C22:6ω3c 
trans fatty acids  ∑ of C18:1ω7t and C18:2ω6t 
ω3 fatty acids ∑ of C18:3ω3c, C18:4ω3c, C20:5ω3c, C22:5ω3c, and C22:6ω3c 
ω6 fatty acids  ∑ of C18:2ω6c, C18:2ω6t, C18:3ω6c, C20:2ω6c, C20:3ω6c, C20:4ω6c, and C22:2ω6c 
ω9 fatty acids ∑ of C18:1ω9c, C20:1ω9c, C20:3ω9c, C22:1ω9c, and C24:1ω9c 
  
*Calculations regarding the absolute fatty acid composition and fatty acids expressed in conc% did not include 
C18:1ω7c, C18:1ω7t, C18:4ω3c, C20:3ω9c, and C22:5ω3c. 
 
Fatty acids with the suffix “c” indicate cis, whereas the suffix “t” indicates trans configurations. 
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4 Serum lipid and lipoprotein status in European adolescents                  
- associations with age, gender, maturity, body mass index, and 
percentage body fat  
 
 
Short Summary 
 
Background: Research has confirmed the crucial role of lipids and lipoproteins in the 
development of coronary heart diseases (CHD) and atherosclerosis, which is likely to start in 
childhood and adolescence. However, less is known about communicable (BMI and BF) and 
non-communicable factors (age, gender, and maturity) and their influence on lipids in healthy 
adolescents. Especially for Europe, lipid data is needed to clarify the association of age, 
gender, maturity, BMI, and BF content with growth and development in that particular period 
of life. This information will be conducive to the understanding of lipid patterns in youth. 
Further, the descriptive data may be used as physiological values of adolescents for lipid 
screenings in Europe. 
Objective: To provide a complete lipid and lipoprotein profile of healthy European 
adolescents, analysing the association with age, gender, maturity, BMI, and BF. 
Results: Lipid and lipoprotein parameters were higher in girls than in boys. Maturity was 
related to TC, HDL, apo A-1, and Apo B/LDL in boys and associated with TC, LDL, non 
high density lipoprotein cholesterol (nonHDLC), apo B, and most lipid and lipoprotein ratios 
(Apo B/Apo A-1, TC/HDL, LDL/HDL, nonHDLC/HDL, and the Atherogenic Index [AI]) in 
girls. By contrast, chronological age was only associated with male TG levels and the 
TG/HDL ratio. Body mass index was linked to TG, HDL, nonHDLC, and most lipid and 
lipoprotein ratios (Apo B/Apo A-1, TC/HDL, TG/HDL, LDL/HDL, nonHDLC/HDL, and the 
AI) in girls and not related to lipid and lipoprotein parameters in boys. Triglyceride, LDL, 
nonHDLC, and apo B levels as well as nearly all lipid and lipoprotein ratios (Apo B/Apo A-1, 
TC/HDL, TG/HDL, LDL/HDL, nonHDLC/HDL, and the AI) differed significantly between 
male BF groups. These observations were not present in girls. Further, reference data using 
percentiles (2.5th-97.5th) of healthy adolescents excluding smokers, underweight and obese 
subjects are provided. 
Conclusion: The serum lipid profile of European adolescents depends more on gender, 
maturity, and body fat/ body weight status than on chronological age. The present normal 
values of apparently healthy European adolescents may be used for clinical use. 
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Introduction 
 
Autopsy studies strongly indicated that the origin of artherosclerosis is located in early 
childhood and adolescence: fatty streaks are already present in early age and may progress to 
fibrous plaques after the second decade of life. The main determinants of plaque formation are 
smoking, hypertension, age, gender, race/ ethnicity and apo B-containing lipids [1-7]. 
Moreover, blood lipid concentrations (e.g. TG, TC, LDL, and HDL) and calculations of lipid 
and lipoprotein ratios such as TC/HDL, LDL/HDL, and TG/HDL can be used to assess the 
individual atherogenic risk [8-13]. 
The evaluation of blood lipid profiles in adolescence uses reference data of the American 
NCEP for children and adolescents [14]. For two reasons they might lead to wrong 
conclusions when applying them to healthy European adolescents. First of all, the data is 
based on examinations of children and adolescents from families with hypercholesterolemia 
or premature cardiovascular disease, thus the subjects might not be healthy because of the 
familial predisposition. Secondly, the reference data was defined in the 1980s and is 
addressed to the American adolescent population.  
Furthermore, our knowledge of lipid profiles of children and adolescents is mostly based on 
European and non-European studies examining the lipid status in already diseased subjects, 
e.g. children with obesity or diabetes [13, 15-23]. Data available for healthy adolescents are 
mainly coming from surveys in America [24-26]. In Europe, only one Spanish study, based 
on five representative cities, examined healthy adolescents to present a reference lipid profile. 
This AVENA Study presented age- and sex-specific lipid and lipoprotein profiles of 581 
adolescents aged 13 to 18.5 years [27]. However, reliable reference data considering the 
impact of growth, alterations in body composition and grade of puberty on lipid profiles in 
adolescence is lacking for Europe. Moreover, different methodological and analytical 
approaches have been used in these mentioned studies, which make comparisons on a global 
level difficult. Consequently, an objective evaluation of early atherogenic risks in children 
and adolescents living in Europe is not feasible. The alternative use of risk scores provided by 
NCEP may under- or overestimate individual risks in European adolescents. 
Thus, reliable reference data for Europe should be assessed on the basis of examinations of 
apparently healthy European adolescents, considering communicable and non-communicable 
factors as well as being up-to-date.  
The aim of the present study was, thus, to assess a detailed lipid profile of a healthy European 
adolescent population considering age, gender, sexual maturation, BMI, and percentage BF 
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applying harmonized methodology and analytics. The data representation will also include 
percentiles (2.5th-97.5th) as well as lipid and lipoprotein ratios, which may be used as a 
standard for European adolescents.  
 
 
Subjects and Methods  
 
A detailed description of study design, subject recruitment, medical examination, blood 
sampling, sample treatment, biochemical analysis, and evaluation procedures can be found in 
chapter 3 (General Methodology). 
 
Statistics  
Numeric values are shown as mean±SD. Percentiles (2.5th-97.5th) were calculated to obtain 
reference data of healthy European adolescents excluding smokers, underweight and obese 
subjects. Blood analytes (dependent variables) were skewed and logarithmically 
transformated before statistical analysis. Differences in the main study characteristics of boys 
and girls were analysed using independent t-test (metric variables) and chi square test 
(categorical variables). Age, sexual maturation, BMI, and BF were grouped and defined as 
independent variables. For each of the dependent variables, a univariate analysis of variance 
(ANOVA) was used to analyse the associations with the independent variables. The 
Bonferroni post-hoc tests were used for sub-group analyses. All statistics were made 
separately for boys and girls. A p-value of <0.05 was considered as statistically significant 
and data analysis was performed by using Statistical Package for Social Sciences version 17.0 
for Windows (SPSS Inc., Chicago, Illinois, USA).  
To assure optimal validity of the results, a post hoc analysis for achieved power was 
conducted exemplarily with logarithmically transformated data for independent t-tests with a 
two-tailed significance of p=0.05 using GPower® version 3.0.10 [28]. The achieved power 
was >99% for all lipid parameters except for TG and Lp(a) with a power of 46% and 65%. 
 
 
Results 
 
The HELENA-CSS consisted of 1,097 adolescent subjects with blood measurements 
including complete data about basic characteristics (e.g. BMI and age). A total number of 
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1,084 blood samples was analysed completely for all lipid parameters. Apolipoprotein A-1, 
apo B and Lp(a) levels were determined in 1,056 samples because of sufficient blood volume 
for complete lipid analysis. Table 4.1 presents the basic characteristics of all study 
participants. Tables 4.2a-c show the percentiles (2.5th-97.5th) of the selected study group as 
well as for boys and girls. The present percentiles did not include smokers, underweight and 
obese participants to represent an apparently healthy population. Thus, data of 774 
adolescents (369 boys and 405 girls) is presented in those tables.  
Compared to boys, girls showed higher mean values for all lipid and lipoprotein parameters as 
highlighted in table 4.1. 
With respect to age, there was an increase in TG levels in boys with higher age (p=0.013, 
table 4.3a). This effect was also present in the male TG/HDL ratio (table 4.3b). All other 
parameters remained unaffected by age in both boys and girls (tables 4.3a and 4.3b). 
In boys, pubertal maturation was associated with TC, HDL and apo A-1 levels in a mostly 
inverse manner (table 4.4a). Additionally, Apo B/LDL increased slightly in the final stages of 
maturity (table 4.4b). By contrast, maturity was associated with TC, LDL, nonHDLC, and apo 
B levels without clear increasing/ decreasing tendency in girls (table 4.4a). Further, most 
female lipid and lipoprotein ratios (Apo B/Apo A-1, TC/HDL, LDL/HDL, nonHDLC/HDL, 
and the AI) increased between Tanner stage IV and V (table 4.4b).  
Body mass index was associated with serum lipids and lipoproteins levels only in girls (table 
4.5a). Girls tended to increase TG, nonHDLC and all of the risk indices except for Apo 
B/LDL, and tended to decrease HDL levels with higher BMI (tables 4.5a and 4.5b).  
The results according to the assessment of percentage BF showed a different pattern. 
Significantly higher TG, LDL, and nonHDLC levels as well as lower HDL levels were found 
in boys with higher BF (table 4.5a). Additionally, all lipid and lipoprotein ratios showed 
higher values in the high BF group except for Apo B/LDL (table 4.5b). In girls, no 
relationship was observed between lipid parameters and BF content (tables 4.5a and 4.5b). 
 
 
Discussion 
 
With respect to gender, the most striking results were higher values in girls within each of the 
lipid variables analysed (table 4.1). This result is in accordance with findings in a Turkish 
study cohort of 2,896 schoolchildren aged 7-18 years [29]. In the Spanish AVENA Study 
(n=581, age 13-18.5 years), however, girls had only significantly higher HDL and TC levels 
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(p<0.05), whereas LDL, TG, nonHDLC, Lp(a), apo A-1, and apo B levels remained 
unaffected by gender [27]. In a Mexican study (1,076 girls and 770 boys, mean age 13.2±1 
years), lipid parameters were increased in girls except for HDL [30]. These inconsistent 
results may be due to genetic variations and/ or different eating behaviours in Spain, Turkey, 
and Mexico. In the HELENA project because of the multinational design such effects are 
minimized. Moreover, different age categorizations may contribute to the different results, 
because with increasing age the influence of sex hormones becomes more obvious and is 
mirrored in altered lipid levels between sexes [31]. The absolute lipid concentrations of the 
present study showed some differences compared to the other study results. In HELENA, 
male participants had the lowest TG levels (65 mg/dL) compared to their Turkish and 
Mexican (88 mg/dL), and Spanish (73 mg/dL) counterparts. By contrast, the TG levels of the 
present European girls (73 mg/dL) lay in between the concentrations of Spanish (66 mg/dL), 
Turkish (82 mg/dL), and Mexican (97 mg/dL) girls. Further, Mexican adolescents had lower 
HDL values (♂=44 mg/dL; ♀=45 mg/dL) and lower TC levels (♂=150 mg/dL; ♀=156 
mg/dL) compared to the HELENA participants (HDL: ♂=53 mg/dL, ♀=57 mg/dL; TC: 
♂=154 mg/dL, ♀=167 mg/dL). No gender-specific differences in the lipid and lipoprotein 
ratios were found in other studies [27, 30]. In HELENA, the mean TG/HDL ratio was 
significantly higher in girls versus boys (p=0.01), whereas the other ratios (Apo B/Apo A-1, 
TC/HDL, LDL/HDL, Apo B/LDL, nonHDLC/HDL, and the AI) did not differ (data not 
shown). These results showed that, although girls had higher lipid concentrations, the 
proportions between those serum lipids and lipoproteins (expressed as ratio) are equal 
between European boys and girls (except for TG/HDL).  
In the present study, age was only associated with TG levels in males (table 4.3a). The 
increase over age may reflect changes in eating habits during growth. For instance, an 
increased carbohydrate consumption induces an elevation of the serum TG levels. The TG 
increase over age was also found in most [29, 32, 33] but not all [27] studies. For example, 
serum TG levels of male Tehranian adolescents were higher in 17-19 year-olds compared to 
11-13 year-olds including higher concentrations than in the HELENA Study (124 mg/dL vs 
73 mg/dL) [32]. In contrast to the present results, most studies found also age-dependent 
changes within the other lipids for boys and girls [27, 29, 32, 33]. In HELENA, the 
association of TG levels with age in boys was mirrored in the TG/HDL ratio as well. All other 
ratios remained unaffected by age in both sexes (table 4.3b). These results are similar to the 
AVENA Study except for a decrease of LDL/HDL between 14 and 15 year-old Spanish girls 
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[27]. Thus, the proportions between serum lipids (expressed as ratios) are hardly associated 
with age in European adolescents. 
However, it is likely that the age-associated findings in the studies mentioned before are 
related to pubertal progression, because the chronological development of individuals 
expressed by age mirrors partly the biological development. Indeed, age is an inappropriate 
marker for biological development and it is known that sexual maturation due to changes in 
sex hormones influences the lipid profile of adolescents [31, 34, 35]. These facts support the 
use of pubertal stages instead of age categories to investigate the influence of biological 
development in adolescence. In HELENA, boys showed decreased TC levels likely due to a 
decrease in HDL levels accompanied by apo A-1 alterations during puberty, whereas in girls 
TC, LDL, nonHDLC, and apo B levels were related to the grade of maturity (table 4.4a). 
Studies showed inconsistent findings probably due to sample size, classification of maturity, 
and geographic differences based on different genetic backgrounds, food patterns and 
lifestyles [15, 21, 36-38]. This should be kept in mind when comparing different study results. 
Lower HDL levels with advancing pubertal stages are in accordance with data from white 
boys of the Bogalusa Heart Study [38] and study results of Güven and Sanisoglu [15]. Güven 
and Sanisoglu measured the serum lipid profile with respect to pubertal progression in 182 
obese girls and 158 obese boys aged 3.6-17.8 years. Sexual maturity was stratified into 
prepuberty, early puberty, mid-puberty, and late puberty. High density lipoprotein cholesterol 
was lower in late pubertal boys compared to pre- and early pubertal boys. By contrast, LDL 
gradually decreased parallel with pubertal progression in girls [15]. The study population 
based on obese subjects only, thus comparisons with the present study population should be 
made with caution and an influence of sex hormones on adipose tissue should be taken into 
account. In fact, a decrease of HDL in boys is seen as a consequence of higher testosterone 
levels compared to girls leading to a reduction of apolipoproteins associated with HDL [34]. 
Most studies did not evaluate lipid and lipoprotein ratios related to sexual maturity [21, 36-
38]. In girls, there was an increament between Tanner stage IV and V for most lipid and 
lipoprotein ratios (Apo B/Apo A-1, TC/HDL, LDL/HDL, nonHDLC/HDL, and the AI), 
which was not apparent in males (table 4.4b). The gender-specific differences may be directly 
related to hormonal status, fat mass and/ or fat allocation. However, the measurement of sex 
hormones was not feasible. Thus, a direct relationship between hormones and lipids could not 
be investigated within the HELENA Study.  
Beside the BMI status, percentage BF content was related to serum lipid status. The most 
striking finding was that female lipid parameters were associated with BMI alone, whereas 
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male serum lipids were related to BF content only (table 4.5a). More precisely, higher lipid 
and lipoprotein ratios (Apo B/Apo A-1, TC/HDL, TG/HDL, LDL/HDL, nonHDLC/HDL, and 
the AI) were observed in boys with high BF (≥25%), whereas in girls those ratios were 
increased with higher BMI status. Generally, these findings indicate that higher fat/ weight 
status is associated with a more unfavourable lipid profile and an increased atherogenic risk. 
It is not clear why male lipid levels are associated with BF content alone, whereas lipid 
parameters of girls are related solely to BMI status. Differences may be obtained due to the 
assessment methods. Fat allocation is different between boys and girls and this may be 
reflected in the different skinfold measurements. It may also be possible that the sub-group 
classification (two BF sub-groups vs. four BMI sub-groups) with different group sizes results 
in altered findings.  
A French study by Klein-Platat et al. [39] found higher TG levels of 0.98 mmol/L (approx. 87 
mg/dL) in 12 year-old overweight adolescents (n=60, BMI=23.3±0.3) compared to their 
normal weight counterparts with TG levels of 0.80 mmol/L (approx. 71 mg/dL; n=60, BMI 
17.4±0.3), whereas HDL did not differ between obese (1.09 mmol/L; approx. 42 mg/dL) and 
normal weight (1.30 mmol/L; approx. 50 mg/dL) subjects. Body mass index and BF differed 
significantly between the groups, but only BMI was used for associations. In the present male 
subjects, HDL values were also not significantly altered with respect to BMI status. By 
contrast, lower HDL levels were observed in boys with higher BF; this effect was not 
investigated in the French study. The association between lipids and BMI status was observed 
in the French study group with both genders, thus gender-specific differences as observed in 
the present study might have disappeared [39]. A Swedish study (n=25) in obese (median age 
12.0 years, median BMI 30.7 kg/m²) and non-obese (median age 12.6 years, median BMI 19.5 
kg/m²) adolescents found no association with BMI except for lower HDL levels in obese girls. 
These results are not in accordance with the present findings; however, the results of the 
Swedish study may be limited because of the group size (5-9 subjects per group) [40]. In the 
Mexican study, the prevalence of different forms of dyslipidemia were significantly higher in 
obese and overweight than in normal weight boys and girls [30]. This supports the assumption 
that higher weight status leads to altered, unfavourable lipid profiles at younger ages. With 
respect to weight status, lipid and lipoprotein ratios showed the same pattern as observed for 
lipid parameters.  
Beside gender, pubertal development and BF/ weight status are associated with changes in the 
adolescent lipid profile as seen in the HELENA Study as well as found by others [27, 29, 30, 
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32, 37-40]. These results suggest a strong association between those factors (i.e. gender, 
maturity, BMI, and BF) and serum lipid profiles during growth and development. 
A few limitations of the present study deserve comment. Because of the CSS design, the 
temporal relationships are unknown; we cannot say anything about causality of the 
relationships. 
The discussion about reference values for a healthy adolescent population and its application 
for lipid screening and prevention strategies is ongoing and the question, which percentiles/ 
cut-offs should be used, is not answered sufficiently yet. Moreover, it is still discussible how 
to develop reliable reference values for lipids in adolescence. However, within the HELENA 
study design it was not realizable to create reference values per se. Nonetheless, the data 
presented here is proposed to be used as physiological values of apparently healthy European 
adolescents for comparing the serum lipid profile in various disease conditions.  
Additionally, a look at approaches of former reference data may be helpful to survey the 
present approach. The NCEP published blood cholesterol cut-offs for children and 
adolescents in 1992 [14]. In the age range of 2-19 years, TC was defined as high ≥200 mg/dL 
and normal <170 mg/dL. The lipoprotein levels of LDL and HDL were set as normal <110 
mg/dL and >60 mg/dL, whereas high/ low levels were determined at ≥130 and ≤35 mg/dL. 
High TG levels were defined as ≥130 mg/dL and normal levels <90 mg/dL in the age range of 
10-19 years. These cut-offs are based on the 75th percentile for normal levels and the 95th 
percentile for high levels, and for HDL on the 25th and 5th percentile, respectively. This 
approach has some limitations. These selected percentiles are fixed for an age range between 
2 to 19 years, and the HELENA results showed fluctuations in the lipid and lipoprotein levels 
due to maturity, which make it reasonable to adapt the cut-offs to specific pubertal stages, or 
at least, but more inaccurate, to age categories. The selected percentiles are completely 
arbitrary. Further, the lipid screening of the American referent population was made in the 
early 1980s, but lifestyle and eating habits have changed. The reference data is based on data 
from children and adolescents from families with hypercholesterolemia or premature 
cardiovascular disease, and thus not applicable to a healthy population. Jolliffe and Janssen 
published age-specific lipid and lipoprotein thresholds for adolescents in 2008 [26]. They 
used data of an adolescent population (n=6,067) of the National Health and Nutrition 
Examination Surveys (NHANES) measured between 1988 and 2002. Their new approach was 
to create growth curves with the Lambda-Mu-Sigma method. They adapted the NCEP cut-
offs for adults at age 20 and applied those particular percentiles to the age range of 12-20 
year-old boys and girls. For example, 150 mg/dL is the borderline-high cut-off for TG in 
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adults defined by NCEP, which is equivalent to the 89th percentile at 20 years of age (entry 
into adulthood). This 89th percentile was then used to create the age-specific threshold for 
borderline-high TG at each age [41]. This approach is still discussible, because the risk factors 
of adults are not applicable to youth. Furthermore, the data measurement is based on a quite 
large period (1988-2002). How to overcome this problematic is not solved yet. The use of the 
75th and 95th percentiles, 5th and 25th percentile in the case of HDL, by NCEP is very common 
and established.  
However, a comparison of the American data with the present European data may identify 
possible differences in the absolute lipid values. Most American studies used NHANES data 
to present percentiles for concentrations of lipids and lipoproteins [25, 26, 41]. Ford et al. [25] 
used current NHANES data from 1999 to 2006. The 75th percentile of LDL was 104 mg/dL in 
1,324 girls and 1,400 boys aged 12-17 years and the 95th percentile was 133 and 136 mg/dL in 
girls and boys. This is quite similar to the HELENA population; only the girls had 
approximately 10 mg/dL higher values in the 75th and 95th percentile (table 4.2c). The TC 
levels of 3,167 boys and 3,108 girls were 174/178 mg/dL in the 75th percentile and 212/214 
mg/dL in the 95th percentile. The HELENA girls are in the same range (75th percentile 185 
mg/dL and 95th percentile 214 mg/dL), whereas the boys have lower levels of 168 (75th 
percentile) and 198 (95th percentile) mg/dL. Kwiterovich took data from the Lipid Research 
Population Studies including 11,219 white subjects [24]. He used the mean, the 5th and the 
95th percentile to categorize the population. The lipid profile of the 15-19 years-olds (1,980 
males and 2,079 females), based on the selected percentiles (5th and 95th), differed somewhat 
compared to the current European population. Girls of the HELENA Study had 11 mg/dL 
higher TC levels in the 95th percentile. The male TG levels showed a decline of 11 mg/dL in 
the 5th percentile and a decline of 36 mg/dL in the 95th percentile compared with the 
American counterparts. The lipoprotein measurements of HDL and LDL were based on 300 
male and 297 female Americans. The LDL and HDL levels were slightly different between 
the two study groups. The HDL levels of the male HELENA participants were 8-9 mg/dL 
higher in both percentiles, whereas female levels were 3-5 mg/dL higher compared to the 
American levels. The male LDL levels of the European group were 5 mg/dL lower in the 5th 
percentile, but nearly similar (3 mg/dL higher) in the 95th percentile. The present European 
girls showed higher LDL values in the 95th percentile of 143 mg/dL vs. 137 mg/dL in the 
American female group. Kwiterovich recommended the same lipid and lipoprotein cut-offs 
for adolescents as the NCEP, except for HDL. He defined normal levels of HDL by >45 
mg/dL instead of >60 mg/dL as proposed by the NCEP.  
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There are some differences in the lipid concentrations with respect to the selected studies, 
which may reflect differences between American and European lifestyle habits and may be 
further dependent on the date of assessment. But the specific percentiles (75th/ 95th for TC, 
TG, LDL and 25th/ 5th for HDL) are established in the literature, although they are arbitrary 
and not connected to any risk factor. However, risk factors are difficult to determine in an 
apparently healthy adolescent population. Thus, those percentiles seem also to be appropriate 
to select borderline and high/ low lipid and lipoprotein concentrations within the reference 
profile of the present European adolescents. 
 
 
Conclusion 
 
The current cross-sectional data of an adolescent population of Europe brought some reliable 
insights into the relationship of lipids and gender, age, maturity, BMI, and BF. Lipid 
parameters are higher in female than in male European adolescents, thus gender-specific lipid 
research is more appropriate in adolescence. The use of chronological age in adolescence can 
lead to falsified assumptions with regard to growth and development. To avoid this bias, the 
use of biological age is recommended. Higher adipose tissue content, expressed as BMI or 
BF, leads to a more unfavourable lipid pattern. In general, the data suggests a stronger effect 
of sexual maturity, BMI, and BF on adolescents than age or gender alone. The results may be 
used as normal values of European adolescents.  
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Table 4.1: Basic characteristics of the study population as mean (standard deviation). 
 
 
*p values (2-tailed) are based on independent t-test; # based on Chi square test. 
1boys n=448, and girls n=524; 2boys n=495, and girls n=560;  
3boys n=512, and girls n=572; 4boys n= 500, and girls n=556. 
 HDL:High density lipoprotein cholesterol, LDL:Low density lipoprotein cholesterol, nonHDLC: 
 Non high density lipoprotein cholesterol, ns:non significant. 
 
 
 
 
 
 Males Females p value* 
n 513 584  
Age (years) 14.92 (1.25) 14.91 (1.20) ns 
Height (cm) 169.9 (9.9) 161.8 (7.0) 0.000 
Weight (kg) 62.1 (13.9) 56.0 (10.2) 0.000 
Body mass index (kg/m²) 21.4 (3.8) 21.3 (3.4) ns 
Tanner stage1 3.9 (1.0) 4.0 (0.8) 0.006# 
Body fat (%)2 20.9 (10.5) 27.4 (7.6) 0.000 
Triglycerides (mg/dL)3 65 (32) 73 (37) 0.000 
Total cholesterol (mg/dL)3 154 (26) 167 (28) 0.000 
nonHDLC (mg/dL)3 101 (25) 110 (26) 0.000 
HDL (mg/dL)3 53 (10) 57 (11) 0.000 
LDL (mg/dL)3 91 (24) 98 (25) 0.000 
Lipoprotein(a) (mg/L)4 175 (215) 207 (256) 0.027 
Apolipoprotein A-1 (g/L)4 1.45 (0.21) 1.55 (0.23) 0.000 
Apolipoprotein B (g/L)4 0.63 (0.19) 0.68 (0.16) 0.000 
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Table 4.5a: Gender-specific  lipids  and  lipoproteins  as  mean  (standard deviation)  in relation  
      to body mass index and body fat. 
 
Body mass 
index and  
body fat 
n 
TG+ 
(mg/dL) 
TC 
(mg/dL) 
HDL+ 
(mg/dL) 
LDL 
(mg/dL) 
NonHDLC+ 
(mg/dL) 
Lp(a) 
(mg/L) 
Apo A-1 
(g/L) 
Apo B 
(g/L) 
Males 
BMI          
Underweight 26 64 (33) 152 (23) 55 (8) 87 (21) 97 (23) 159 (196) 1.52 (0.17) 0.61 (0.14) 
Normal weight 358/351 a 60 (27) 153 (25) 54 (10) 88 (23) 98 (23) 174 (222) 1.47 (0.21) 0.61 (0.14) 
Overweight 90/87 a 70 (33) 155 (27) 50 (8) 96 (24) 106 (25) 183 (197) 1.40 (0.18) 0.66 (0.15) 
Obesity 38/36 a 96 (46) 163 (32) 47 (9) 104 (30) 116 (32) 176 (199) 1.37 (0.19) 0.71 (0.18) 
Total group 512/500a 65 (32) 154 (26) 53 (10) 91 (24) 101 (25) 176 (216) 1.45 (0.21) 0.63 (0.15) 
p-value*  ns ns ns ns ns ns ns ns 
Body fat          
Normal 361/357 a 61 (27) 152 (24) 54 (10) 88 (22) 98 (22) 174 (226) 1.47 (0.21) 0.61 (0.14) 
High 133/125 a 74 (40) 158 (29) 50 (9) 97 (25) 107 (27) 175 (181) 1.42 (0.20) 0.67 (0.16) 
Total group 494/482 a 64 (31) 154 (25) 53 (10) 90 (23) 100 (24) 175 (215) 1.46 (0.21) 0.62 (0.15) 
p-value*  0.002 ns 0.045 0.049 0.026 ns ns ns 
 
Females 
BMI          
Underweight 33 66 (22) 159 (27) 57 (10)2 91 (26) 102 (25)5 275 (393) 1.56 (0.17) 0.64 (0.16) 
Normal weight 425/414 a 70 (33)1 167 (28) 58 (11)3,4 97 (25) 109 (26) 203 (249) 1.57 (0.22) 0.67 (0.16) 
Overweight 92/88 a 90 (54) 169 (27) 53 (11) 103 (23) 116 (24) 185 (211) 1.51 (0.25) 0.72 (0.15) 
Obesity 22/21 a 74 (27) 164 (27) 48 (10) 105 (24) 116 (25) 280 (279) 1.36 (0.26) 0.75 (0.16) 
Total group 572/556 a 74 (38) 167 (28) 57 (11) 98 (25) 110 (26) 203 (244) 1.55 (0.23) 0.68 (0.16) 
p-value*  0.001 ns 0.000 ns 0.024 ns ns ns 
Body fat          
Normal 460/454 a 73 (38) 167 (28) 58 (11) 97 (25) 109 (25) 209 (260) 1.56 (0.22) 0.67 (0.16) 
High 88/79 a 73 (33) 166 (28) 53 (11) 102 (24) 113 (26) 213 (246) 1.47 (0.28) 0.70 (0.16) 
Total group 548/533 a 73 (38) 166 (28) 57 (11) 98 (25) 109 (26) 210 (258) 1.55 (0.23) 0.68 (0.16) 
p-value*  ns ns ns ns ns ns ns ns 
       
 
*Based on the ANOVA F-Test including centre, body mass index or percentage body fat, maturity and age in the model; ns:not significant. 
 +Based on Bonferroni post-hoc tests: 1 p<0.01 compared to overweight;2 p<0.05 compared to obesity; 3 p<0.001 compared to overweight;  
  
4
 p<0.001 compared to obesity; 5 p<0.05 compared to overweight. 
a
 n for Lp(a), apo A-1, and apo B. 
 Apo:Apolipoprotein; BMI:Body mass index; HDL:High density lipoprotein cholesterol; LDL: Low density lipoprotein cholesterol;   
 Lp(a):Lipoprotein(a); NonHDLC:Non high density lipoprotein cholesterol; TC:Total cholesterol; TG:Triglycerides. 
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Table 4.5b: Gender-specific lipid  and lipoprotein ratios  as mean (standard deviation)  in relation 
                     to body mass index and body fat.  
 
Body mass 
index and 
body fat 
Apo B/Apo A-1+ TC/HDL+ TG/HDL+ LDL/HDL+ Apo B/LDL nonHDLC/HDL+ Atherogenic Index+ 
Males 
BMI        
Underweight 0.41 (0.11) 2.81 (0.52) 1.21 (0.65) 1.63 (0.49) 0.72 (0.08) 1.81 (0.52) 0.79 (0.43) 
Normal weight 0.42 (0.12) 2.89 (0.65) 1.19 (0.70) 1.70 (0.63) 0.70 (0.08) 1.89 (0.65) 0.87 (0.64) 
Overweight 0.48 (0.12) 3.17 (0.56) 1.47 (0.87) 1.96 (0.53) 0.70 (0.08) 2.17 (0.56) 1.10 (0.55) 
Obesity 0.53 (0.18) 3.57 (0.97) 2.20 (1.38) 2.31 (0.89) 0.70 (0.08) 2.57 (0.97) 1.49 (1.34) 
Total group 0.44 (0.13) 2.99 (0.70) 1.32 (0.85) 1.80 (0.66) 0.70 (0.08) 1.99 (0.70) 0.96 (0.72) 
p-value* ns ns ns ns ns ns ns 
Body fat        
Normal 0.42 (0.12) 2.88 (0.61) 1.19 (0.66) 1.69 (0.60) 0.70 (0.08) 1.88 (0.61) 0.86 (0.61) 
High 0.48 (0.12) 3.21 (0.73) 1.57 (1.09) 1.99 (0.64) 0.70 (0.08) 2.21 (0.73) 1.11 (0.65) 
Total group 0.44 (0.12) 2.97 (0.66) 1.29 (0.82) 1.77 (0.62) 0.70 (0.08) 1.97 (0.66) 0.92 (0.63) 
p-value* 0.022 0.003 0.001 0.008 ns 0.003 0.007 
        
Females 
BMI        
Underweight 0.41 (0.11)1,2 2.83 (0.58)2,3 1.18 (0.44)1 1.64 (0.59)2,3 0.72 (0.08) 1.83 (0.58)2,3 0.81 (0.48)2,3 
Normal weight 0.44 (0.12)2,3, 2.94 (0.59)2,4 1.28 (0.77)4,5 1.73 (0.56)2,4 0.70 (0.08) 1.94 (0.59)2,4 0.90 (0.52)2,4 
Overweight 0.49 (0.12) 3.25 (0.62) 1.80 (1.36) 2.00 (0.58) 0.72 (0.08) 2.25 (0.62) 1.16 (0.66) 
Obesity 0.57 (0.18) 3.53 (0.89) 1.64 (0.81) 2.30 (0.83) 0.72 (0.08) 2.53 (0.89) 1.59 (1.15) 
Total group 0.45 (0.13) 3.01 (0.63) 1.38 (0.92) 1.80 (0.59) 0.70 (0.08) 2.01 (0.63) 0.97 (0.60) 
p-value* 0.007 0.000 0.000 0.002 ns 0.000 0.001 
Body fat        
Normal 0.44 (0.12) 2.95 (0.58) 1.35 (0.92) 1.74 (0.55) 0.70 (0.08) 1.95 (0.58) 0.92 (0.52) 
High 0.49 (0.15) 3.23 (0.78) 1.48 (0.88) 2.01 (0.72) 0.70 (0.05) 2.23 (0.78) 1.18 (0.88) 
Total group 0.45 (0.12) 3.00 (0.63) 1.37 (0.91) 1.78 (0.59) 0.70 (0.08) 2.00 (0.63) 0.96 (0.60) 
p-value* ns ns ns ns ns ns ns 
     
 
*Based on the ANOVA F-Test including centre, body mass index or percentage body fat, maturity and age in the model; ns:not significant.  
 +Based on Bonferroni post-hoc tests: 1 p<0.05 compared to overweight; 2 p<0.01 compared to obesity, 3 p<0.01 compared to overweight; 
                
4
 p<0.001 compared to overweight; 5 p<0.05 compared to obesity. 
 Apo:Apolipoprotein; BMI:Body mass index; HDL:High density lipoprotein cholesterol; LDL: Low density lipoprotein cholesterol;   
 NonHDLC:Non high density lipoprotein cholesterol; TC:Total cholesterol; TG:Triglycerides. 
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5 Fatty acid status of the serum phospholipid fraction in European 
adolescents – associations with age, gender, maturity, body mass 
index, percentage body fat, and fat free mass 
 
Short Summary 
 
Background: Fatty acids are involved in many important tasks in physiology including 
modifications of cell membrane fluidity, gene expression, and eicosanoid synthesis, which 
affects inflammatory and immunological processes. Current research is focusing on FA 
patterns of diseased children/ adolescents, which likely show altered FA profiles. Less is 
known about the association of factors like age, gender, maturity, BMI, BF, and FFM with the 
FA composition of serum PL in healthy adolescents. These factors may influence the FA 
composition and consequently growth and development. Further, available and adequate 
reference data for the adolescent age group are an essential condition for the diagnosis of an 
altered FA status and the monitoring of a therapeutic intervention, but limited until now. 
Objective: To investigate the association of age, gender, maturity, BMI, BF, and FFM with 
the serum FA composition of PL in a large European adolescent study population.  
Results: The study population consisted of 1,026 adolescents aged 12.5-17.49 years. The FA 
profile (conc%) indicated differences for C16:1ω7c, C17:1ω7c, C18:1ω9c, C20:0, C20:3ω6c, 
C21:0, C23:0 C22:6ω3c, C24:1ω9c, ω3 FA, and ω9 FA between girls and boys. Changes in 
FA were associated with sexual maturation (C17:1ω7c, C18:3ω3c, C20:1ω9c, C20:2ω6c, 
C20:5ω3c, C22:1ω9c, and ω9 FA), age (C14:1ω5c, C18:0, C18:3ω6c, C20:2 ω6c, C23:0, and 
SFA), FFM (C16:0, C17:0, C18:2ω6c, C20:2ω6c, C20:4ω6c, C23:0, SFA, PUFA, and ω6 
FA), and BF content (C24:1ω9c and trans FA) in boys. In girls, FA changes were related to 
sexual maturation (C17:1ω7c, C20:0, C21:0, C22:1ω9c, and C24:1ω9c), age (C16:0, C18:0, 
PUFA, trans FA, and ω3 FA), BMI (C18:2ω6c, C18:1ω9c, C21:0, and trans FA), and FFM 
(C18:0). The absolute FA composition (µmol/L) showed an altered pattern. Nearly all 
individual FA concentrations except for C15:1ω5c, C17:1ω7c, C18:1ω9c, C18:3ω6c, 
C20:3ω6c, and C20:5ω3c were higher in girls than in boys. 
Conclusion: The presented FA profile may be used as a European standard. Further effort in 
the establishment and use of absolute FA values must be made. Gender differences should be 
considered and age, maturity, BMI, BF and FFM do affect serum FA profiles.  
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Introduction 
 
Serum FA reflect the dietary FA intake as well as endogenous FA metabolism. Fatty acids are 
incorporated into PL and perform a variety of different tasks including the modification of 
cell membrane fluidity, and thus influencing pinocytosis, ion channel modulation, and 
membrane-associated receptor activities. Fatty acids can regulate gene expression as a result 
of the interaction with transcription factors as specific and non-specific ligands [1]. Moreover, 
FA modulate inflammatory and immunological processes due to the provision of precursors 
for eicosanoids (i.e. thromboxanes, leukotrienes, prostaglandins, and prostacyclins) in an ω3 
and ω6 FA-dependent manner [2].  
The metabolic situation of the last few days is reflected best by the FA pattern of serum PL 
[3, 4] because of the slower metabolic turnover of PL compared to other blood lipid classes 
(e.g. cholesteryl esters, TG or free FA) [5]. Thus, serum FA of the PL fraction are suitable in 
documenting the short-term FA status in humans [6].  
Westernized eating habits do not meet the current fat recommendations and thus lead to an 
inadequate dietary fat supply. This fat supply is characterized by higher consumptions of 
SFA, trans FA, a decreased intake of α-linolenic acid (C18:3ω3; ALA), and an increased 
dietary intake of linoleic acid (C18:2ω6; LA) [7, 8]. This dietary fat supply reflects an 
unfavourable FA composition and will also be present in the serum FA profile assuming 
disadvantages for a normal growth and development in adolescence. This unfavourable FA 
composition may also contribute to the development of several diseases affecting today’s 
civilizations. This implies atherosclerosis and CHD [2, 9-20] in adults as well as obesity [21-
23], diabetes [24, 25], and the metabolic syndrome [26] in youth. 
However, evaluating the risk or risk factors of a healthy adolescent population with respect to 
the FA profile is quite difficult. In a former step, the evaluation of factors that are 
physiologically more important in adolescence should be implied. This includes gender, age, 
sexual maturation, BMI, BF, and FFM. The assessment would clarify, which factors influence 
the FA profile in apparently healthy adolescents; however, this approach is still not 
sufficiently investigated. Further, Decsi and Koletzko [27] mentioned the importance of 
having available and adequate reference data from a healthy population for the adolescent age 
group as essential condition for the diagnosis of an altered FA status and the monitoring of a 
therapeutic intervention. But their data is based on a quite large age group (0-26 years) and a 
relative small sample size (n=115). 
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Generally, FA compositions are widely expressed as relative percentages but it may be less 
accurate than absolute concentrations. For instance, the relative percentage of total FA with 
high levels of non-essential FA may lead to a falsely decreased percentage of essential FA. 
Thus, the essential FA profile could be described inaccurately and important information may 
be unrecognized [28, 29]. 
Therefore, in the frame of this project the FA profiles were associated with age, gender, 
sexual maturity, BMI, BF, and FFM. Further, the HELENA Study assessed both the FA 
profile expressed as absolute concentrations and as percentages of the FA concentrations.  
 
 
Subjects and Methods  
 
A detailed description of study design, subject recruitment, medical examination, blood 
sampling, sample treatment, biochemical analysis, and evaluation procedures can be found in 
chapter 3 (General Methodology). 
 
Statistics 
Numeric values are shown as mean±SD. Percentiles (5th-95th) were calculated to obtain 
reference standards of healthy European adolescents excluding smokers, underweight and 
obese subjects. Differences in the main study characteristics of boys and girls were analysed 
using independent t-tests (metric variables) and chi square test (categorical variables). 
Comparison between individual FA in area% and conc% were made using paired t-tests. 
Blood analytes (dependent variables) were skewed and logarithmically transformated before 
statistical analysis. All statistics were performed separately for boys and girls. Age, sexual 
maturation, FFM, BMI and BF were determined as independent variables and grouped. 
Further, insulin and leptin were used as covariates in the following model. For each of the 
dependent variables (FA), a univariate analysis of covariance (ANCOVA) was used to 
analyse the association with the independent variables. The Bonferroni post-hoc tests were 
used for sub-group analyses. Data analysis was performed by using Statistical Package for 
Social Sciences version 17.0 for Windows (SPSS Inc., Chicago, Illinois, USA) and p values 
<0.05 were considered as statistically significant. 
To test for the current power of the results, a post hoc analysis for achieved power was 
conducted exemplarily with logarithmically transformated data of selected FA concentrations 
(i.e. LA, arachidonic acid [AA], oleic acid, ALA, eicosapentaenoic acid [EPA], 
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docosahexaenoic acid [DHA]) for independent t-tests with a two-tailed significance of p=0.05 
using GPower® version 3.0.10 [30]. The achieved power was >98% for LA, AA, and DHA, 
whereas ALA reached 84%, oleic acid 21%, and EPA 12%.  
 
 
Results 
 
The HELENA-CSS consisted of 1,097 adolescent subjects including blood measurements. 
Due to insufficient blood volume for complete analysis, FA data of 73 subjects were missing. 
Thus, 1,024 subjects contributed to the following results. Table 5.1 presents the basic 
characteristics of the study population, whereas tables 5.2a-c show the percentiles (5th-95th) of 
the total population as well as separately for boys and girls. To present percentiles of an 
apparently healthy population, tables 5.2a-c did not include smokers, underweight and obese 
participants. Thus, data of 733 adolescents (349 boys and 384 girls) were included in those 
tables. 
The absolute FA values measured in PL are shown in table 5.3. Table 5.4 presents the FA 
profile in area% and conc% of male and female subjects. After comparing both percentaged 
FA profiles, significant differences were found (all p=0.000, paired t-test; data not shown). 
Thus, for the detailed analyses only the FA in conc% were used. This guaranteed more 
reliable results due to the more precise calculation of the FA profile as well as comparability 
with other studies. 
 
Results of the fatty acid profile expressed as percentage of the concentration (conc%) 
Based on the present FA profile including 33 measured FA, approximately 95% of the FA 
profile was determined by ten FA exceeding ≥1conc% of the total FA, i.e. C16:0, C18:0, 
C18:1ω9c, LA, C20:3ω6c, AA, C22:0, C24:0, DHA and C24:1ω9c. α-linolenic acid and EPA 
were below 1% in the present profile. The trans FA accounted for 0.1conc% for both boys 
and girls. Table 5.4 highlights the complete FA profile according to gender.  
Girls had higher levels of C20:1ω9c, DHA, and ω3 FA, whereas lower levels of ω9 FA 
including C18:1ω9c were found in female profiles compared to male profiles (table 5.4). No 
differences were observed between male and female levels for LA, ALA, EPA, and ω6 FA. 
Table 5.5 presents the FA composition of PL according to age. In boys, single FA accounting 
for <1.0conc% of total FA, i.e. C14:1ω5c, C18:3ω6c, C20:2ω6c, and C23:0 were associated 
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with age. Further, C18:0 and SFA differed within the four age categories. In girls, age was 
associated with C16:0, C18:0, PUFA, ω3 FA and trans FA (table 5.5). 
Sexual maturation was associated with FA in both sexes as can be seen in table 5.6. Single FA 
accounting for <1.0conc% were more often associated with maturation than FA accounting 
for >1.0conc%. In boys, C17:1ω7c, ALA, C20:1ω9c, C20:2ω6c, EPA, and C22:1ω9c showed 
significant differences. Further, ω9 FA were significantly lower in Tanner stage I compared to 
Tanner stages III, IV, and V. In girls, pubertal progression was associated with altered levels 
of C17:1ω7c, C20:0, C21:0, C22:1ω9c, and C24:1ω9c (table 5.6). 
The parameters of body composition (i.e. BMI, BF and FFM) were also associated with 
different FA levels in male and female European adolescents. In boys, C14:0 (p<0.019, F-
test) and C18:0 (p<0.030, F-test) differed between the BMI groups. More precisely, 
underweight boys showed lower C14:0 values than their normal weight and overweight 
counterparts (p<0.05, post hoc test), and C18:0 decreased from underweight to normal weight 
(p=0.020, post hoc test). In girls, BMI was associated with C18:1ω9c, LA, AA, DHA, and 
long-chain PUFA (LCPUFA) (all p<0.05, F-tests). Oleic acid was lower in obese girls 
compared to their normal weight and overweight counterparts (p<0.011 and p<0.013, post hoc 
tests). Further, normal weight girls had higher values of LA compared to overweight and 
obese females (p<0.01 and p<0.05, post hoc tests). Moreover, AA increased significantly 
between normal weight and overweight girls (p=0.002, post hoc test). The LCPUFA status 
(i.e. C20:3ω6c, AA, EPA, and DHA) increased with higher BMI, thus, overweight girls had 
higher levels than underweight and normal weight subjects (p<0.05 and p<0.01, post hoc 
tests). 
Some changes in the male FA profile were observed with respect to percentage BF content. 
More detailed, C18:1ω9c, C22:0, and trans FA were higher in boys with a BF content of 
<25% (p=0.007, p=0.036, and p=0.011, F-tests), whereas DHA and C24:1ω9c were lower in 
male subjects of the same sub-group (p=0.028 and p=0.010, F-tests). In girls, no relationship 
between BF and individual FA was found. 
In boys higher levels of EPA were associated with higher FFM quartiles (p=0.003, F-test). 
The 1st and 2nd quartile showed lower levels compared to the 3rd and 4th quartile (p<0.05, post 
hoc tests). By contrast, girls had higher levels of C22:1ω9c in the 4th quartile compared to the 
1st quartile (p=0.044, post hoc test). 
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Results of the fatty acid profile expressed as concentrations (µmol/L) 
Table 5.3 highlights the absolute FA composition according to gender. Compared to boys, all 
FA were higher in girls except for C15:1ω5c, C17:1ω7c, C18:1ω9c, C18:3ω6c, C20:3ω6c, 
and EPA.  
In boys, changed FA levels due to age were seen in C14:1ω5c and C20:1ω9c. Both levels 
increased significantly from 14.0-14.99 years to 16.0-17.49 years (p<0.02, post hoc tests). 
Palmitic acid, C17:1ω7c, C20:1ω9c, C22:1ω9c, C22:2ω6c, C24:0, C24:1ω9c, MUFA, and ω9 
FA increased from 12.5-13.99 years to 16.0-17.49 years significantly in female subjects 
(p<0.05, post hoc tests). Further, trans FA increased from 14.0-14.99 years to 16.0-17.49 
years as well as C24:1ω9c and ω3 FA between the age groups 12.5-13.99 and 14.0-14.99. 
Changes in the measured FA profile were also associated with sexual maturation. In boys, 
ALA and C20:1ω9c decreased between Tanner stage IV and V (p=0.008 and p=0.025, post 
hoc tests). Furthermore, EPA showed lower levels in Tanner stage III, IV, and V compared to 
Tanner stage II (p=0.047, p=0.032, and p=0.010, post hoc tests). By contrast, C20:0, C22:0, 
C22:1ω9c, C23:0, and C24:1ω9c decreased between Tanner stage III and IV in female 
participants (p<0.05, post hoc tests).  
No association between the FA profile of boys and the BMI status could be found, whereas in 
girls some differences were observed. Normal weight girls showed a higher pattern of LA and 
trans FA compared to their overweight counterparts (p<0.025, post hoc tests). Additionally, 
LA and C18:1ω9c were lower in obese girls compared to girls with a BMI in the normal range 
(p<0.023, post hoc tests). Underweight girls had lower C21:0 levels than normal weight girls 
(p=0.048, post hoc test). 
The FA composition of girls was not influenced by BF content, whereas trans FA were higher 
in boys with adequate BF (p=0.022, F-test), and C24:1ω9c was lower in the <25% BF group 
(p=0.024, F-test). 
A relationship between FA and FFM was present in male and female FA profiles. In girls, 
C18:0 showed a significant decline between the 1st and the 4th quartile (p=0.013, post hoc 
test). In boys, C16:0, C17:0, LA, C20:2ω6c, AA, SFA, PUFA, and ω6 FA showed a decrease 
between the 2nd and 3rd FFM quartile (p<0.022, post hoc tests). Furthermore, C23:0 were 
lower in the 3rd quartile compared to the 1st quartile (p=0.027, post hoc test).  
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Discussion 
 
The present study found some differences in the percentaged FA composition between boys 
and girls as shown in table 5.4. However, the essential FA LA and ALA as well as EPA and 
AA did not differ between sexes. Solely DHA was higher in female than in male adolescents. 
This finding may be due to a higher dietary intake of DHA in girls. Docosahexaenoic acid is 
found in fatty fish and seafood, and especially long-chain ω3 FA have been proposed as 
dietary intake markers of such food groups [31-33]. However, more reasonable are gender-
specific differences in sex hormone concentrations, which may affect enzyme activities and 
have led to the present findings [34]. Other studies indicated no sex differences in their study 
populations [22, 23, 27, 35]. However, the present study population consists of a larger 
sample size and is more heterogeneous than the other study groups. Thus, it is likely that 
gender differences may only be detected in larger sample sizes or biased by the gender-
specific food and FA intake of the participating countries [31]. Variations in the genetic 
background may also influence enzyme activities, which modify the present FA profile, and 
thus change some FA levels, especially of LCPUFA [36]. 
In most studies, differences in the FA profile due to age were not presented [21-24, 26, 35, 37, 
38]. Nonetheless, in one Hungarian adolescent study group (n=115) age classifications were 
made, but there were no dissimilarities in the FA composition of PL between the age groups 
5-10 years (n=18, 7.2±1.3 years), 10-15 years (n=25, 12.9±1.6 years), and 20-26 years (n=10, 
23±2.8 years). Significant changes were only observed when comparing 20-26 year-olds with 
much younger age groups (i.e. 0-1 month, or 1-12 months), for example in C18:1ω9c, AA, 
DHA, and MUFA [27]. The present study found differences between the age groups for 
C16:0, C18:0, PUFA, ω3 FA, and trans FA in the female subjects, and in C14:1ω5c, C18:0, 
C18:3ω6c, C20:2ω6c, C23:0, and SFA in boys (table 5.5), probably as a result of altered 
dietary FA patterns.  
Relationships between maturity and the present FA composition were observed. In girls, FA 
accounting for <1.0conc% like C17:1ω7c, C20:0, C22:0, C23:0 and C24:1ω9c differed during 
puberty. In boys, C17:1ω7c, ALA, C20:1ω9c, C20:2ω6c, EPA, C22:1ω9c, and ω9 FA were 
associated with sexual maturation (see table 5.6). These observations may be a consequence 
of altered dietary FA supply and/ or increasing sex hormone concentrations during puberty. 
Both possibilities could not be verified, because it was not feasible to measure sex hormones 
in the study population, and dietary FA evaluation did not contain such a broad spectrum of 
FA, as it is available in blood analytics to guarantee a reliable interpretation of the results. 
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However, none of the mentioned studies investigated the FA profile with respect to maturity; 
thus, no comparisons can be made. 
Body composition is also linked to FA composition. In this study, changes in the FA profile 
with respect to BMI were more apparent in girls than in boys. On the other hand, BF was only 
related to FA profiles of male subjects. The majority of studies investigated the FA 
composition related to obesity and reported no sex differences within the individual FA, thus 
they analysed boys and girls together [23, 26, 35]. In HELENA, boys and girls were analysed 
separately making direct comparisons difficult. In the present study, underweight and/ or 
normal weight girls had higher levels of C18:1ω9c and LA as well as lower levels of AA and 
LCPUFA (i.e. C20:3ω6c, AA, EPA, and DHA) than their overweight and/ or obese 
counterparts. Another study found higher amounts of C18:1ω9c/ 7c and lower levels of AA 
and ω6 LCPUFA in obese subjects (n=22, body weight relative to normal weight for 
height=170±24%) compared to age-matched controls (n=25, mean age 13.7±1.4 years) of 
both sexes [23]. Others studies were not in accordance with the present findings [22, 26, 35]. 
However, in the HELENA Study higher levels of C18:1ω9c, trans FA and lower levels of 
DHA and C24:1ω9c were associated with boys having a BF content of <25%. This parameter 
was not investigated in other studies, thus comparisons cannot be made [22, 23, 26, 35].  
As already mentioned in chapter 4, associations between body composition and lipid values 
are linked to gender. Changes in the FA profiles of girls are mainly associated with BMI 
status, while changes in the male FA profile are more present as a result of BF content 
categorization. The differences may be obtained due to the assessment methods. Fat allocation 
is different between sexes and this may be reflected in the different skinfold measurements. It 
may also be possible that the sub-group classification (two BF sub-groups vs. four BMI sub-
groups) with different group sizes results in altered findings.  
The current serum FA composition of European adolescents (12.5-17.49 years) is comparable 
with the FA profile of the Hungarian study group of Decsi and Koletzko [27]. Slight 
deviations can be explained by the fact that the HELENA FA profile consists of more 
measured FA (e.g. C22:1ω9c, C22:2ω6c, C23:0, C24:0, and C24:1ω9c), thus the percentaged 
proportion shifted. The HELENA Study results may be a more reliable approach for 
presenting physiological reference data of European adolescents because of the detailed FA 
spectrum, the larger study group, and the narrow age range. Thus, the current FA profile, 
presented as percentiles in the tables 5.2a-c, may be used as an appropriate reference standard 
for healthy European adolescents. 
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As already mentioned in the introduction of this chapter, the absolute FA profile could give 
additional, important information. However, the use of the absolute FA profile is very limited 
in current research. The relative FA composition is very well established because 
measurements of absolute amounts are more sophisticated and more expensive. Nevertheless, 
it may be important to analyse the absolute FA profile to avoid falsified results because of 
percentaged weighting. For instance, the relative percentage of total FA is dependent of the 
total number of measured FA as well as of their heights. Shifted proportions of non-essential 
FA may therefore easily alter the proportion of essential FA. As a consequence of the shifted 
proportion, the information value may be weaker or even incorrect [28, 29]. In the HELENA 
Study, nearly all absolute values of the FA, except for C15:1ω5c, C17:1ω7c, C18:1ω9c, 
C18:3ω6c, C20:3ω6c, and EPA, were higher in girls than in boys (table 5.3). This finding 
may be explained by the higher levels of transport lipoproteins in girls (table 5.1). The higher 
amounts of the essential FA ALA and LA in girls indicate different food choices (e.g. fish and 
seafood, walnuts, and green leafy vegetables) compared to boys. Further, the higher amount 
of DHA may be a result of higher elongase/ desaturase activities, probably influenced by the 
oestrogen status [39]. Moreover, the results between the absolute FA profile and the relative 
FA profile differed with respect to the association with age, maturity, BMI, BF, and FFM as 
pointed out in the results above. Therefore, it is not clear, which results are more reliable and/ 
or more usable as an approach in FA research. However, this cannot be decided within this 
thesis. 
Lagerstedt et al. [29] presented a detailed FA profile of 37 subjects (boys and girls, aged 1-17 
years). Their FA reference ranges are in accordance with the ranges of C16:0, C18:0, EPA, 
AA, C20:3ω6c, C20:0, DHA, C22:0, C24:1ω9c, C24:0, SFA, and ω3 FA found in the 
HELENA Study. The remaining FA (C12:0, C14:0, C16:1ω7c, C18:3ω6c, ALA, LA, 
C18:1ω9c, C22:1ω9c, MUFA, PUFA, and ω6 FA) were lower in the HELENA study 
population. These different findings may be explained by the smaller sample size and the 
larger age range of the other study as well as by differences in the methodological approach 
[29].  
With respect to BMI, Larqué et al. [40] found higher trans FA in obese subjects (n=34, 
9.41±0.36 years) compared to controls (n=20, 9.75±0.37 years). In the HELENA Study trans 
FA were higher in boys with normal BF content as well as lower in overweight girls than in 
their normal weight counterparts. The different study results indicate different food choices, 
because trans FA are solely found in industrially processed foods or milk and dairy products. 
This suggests a higher dietary intake of those food groups in the Spanish obese population 
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investigated by Larqué et al. compared to the European study group. The complete FA profile 
of the same Spanish study population were used by Gil-Campos et al. [41]. They found no 
significant differences in the FA profile of PL between obese and normal weight prepubertal 
children. We found an association between LA, trans FA, C18:1ω9c, and C21:0 and BMI 
only in girls. Oleic acid and LA were lower in obese and overweight subjects compared to 
girls with normal BMI. This effect was not apparent in the study population of Gil-Campos et 
al., probably as a result of the mixed group design or the lower number of subjects (n=54). 
A few limitations of the present study deserve comment. Because of the CSS design, the 
temporal relationships are unknown; one cannot say anything about causality of the 
relationships. Furthermore, dietary FA intake was not taken into account. Dietary FA data 
based on questionnaires or interviews are mostly biased by underreporting and become 
therefore unreliable [42-44]. Additionally, available food composition tables and food data 
bases lack of sufficient information especially for individual FA of several food groups, 
indicating that FA measured in serum are more reliable parameters for the assessment of the 
FA status. 
 
 
Conclusion 
 
The results indicate gender differences, which are trustable because of the large sample size, 
and should be taken into account in future studies. It has to be emphasized that the 
methodology of FA measurement and analysis differ between the research groups and need 
harmonization. Age, maturity, BMI, BF, and FFM are associated with FA and should be taken 
into account when interpreting the FA profile of adolescents. Further effort in the 
establishment and use of absolute FA values must be undertaken, because differences 
between absolute and percentaged FA profiles do exist. 
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Table 5.1: Basic characteristics of the study population as mean (standard deviation). 
 
*p values (2-tailed) are based on an independent t-test; # based on Chi square test 
1boys n=418, and girls n=495; 2boys n=461, and girls n=529;  
3boys n=469, and girls n=541; 4boys n=472, and girls n=543; 
5boys n= 436, and girls n=525; 6boys n=475 and girls n=548; 
7boys n= 464 and girls n=532. 
 HDL:High density lipoprotein cholesterol, LDL:Low density lipoprotein cholesterol. 
 Boys Girls p value* 
n 475 551  
Age (years) 14.75 (1.19) 14.78 (1.15) ns 
Height (cm) 169.8 (9.8) 161.8 (7.0) 0.000 
Weight (kg) 61.7 (13.7) 56.0 (10.2) 0.000 
Body mass index (kg/m²) 21.3 (3.8) 21.3 (3.4) ns 
Tanner stage1 3.9 (1.0) 4.0 (0.8) 0.007# 
Body fat (%)2 21.0 (10.5) 27.3 (7.6) 0.000 
Fat free mass (kg)3 51.8 (9.6) 41.8 (7.0) 0.000 
Insulin (mLU/L)4 9.9 (8.0) 10.7 (11.2) ns 
Leptin (ng/mL)5 9.30 (14.06) 28.29 (24.20) 0.000 
Triglycerides (mg/dL)6 64 (31) 73 (37) 0.000 
Total cholesterol (mg/dL)6 154 (26) 167 (28) 0.000 
HDL (mg/dL)6 53 (10) 57 (11) 0.000 
LDL (mg/dL)6 91 (25) 98 (25) 0.000 
Apolipoprotein A-1 (g/L)7 1.45 (0.21) 1.55 (0.23) 0.000 
Apolipoprotein B (g/L)7 0.62 (0.15) 0.68 (0.16) 0.000 
Lipoprotein(a) (mg/L)7 176 (218) 209 (257) 0.021 
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Table 5.2a:  Percentiles#  of  the  total  study  population  (n=733)  excluding  
          smokers,  obese  and  underweight  adolescents.  
 
Percentile 5th  25th  50th  75th  95th  
Fatty acid conc% 
Saturates      
C12:0 0.01 0.03 0.04 0.05 0.11 
C14:0 0.28 0.37 0.46 0.55 0.72 
C16:0 29.42 31.00 32.01 32.89 34.56 
C17:0 0.35 0.41 0.45 0.50 0.57 
C18:0 12.19 13.12 13.78 14.46 15.46 
C20:0 0.42 0.50 0.56 0.62 0.73 
C21:0 0.00 0.00 0.03 0.04 0.06 
C22:0 0.99 1.19 1.31 1.46 1.72 
C23:0 0.36 0.46 0.53 0.61 0.73 
C24:0 0.78 0.94 1.04 1.17 1.38 
∑ SFA 47.93 49.32 50.27 51.08 52.49 
 
     
Monounsaturates and ω9 Family     
C14:1ω5c 0.01 0.02 0.10 0.17 0.27 
C15:1ω5c 0.02 0.04 0.05 0.06 0.08 
C16:1ω7c 0.35 0.48 0.58 0.71 0.93 
C17:1ω7c 0.05 0.08 0.10 0.11 0.16 
C18:1ω9c 5.31 6.22 6.95 7.73 8.91 
C20:1ω9c 0.10 0.12 0.14 0.16 0.20 
C22:1ω9c 0.00 0.00 0.04 0.05 0.08 
C24:1ω9c 1.38 1.68 1.93 2.17 2.65 
∑ MUFA 7.82 9.01 9.88 10.83 12.20 
∑ ω9 FA 7.09 8.24 9.06 9.90 11.13 
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Percentile 5th  25th  50th  75th  95th  
Fatty acid conc% 
Polyunsaturates      
∑ PUFA 36.96 38.65 39.75 40.97 42.86 
∑ LCPUFA 12.58 14.40 15.80 17.25 19.19 
 
     
ω6 Family      
C18:2ω6c 18.99 21.44 22.98 24.78 27.13 
C18:2ω6t 0.03 0.04 0.05 0.07 0.09 
C18:3ω6c 0.06 0.07 0.08 0.10 0.17 
C20:2ω6c 0.21 0.26 0.29 0.33 0.39 
C20:3ω6c 1.97 2.50 2.91 3.38 4.13 
C20:4ω6c 7.07 8.49 9.52 10.67 12.25 
C22:2ω6c 0.24 0.28 0.31 0.35 0.42 
∑ ω6 FA 32.66 34.93 36.29 37.76 40.05 
 
     
ω3 Family      
C18:3ω3c 0.06 0.09 0.13 0.18 0.30 
C20:5ω3c 0.15 0.30 0.42 0.60 1.08 
C22:6ω3c 1.70 2.17 2.66 3.31 4.54 
∑ ω3 FA 2.05 2.64 3.24 4.02 5.54 
 
     
∑ trans FA 0.03 0.04 0.05 0.07 0.09 
 
    
 
#
 rounded values 
 
 FA:Fatty acids; LCPUFA:Long-chain PUFA; MUFA:Monounsaturated FA;  
PUFA: Polyunsaturated FA; SFA:Saturated FA 
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Table 5.2b:  Percentiles#  of  the  male  study  population  (n=349)  excluding  
          smokers,  obese  and  underweight  adolescents.  
 
Percentile 5th  25th  50th  75th  95th  
Fatty acid conc% 
Saturates      
C12:0 0.02 0.03 0.04 0.05 0.11 
C14:0 0.27 0.36 0.45 0.54 0.77 
C16:0 29.37 31.04 32.14 33.00 34.47 
C17:0 0.35 0.41 0.45 0.50 0.57 
C18:0 12.27 13.09 13.65 14.33 15.48 
C20:0 0.41 0.48 0.54 0.61 0.71 
C21:0 0.00 0.00 0.02 0.04 0.06 
C22:0 0.97 1.16 1.29 1.45 1.72 
C23:0 0.35 0.45 0.52 0.60 0.72 
C24:0 0.79 0.94 1.06 2.15 2.65 
∑ SFA 47.83 49.22 50.29 51.30 52.64 
 
     
Monounsaturates and ω9 Family     
C14:1ω5c 0.01 0.02 0.09 0.18 0.28 
C15:1ω5c 0.02 0.04 0.05 0.06 0.09 
C16:1ω7c 0.34 0.46 0.56 0.69 0.89 
C17:1ω7c 0.05 0.08 0.10 0.12 0.17 
C18:1ω9c 5.37 6.40 7.03 7.82 9.07 
C20:1ω9c 0.10 0.12 0.14 0.16 0.20 
C22:1ω9c 0.00 0.00 0.04 0.05 0.07 
C24:1ω9c 1.35 1.67 1.90 2.15 2.65 
∑ MUFA 7.93 9.12 9.98 10.98 12.30 
∑ ω9 FA 7.15 8.39 9.16 9.98 11.25 
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Percentile 5th  25th  50th  75th  95th  
Fatty acid conc% 
Polyunsaturates      
∑ PUFA 36.42 38.53 39.73 40.86 42.84 
∑ LCPUFA 12.60 14.44 15.87 17.29 19.20 
 
     
ω6 Family      
C18:2ω6c 18.75 21.43 22.85 24.56 26.86 
C18:2ω6t 0.03 0.04 0.05 0.07 0.09 
C18:3ω6c 0.06 0.07 0.08 0.10 0.18 
C20:2ω6c 0.21 0.26 0.29 0.33 0.39 
C20:3ω6c 2.03 2.55 3.01 3.43 4.07 
C20:4ω6c 7.32 8.51 9.62 10.73 12.56 
C22:2ω6c 0.23 0.28 0.31 0.35 0.41 
∑ ω6 FA 32.28 34.91 36.35 37.84 40.03 
 
     
ω3 Family      
C18:3ω3c 0.06 0.09 0.13 0.18 0.31 
C20:5ω3c 0.15 0.30 0.45 0.62 1.05 
C22:6ω3c 1.63 2.10 2.55 3.12 4.28 
∑ ω3 FA 2.03 2.57 3.15 3.88 5.49 
 
     
∑ trans FA 0.03 0.04 0.05 0.06 0.09 
 
    
 
#
 rounded values 
 
 FA:Fatty acids; LCPUFA:Long-chain PUFA; MUFA:Monounsaturated FA;  
PUFA: Polyunsaturated FA; SFA:Saturated FA 
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Table 5.2c:  Percentiles#  of  the  female  study  population  (n=384) excluding  
         smokers,  obese  and  underweight  adolescents.  
 
Percentile 5th  25th  50th  75th  95th  
Fatty acid conc% 
Saturates      
C12:0 0.02 0.03 0.04 0.05 0.10 
C14:0 0.29 0.38 0.46 0.56 0.71 
C16:0 29.44 30.92 31.92 32.77 34.67 
C17:0 0.35 0.40 0.45 0.50 0.56 
C18:0 11.93 13.14 13.87 14.54 15.45 
C20:0 0.44 0.51 0.57 0.63 0.75 
C21:0 0.00 0.00 0.03 0.04 0.06 
C22:0 1.01 1.20 1.33 1.47 1.70 
C23:0 0.37 0.47 0.54 0.61 0.74 
C24:0 0.75 0.93 1.03 1.15 1.33 
∑ SFA 48.05 49.39 50.27 50.98 52.23 
 
     
Monounsaturates and ω9 Family     
C14:1ω5c 0.01 0.03 0.12 0.17 0.27 
C15:1ω5c 0.02 0.04 0.05 0.06 0.08 
C16:1ω7c 0.35 0.50 0.60 0.73 0.96 
C17:1ω7c 0.05 0.07 0.09 0.11 0.15 
C18:1ω9c 5.19 6.08 6.80 7.65 8.76 
C20:1ω9c 0.10 0.12 0.14 0.16 0.20 
C22:1ω9c 0.00 0.00 0.04 0.05 0.08 
C24:1ω9c 1.40 1.68 1.96 2.17 2.65 
∑ MUFA 7.77 8.90 8.92 10.73 12.09 
∑ ω9 FA 7.02 8.13 8.99 9.83 11.07 
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Percentile 5th  25th  50th  75th  95th  
Fatty acid conc% 
Polyunsaturates      
∑ PUFA 37.13 38.76 39.79 41.03 42.92 
∑ LCPUFA 12.52 14.34 15.79 17.21 19.27 
 
     
ω6 Family      
C18:2ω6c 19.07 21.46 23.08 24.92 27.28 
C18:2ω6t 0.03 0.05 0.05 0.07 0.09 
C18:3ω6c 0.06 0.07 0.08 0.10 0.17 
C20:2ω6c 0.21 0.26 0.29 0.33 0.40 
C20:3ω6c 1.95 2.45 2.87 3.33 4.20 
C20:4ω6c 6.95 8.42 9.41 10.56 12.23 
C22:2ω6c 0.24 0.28 0.31 0.35 0.44 
∑ ω6 FA 32.76 34.94 36.24 37.62 40.10 
 
     
ω3 Family      
C18:3ω3c 0.06 0.09 0.13 0.17 0.30 
C20:5ω3c 0.14 0.30 0.41 0.57 1.14 
C22:6ω3c 1.74 2.28 2.80 3.50 4.66 
∑ ω3 FA 2.09 2.72 3.34 4.23 5.61 
 
     
∑ trans FA 0.03 0.05 0.05 0.07 0.09 
 
    
 
#
 rounded values 
 
 FA:Fatty acids; LCPUFA:Long-chain PUFA; MUFA:Monounsaturated FA;  
PUFA: Polyunsaturated FA; SFA:Saturated FA 
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Table 5.3: Gender-specific fatty acid composition of serum phospholipids as mean (SD)#. 
 
Fatty acid  Total (n=1,024) Boys (n=475) Girls (n=549) p value* 
  (µmol/L)   
Saturates     
C12:0 2 (2) 2 (2) 2 (2) 0.031 
C14:0 18 (8) 17 (7) 19 (8) 0.000 
C16:0 1,182 (212) 1,136 (191) 1,222 (221) 0.000 
C17:0 17 (4) 16 (4) 17 (4) 0.000 
C18:0 508 (99) 491 (99) 523 (97) 0.000 
C20:0 21 (5) 19 (5) 22 (5) 0.000 
C21:0 1 (1) 1 (1) 1 (1) 0.000 
C22:0 49 (12) 47 (12) 51 (11) 0.000 
C23:0 20 (5) 18 (5) 21 (5) 0.000 
C24:0 39 (10) 38 (10) 39 (10) 0.044 
∑ SFA 1,855 (324) 1,785 (309) 1,915 (326) 0.000 
 
    
Monounsaturates and ω9 Family    
C14:1ω5c 4 (3) 4 (3) 4 (3) 0.006 
C15:1ω5c 2 (1) 2 (1) 2 (1) ns 
C16:1ω7c 23 (11) 22 (9) 25 (11) 0.000 
C17:1ω7c 4 (2) 4 (2) 4 (2) ns 
C18:1ω9c 259 (76) 255 (73) 263 (78) ns 
C20:1ω9c 5 (2) 5 (2) 6 (2) 0.000 
C22:1ω9c 1 (1) 1 (1) 1 (1) 0.008 
C24:1ω9c 71 (20) 68 (19) 75 (20) 0.000 
∑ MUFA 370 (95) 359 (91) 379 (98) 0.000 
∑ ω9 FA 337 (86) 329 (83) 344 (88) 0.001 
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Fatty acid  Total (n=1,024) Boys (n=475) Girls (n=549) p value* 
  (µmol/L)   
Polyunsaturates     
∑ PUFA 1,470 (278) 1,412 (270) 1,520 (275) 0.000 
∑ LCPUFA 586 (142) 565 (136) 604 (145) 0.000 
 
    
ω6 Family     
C18:2ω6c 850 (178) 814 (170) 880 (179) 0.000 
C18:2ω6t 2 (1) 2 (1) 2 (1) 0.000 
C18:3ω6c 4 (2) 4 (2) 4 (2) ns 
C20:2ω6c 11 (3) 11 (3) 12 (4) 0.001 
C20:3ω6c 111 (37) 109 (34) 114 (39) ns 
C20:4ω6c 354 (94) 345 (89) 363 (97) 0.000 
C22:2ω6c 12 (4) 11 (3) 12 (4) 0.000 
∑ ω6 FA 1,344 (258) 1,295 (249) 1,386 (257) 0.000 
 
    
ω3 Family     
C18:3ω3c 5 (3) 5 (3) 6 (4) 0.003 
C20:5ω3c 18 (13) 18 (13) 19 (14) ns 
C22:6ω3c 102 (40) 94 (38) 110 (40) 0.000 
∑ ω3 FA 126 (50) 117 (48) 134 (51) 0.000 
 
    
∑ trans FA 2 (1) 2 (1) 2 (1) 0.000 
 
   
 
*P values are based on independent t-test comparing boys and girls, ns:non significant. 
  FA:Fatty acids; LCPUFA:Long-chain PUFA; MUFA:Monounsaturated FA; PUFA: Polyunsaturated FA;   
  SD:Standard deviation, SFA:Saturated FA 
#
 rounded values 
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6 Fatty acid ratios in European adolescents – associations with age, 
gender, maturity, body mass index, percentage body fat, and             
fat free mass 
 
 
Background: Essential FA LA and ALA have to be provided by the normal diet. These 
dietary FA are precursors for LCPUFA of the ω6 and ω3 family. Omega 6 and ω3 FA 
compete against the same enzymes for elongation and desaturation, thus a particular relation 
is necessary to obtain adequate amounts of both LCPUFA of the ω6 and ω3 series. This 
relation will maintain optimal health and development, especially important in the period of 
adolescence. Estimated ratios like ω6/ω3, LA/ALA, AA/EPA, AA/(EPA+DHA) are used to 
evaluate the relationship between ω6 and ω3 FA and can be calculated by dietary intake data 
or blood levels. If these ratios are influenced by FA intake alone or associated with age, 
gender, maturity, BMI, BF, and FFM is not investigated sufficiently, especially in adolescent 
subjects. 
Objective: To investigate the association of FA ratios with age, gender, maturation, BMI, BF, 
and FFM based on serum FA of PL estimated by different calculation methods. 
Results: Gender differences were seen between boys and girls and differed due to the 
calculation method. Male FA ratios showed no association with age. In girls, EPA/ALA ratios 
decreased with age significantly in both conc% and area% calculations. Maturation was 
associated with LA/ALA and EPA/ALA ratios in boys (conc% and area% calculations). In 
girls, ω6/ω3 (based on area%) was related to maturation. The ω6/ω3 ratio of boys (conc% 
calculation) showed some kind of U-shaped curve, whereas female ratios of AA/LA increased 
with BMI status based on FA measured in conc% and absolute values. 
Conclusion: The associations of the different FA ratios with age, maturation, BF, FFM, and 
BMI are minimal and follow no clear pattern. Thus, it can be speculated that these FA ratios 
are mainly modified by dietary factors such as amount of fat and dietary FA pattern. 
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Introduction 
 
Linoleic acid and ALA are essential FA and have to be provided by the normal diet. These 
two FA are termed parent essential FA because they are the starting point for the elongation-
desaturation cascade leading to LCPUFA of the ω6 and ω3 family. Due to the fact that ω6 and 
ω3 FA compete against the same enzymes for elongation and desaturation, a particular 
relation, provided by the diet, is necessary to obtain a satisfactory amount of LCPUFA of both 
ω6 and ω3. This relation is prerequisite to ensure the fulfillment of the physiological functions 
LCPUFA are involved in. For instance, a balanced relation of ω6 and ω3 LCPUFA in 
different lipid fractions is particularly important for the regulation of the immune system and 
inflammation processes. Thus, for optimal health and development an adequate relationship/ 
ratio between ω6 and ω3 FA is needed in all lipid classes.  
Fatty acid ratios are commonly calculated by using total ω6/ω3 FA or LA/ALA. Furthermore, 
other ratios are used to indicate the relationship between ω6 and ω3 FA (e.g. AA/EPA, 
AA/[EPA+DHA]) or, to show the relationships within the ω6 or ω3 family (e.g. DHA/EPA, 
AA/LA). Fatty acid ratios are based on dietary intake data or blood levels. 
The current dietary ω6/ω3 ratio in countries with Westernized eating patterns is approx. 15:1-
16:1 [1]. The recommended ratio of 5:1, suggested by some nutrition societies [2], indicates 
discrepancies between current ω6/ω3 FA intakes and recommendations. This is due to the 
high dietary intake of LA and the lower dietary intake of ALA, EPA, and DHA as well as due 
to the insufficient conversion of EPA and DHA from ALA in humans. Moreover, with respect 
to evolutionary aspects and the genetic background, which is adapted to a hunter-gatherer 
diet, a ω6/ω3 ratio of 2.4:1-1:1 is estimated as best possible. Thus, an even lower ratio would 
support optimal health [3]. As a consequence, increased ω6/ω3 ratios are related to several 
diseases of today’s civilisations [4-8]. These increased ratios may also be present in 
adolescents with Westernized eating habits [9], suggesting a risk factor for later diseases and 
insufficient conditions for adequate growth and development. According to that, it is 
important to assess the FA ratios of adolescents, which are not assessed satisfactorily so far. If 
FA ratios are only determined by the dietary intake of ω6 or ω3 FA or if they are influenced 
by other parameters like age, gender, maturity, BMI, BF, and FFM is not clear yet. However, 
that could be of importance for improving FA ratios, and thus health, and assessing potential 
risk factors especially in adolescence. 
Therefore, the HELENA Study assessed several FA ratios based on individual FA measured 
in serum PL in a healthy adolescent group. The ratios [AA/LA, (DHGLA+AA)/LA, 
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EPA/ALA, DHA/EPA, AA/EPA, LA/ALA, AA/(EPA+DHA), total ω6/ω3, 
Polyunsaturates/Saturates, and Monounsaturates/Saturates] were associated with age, gender, 
maturity, BMI, BF, and FFM. Furthermore, due to the different approaches to measure FA 
and to calculate their ratios afterwards, this chapter will also compare the results of FA ratios 
based on FA measured as area%, conc% and as absolute concentrations (µmol/L). 
 
 
Subjects and Methods  
 
A detailed description of study design, subject recruitment, medical examination, blood 
sampling, sample treatment, analytical methods, evaluation procedures, and calculation of the 
FA ratios can be found in chapter 3 (General Methodology). 
 
Statistics 
Numeric values are shown as mean±SD. Differences in the main study characteristics of boys 
and girls were analysed using independent t-tests (metric variables) and chi square test 
(categorical variables). Fatty acids were skewed and logarithmically transformated before FA 
ratios were calculated. Fatty acid ratios were used as dependent variables in a gender-specific 
statistical analysis. Age, sexual maturation, FFM, BMI, and BF were determined as 
independent variables and grouped. Further, insulin and leptin were used as covariates in the 
present model. For each of the dependent variables, a univariate ANCOVA were used to 
analyse the association with the independent variables. The Bonferroni post-hoc tests were 
used for sub-group analyses. Data analysis was performed by using Statistical Package for 
Social Sciences version 17.0 for Windows (SPSS Inc., Chicago, Illinois, USA) and a p value 
of <0.05 was considered as statistically significant 
 
 
Results 
 
The HELENA-CSS consisted of 1,097 adolescent subjects including blood measurements. A 
number of 73 adolescents gave insufficient blood for FA analysis, thus 1,024 subjects 
contributed to the following results. Table 6.1 highlights the basic characteristics of the study 
population. Individual FA and their sums as basis for the different FA ratios are presented in 
the tables 6.2a-c followed by the gender-specific FA ratios in tables 6.3a-c. Table 6.3d shows 
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the differences between FA ratios based on area% and conc% within the male and female 
groups. 
In detail, within the male groups as well as within the female groups, the comparison between 
FA ratios based on FA measured as area% and conc% showed significant differences (table 
6.3d). All ratios except for DHA/EPA, AA/EPA, and AA/(EPA+DHA) were significantly 
different due to the calculation method. In male and female groups, ratios estimated by FA 
measured as area% were higher compared to ratios based on conc% calculations, except for 
ω6/ω3. 
 
Fatty acid ratios based on calculations of fatty acids expressed as conc% 
Gender-specific differences were observed for the (DHGLA+AA)/LA ratio (table 6.3a) with 
higher ratios in boys compared to girls.  
With respect to age, female EPA/ALA ratios decreased significantly from 4.33±3.96 to 
3.63±2.63 between 14.0-14.99 years and 16.0-17.49 years (p=0.041, post hoc test). All other 
FA ratios showed no association with age in girls. By contrast, no association was found 
between male FA ratios and age. 
In boys, maturation was associated with LA/ALA (p=0.030, F-test) and EPA/ALA (p=0.036, 
F-test). The LA/ALA ratio increased from 184±98 to 221±111 between Tanner stage IV and 
V (p=0.023, post hoc test), whereas the EPA/ALA ratio decreased from 3.99±1.71 to 
3.81±2.54 between Tanner stage II to IV (p=0.019, post hoc test). Girls showed no 
associations between maturity and FA ratios. 
Gender-specific FA ratios categorized as BMI groups are presented in the tables 6.4a and 
6.4b. A higher ratio of ω6/ω3 was present in underweight compared to normal weight boys. 
Moreover, the ω6/ω3 ratio showed some kind of U-shaped curve in boys, whereas girls 
showed no differences in the ratios according to the BMI categories. Additionally, 
AA/(EPA+DHA) were lower in obese compared to overweight boys (see table 6.4a). In girls, 
(DHGLH+AA)/LA and AA/LA ratios increased from normal weight to overweight (table 
6.4b). 
Differences between the FA ratios were neither observed in girls nor in boys when splitting 
the group according to percentage BF. 
Fat free mass was associated with EPA/ALA in boys. The EPA/ALA ratio increased from the 
1st quartile (3.56±2.27) to the 3rd (3.98±3.42) and 4th quartile (4.14±2.26, both p<0.04, post 
hoc tests). Fatty acid ratios of girls were not related to FFM quartiles. 
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Fatty acid ratios based on calculations of absolute fatty acid concentrations (µmol/L) 
The ratios AA/(EPA+DHA) and ω6/ω3 showed gender-specific differences with higher ratios 
in male subjects. All other FA ratios remained unaffected by gender (table 6.3b).  
The ω6/ω3 ratio was higher in 14.0-14.99 year-old compared to 12.5-13.99 year-old girls 
(p=0.015, post hoc test). Additionally, the M/S ratio decreased between 12.5-13.99 year-old 
girls and 16.0-17.49 year-old girls (p=0.041). The FA ratios of boys were not associated with 
age groups. 
Fatty acid ratios showed an increase of the M/S ratio between Tanner stage I and IV (p=0.034, 
post hoc test) in boys. On the other hand, female ω6/ω3 ratios were associated with puberty 
(p=0.016, F-test).  
The M/S ratio differed due to BMI status (p=0.038, F-test) in girls. Furthermore, the AA/LA 
ratio increased between normal weight and overweight girls (p=0.001, post hoc test). The FA 
ratios of boys remained unaffected by BMI status.  
Body fat content was associated with male EPA/ALA ratios. The ratio increased with higher 
BF content (p=0.010, F-test). Female FA ratios did not differ significantly as a consequence 
of percentage BF categorization. 
No association between FFM quartiles and FA ratios was found for boys and girls. 
 
Fatty acid ratios based on calculations of fatty acids expressed as area% 
The ratios AA/(EPA+DHA), (DHGLA+AA)/LA, and ω6/ω3 were significantly different 
between sexes. Higher ratios were observed in male subjects compared to females (table 
6.3c). 
The EPA/ALA ratio decreased with age in girls (p=0.034, F-test). Furthermore, the ω6/ω3 
ratio of girls increased between the ages 12.5-13.99 and 14.0-14.99 (p=0.033, post hoc test). 
Male FA ratios were not associated with age as already observed in FA ratios based on conc% 
calculations. 
The (DHGLA+AA)/LA, EPA/ALA, DHA/EPA, AA/EPA, and LA/ALA ratios of male 
subjects were associated with sexual maturation as specified in table 6.4c, whereas female FA 
ratios were not related to maturity.  
Table 6.4d highlights the FA ratio results found in girls according to BMI status. In boys, 
ω6/ω3 differed between BMI groups (p=0.049, F-test). 
Fatty acid ratios showed no association with BF content in boys, whereas in girls higher 
DHA/EPA and AA/EPA ratios were associated with lower BF content (p=0.047 and p=0.037, 
F-tests). 
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With respect to FFM, EPA/ALA increased between the 1st to 3rd, 1st to 4th, and 2nd to 4th 
quartile in boys (p=0.024, p=0.015 and p=0.042, post hoc tests), whereas female FA ratios 
remained unaffected by FFM. 
 
 
Discussion 
 
Generally, most studies did not include such a wide spectrum of FA ratios in their results as it 
is presented within this chapter [15-20]. Thus, it is difficult to compare the observed results 
with the literature especially for adolescents. Therefore, if possible further FA ratios were 
self-calculated on the basis of the available FA data of suitable publications and are included 
in this discussion. This allows a view on the absolute values but did not give any statistically 
significant information of the newly calculated FA ratios. Another difficulty was that some 
authors use dietary intake data mostly without calculating FA ratios [9, 21, 22]. However, 
dietary intake data is easier to assess but is biased by the kind of assessment (questionnaires, 
dietary recalls) and type of food composition table [9, 23]. Moreover, dietary intake cannot 
give a complete overview of the FA status of the human body, because the endogenous FA 
metabolism is not considered. Nonetheless, even within the blood FA measurements results 
differ, based on the chosen blood lipid fractions (e.g. serum/ plasma PL, cholesteryl esters, 
TG, red blood cell PL) or due to the methodological approach of FA analytics. The objectives 
and aims of a planned study, laboratory facilities and the budget of a study may account for 
those different choices.  
However, we found gender-specific differences depending on the calculation basis of the FA. 
Fatty acid ratios based on conc% were significantly different for (DHGLA+AA)/LA whereas 
FA ratios based on absolute values showed significant differences for AA/(EPA+DHA) and 
ω6/ω3. Further, FA ratios estimated by FA expressed as area% included both of the results 
mentioned before. The different results, which have been found between the FA ratios, 
estimated by FA expressed as conc% and measured in absolute values, may be due to the 
logarithmically transformated values. The logarithmical transformation of the FA of both 
calculation methods resulted in different transformated values due to the different units 
(µmol/L and conc%). Those values were the basis for the estimation of the FA ratios, which 
then showed different results in the statistical analysis. This cannot be found in the tables 6.3a 
and 6.3b, because the tables show the raw data of the FA ratios. These FA ratios based on FA 
expressed as conc% and µmol/L are quite similar. Thus, it can be assumed that the 
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transformated data is responsible for the significant findings. This has to be kept in mind, 
when interpreting the present results. The comparison between FA ratios based on area% and 
conc% may therefore be a more reasonable choice to evaluate the results of the same study, 
because both approaches use percentaged values. The present gender differences may be 
explained by different eating habits between boys and girls especially of ω6 and ω3 FA. 
However, most studies in adolescents/ children investigating FA ratios did not separate 
between boys and girls [17, 20] or did not find gender-specific differences in their study 
groups [18, 19]. Thus, the present findings are not in accordance with other studies. In the 
HELENA Study, the LA/ALA ratio was 199 (table 6.3a) which was not found within the 
other studies. In two Hungarian studies, apparently healthy children, used as control groups, 
had LA/ALA ratios of 135 (n=25, mean age 12.9±1.6years) [19] and 254 (n=16, mean age 
16.2±1.0) [20]. By contrast, American normal weight adolescents (n=190, mean age 15±1.2 
years) had a ratio of 124 [18] (these ratios based on self-calculated PL FA provided by the 
publications). These differences may be a result of country-specific and age-dependent eating 
habits. 
Age was associated with variations in the FA ratios of girls, whereas boys may not change 
their dietary FA intake habits over age or more precisely, the proportion of several FA do not 
alter. However, in girls, the decline of the EPA/ALA ratio might indicate lower intakes of 
EPA and/ or higher intakes of ALA and thus shifted dietary habits within the different age 
groups. 
In boys, during maturity, the LA/ALA ratio based on conc% and area% calculations 
increased. Further, the AA/EPA ratio estimated by FA in area% increased as well. Maturity 
may be a better determinant than age to detect alterations in serum FA during growth in boys. 
Changed dietary eating patterns may be reflected in the shifted FA ratios. Hormonal changes 
may also account for fluctuations of FA levels (e.g. AA, EPA) and thus alter those FA ratios, 
because hormones might interact with elongation/ desaturation processes or influence food 
choices. Due to the fact that it was not feasible to measure sex hormones within the HELENA 
Study this question cannot be answered sufficiently.  
Fatty acid ratios in adolescent subjects are commonly used to investigate differences in the 
FA profile between obese and normal weight subjects [17, 19, 20]. However, inconsistencies 
in those findings are present. Self-calculated LA/ALA ratios based on FA data of Decsi and 
coworkers [20] were 218, 213 and 254 for obese children with and without metabolic 
cardiovascular syndrome, and controls. The results show that the highest ratio in healthy 
controls reflects the most undesirable ratio within the three sub-groups. In another study of 
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Decsi et al. [19] LA/ALA ratios in 25 control subjects were 135. The LA/ALA ratio for the 
obese participants was not available, because ALA was not detectable in the obese sub-group 
(self-calculated values of both studies based on FA data in PL provided by the referring 
publication) [19]. In contrast to those Hungarian adolescents, the present European 
participants of the HELENA Study had LA/ALA ratios of 194 and 197 in normal weight boys 
and girls, whereas LA/ALA in obese boys and girls was 215 and 244 (see tables 6.4a and 
6.4b). Those contrasting results of the studies may be a consequence of differences in the diet, 
FA analytics and probably group characteristics (e.g. nationality, age, group size).  
Concerning the results of the different calculation methods, one can say that it is not clear, 
which method is the most reliable. However, some points can be highlighted: fatty acids and 
their ratios based on conc% are more reliable than FA expressed as area%, because conc% 
calculations take the molecular mass of each FA detected into account and thus do not simply 
refer to a peak area. Nevertheless, the percentaged FA profiles of both methods are influenced 
by the number of FA detected and the height of each FA peak, this approach may obscure 
some important findings. This point would be eliminated by using FA expressed as absolute 
concentrations, which are independent of other FA concentrations. Thus, changes in one 
specific FA concentration would not affect another FA concentration of the same profile. 
However, the most common method to express FA in the literature is the use of percentaged 
FA profiles. 
The assessment of dietary FA was not included in this analysis, even though it may help to 
identify the contribution of dietary FA to the FA composition of PL. As already mentioned, 
most food composition data bases lack of reliability concerning FA data and the available 
spectrum of FA in different foods is insufficient in those data bases; thus, from this point of 
view, dietary FA data would weaken the results rather than strengthen them.  
 
 
Conclusion 
 
Although some FA ratios are associated with age, maturation, BMI, BF, and FFM in boys and 
girls, the results follow no clear pattern. Thus, the differences might best be explained by and 
are related to different eating habits in the different sub-groups. Thus, it can be speculated that 
FA ratios are mainly modified by dietary factors such as amount of fat and dietary FA pattern.  
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Table 6.1: Gender-specific characteristics of the study group as mean (standard deviation). 
 
*P values (2-tailed) are based on an independent t-test; # based on Chi square test. ns:non significant 
1 boys n=418, and girls n=495, 2boys n=461, and girls n=529;  
3 boys n=469, and girls n=541, 4boys n=472, and girls n=543; 
5 boys n= 436, and girls n=525, 6boys n=475 and girls n=548; 
7 boys n= 464 and girls n=532. 
  HDL:High density lipoprotein cholesterol, LDL:Low density lipoprotein cholesterol. 
 Boys Girls p value* 
n 475 551  
Age (years) 14.75 (1.19) 14.78 (1.15) ns 
Height (cm) 169.8 (9.8) 161.8 (7.0) 0.000 
Weight (kg) 61.7 (13.7) 56.0 (10.2) 0.000 
Body mass index (kg/m²) 21.3 (3.8) 21.3 (3.4) ns 
Tanner stage1 3.9 (1.0) 4.0 (0.8) 0.007# 
Body fat (%)2 21.0 (10.5) 27.3 (7.6) 0.000 
Fat free mass (kg)3 51.8 (9.6) 41.8 (7.0) 0.000 
Insulin (mLU/L)4 9.9 (8.0) 10.7 (11.2) ns 
Leptin (ng/mL)5 9.30 (14.06) 28.29 (24.20) 0.000 
Triglycerides (mg/dL)6 64 (31) 73 (37) 0.000 
Total cholesterol (mg/dL)6 154 (26) 167 (28) 0.000 
HDL (mg/dL)6 53 (10) 57 (11) 0.000 
LDL (mg/dL)6 91 (25) 98 (25) 0.000 
Apolipoprotein A-1 (g/L)7 1.45 (0.21) 1.55 (0.23) 0.000 
Apolipoprotein B (g/L)7 0.62 (0.15) 0.68 (0.16) 0.000 
Lipoprotein(a) (mg/L)7 176 (218) 209 (257) 0.021 
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Table 6.2a: Selection of fatty acids (conc%) of serum phospholipids as mean (SD)#. 
 
Fatty acid  Total (n=1,024) Boys (n=475) Girls (n=549) p value* 
 --------------------------------- conc% --------------------------------  
Saturates     
C16:0 32.0 (1.6) 32.0 (1.5) 32.0 (1.7) ns 
C18:0 13.8 (1.1) 13.8 (1.0) 13.7 (1.1) ns 
∑ SFA 
 
50.3 (1.5) 50.2 (1.6) 50.3 (1.5) ns 
Monounsaturates     
C16:1ω7c 0.6 (0.2) 0.6 (0.2) 0.6 (0.2) 0.006 
C18:1ω9c 7.0 (1.3) 7.1 (1.4) 6.9 (1.3) 0.001 
∑ MUFA 
 
10.0 (1.5) 10.1 (1.6) 9.9 (1.5) ns 
Polyunsaturates     
∑ PUFA 39.8 (1.9) 39.7 (2.0) 39.8 (1.9) ns 
∑ LCPUFA 
 
15.8 (2.3) 15.8 (2.2) 15.8 (2.4) ns 
ω6 Family     
C18:2ω6c 23.0 (2.6) 22.9 (2.6) 23.1 (2.7) ns 
C18:3ω6c 0.1 (>0.1) 0.1 (0.1) 0.1 (>0.1) ns 
C20:3ω6c 3.0 (0.7) 3.0 (0.7) 2.9 (0.7) 0.006 
C20:4ω6c 9.6 (1.9) 9.7 (1.8) 9.5 (2.0) ns 
∑ ω6 
 
35.4 (2.3) 36.4 (2.4) 36.3 (2.3) ns 
ω3 Family     
C18:3ω3c 0.1 (0.1) 0.1 (0.1) 0.1 (0.1) ns 
C20:5ω3c 0.5 (0.3) 0.5 (0.3) 0.5 (0.3) ns 
C22:6ω3c 2.8 (0.9) 2.6 (0.9) 2.9 (0.9) 0.000 
∑ ω3 3.4 (1.1) 3.2 (1.1) 3.5 (1.2) 0.000 
 
  
*P values are based on independent t-test comparing boys and girls, ns:non significant, # rounded values 
  FA:Fatty acids; LCPUFA:Long-chain polyunsaturated FA, MUFA:Monounsaturated FA;  
  PUFA: Polyunsaturated FA; SD:Standard deviation; SFA:Saturated FA. 
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Table 6.2b: Selection of fatty acids (µmol/L) of serum phospholipids as mean (SD)#. 
 
Fatty acid  Total (n=1,024) Boys (n=475) Girls (n=549) p value* 
 --------------------------------- µmol/L --------------------------------  
Saturates     
C16:0 1,182 (212) 1,136 (191) 1,222 (221) 0.000 
C18:0 508 (99) 491 (99) 523 (97) 0.000 
∑ SFA 
 
1,855 (324) 1,785 (309) 1,915 (326) 0.000 
Monounsaturates     
C16:1ω7c 23 (11) 22 (9) 25 (11) 0.000 
C18:1ω9c 259 (76) 255 (73) 263 (78) ns 
∑ MUFA 
 
370 (95) 359 (91) 379 (98) 0.000 
Polyunsaturates     
∑ PUFA 1,470 (278) 1,412 (270) 1,520 (275) 0.000 
∑ LCPUFA 
 
586 (142) 565 (136) 604 (145) 0.000 
ω6 Family     
C18:2ω6c 850 (178) 814 (170) 880 (179) 0.000 
C18:3ω6c 4 (2) 4 (2) 4 (2) ns 
C20:3ω6c 111 (37) 109 (34) 114 (39) ns 
C20:4ω6c 354 (94) 345 (89) 363 (97) 0.000 
∑ ω6 
 
1,344 (258) 1,295 (249) 1,386 (257) 0.000 
ω3 Family     
C18:3ω3c 5 (3) 5 (3) 6 (4) 0.003 
C20:5ω3c 18 (13) 18 (13) 19 (14) ns 
C22:6ω3c 12 (4) 11 (3) 12 (4) 0.000 
∑ ω3 126 (50) 117 (48) 134 (51) 0.000 
 
  
*P values are based on independent t-test comparing boys and girls, ns:non significant, # rounded values 
  FA:Fatty acids; LCPUFA:Long-chain polyunsaturated FA, MUFA:Monounsaturated FA;  
  PUFA: Polyunsaturated FA; SD:Standard deviation; SFA:Saturated FA. 
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Table 6.2c: Selection of fatty acids (area%) of serum phospholipids as mean (SD)#. 
 
Fatty acid  Total (n=1,024) Boys (n=475) Girls (n=549) p value* 
 --------------------------------- area% --------------------------------  
Saturates     
C16:0 27.5 (1.5) 27.4 (1.4) 27.5 (1.6) ns 
C18:0 13.1 (1.1) 13.1 (1.0) 13.1 (1.1) ns 
∑ SFA 
 
45.4 (1.5) 45.3 (1.6) 45.4 (1.4) ns 
Monounsaturates     
C18:1ω7c 1.5 (0.2) 1.4 (0.2) 1.5 (0.3) 0.031 
C18:1ω9c 10.0 (1.8) 10.2 (1.9) 9.8 (1.8) 0.001 
∑ MUFA 
 
14.8 (2.1) 14.9 (2.2) 14.7 (2.0) ns 
Polyunsaturates     
∑ PUFA 39.8 (2.0) 39.8 (2.0) 39.9 (1.9) ns 
∑ LCPUFA 
 
16.8 (2.4) 16.8 (2.3) 16.8 (2.4) ns 
ω6 Family     
C18:2ω6c 22.1 (2.6) 22.0 (2.6) 22.2 (2.6) ns 
C18:3ω6c 0.1 (>0.1) 0.1 (0.1) 0.1 (>0.1) ns 
C20:3ω6c 3.0 (0.7) 3.0 (0.7) 2.9 (0.7) 0.006 
C20:4ω6c 9.6 (1.9) 9.7 (1.8) 9.5 (2.0) ns 
∑ ω6 
 
35.5 (2.4) 35.5 (2.4) 35.4 (2.4) ns 
ω3 Family     
C18:3ω3c 0.1 (0.1) 0.1 (0.1) 0.1 (0.1) ns 
C20:5ω3c 0.5 (0.3) 0.5 (0.3) 0.5 (0.3) ns 
C22:6ω3c 2.9 (0.9) 2.8 (0.9) 3.0 (1.0) 0.000 
∑ ω3 4.3 (1.3) 4.2 (1.2) 4.4 (1.4) 0.003 
 
  
*P values are based on independent t-test comparing boys and girls, ns:non significant, # rounded values 
  FA:Fatty acids; LCPUFA:Long-chain polyunsaturated FA, MUFA:Monounsaturated FA;  
  PUFA: Polyunsaturated FA; SD:Standard deviation; SFA:Saturated FA. 
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Table 6.3a: Gender-specific  fatty acid  ratios based on individual fatty acids (conc%) of serum  
                    phospholipids as mean (standard deviation) #. 
 
Fatty acid ratio  Total (n=1,024) Boys (n=475) Girls (n=549) p value* 
AA/LA 0.43 (0.11) 0.43 (0.11) 0.42 (0.11) ns 
(DHGLA+AA)/LA 0.56 (0.14) 0.57 (0.14) 0.55 (0.14) 0.006 
EPA/ALA 3.76 (2.80) 3.86 (2.70) 3.68 (2.89) ns 
DHA/EPA 7.11 (3.64) 6.67 (3.35) 7.49 (3.68) ns 
AA/EPA 27.5 (18.9) 27.1 (18.5) 27.8 (19.3) ns 
LA/ALA 199 (103) 202 (102) 197 (103) ns 
AA/(EPA+DHA) 3.31 (1.65) 3.49 (1.87) 3.15 (1.41) ns 
ω6/ω3 12.0 (4.9) 12.5 (5.4) 11.6 (4.5) ns 
P/S 0.79 (0.06) 0.79 (0.06) 0.79 (0.06) ns 
M/S 0.20 (0.03) 0.20 (0.03) 0.20 (0.03) ns 
 
   
*P values are based on independent t-test comparing boys and girls, ns:non significant.  
 
 
 
Table 6.3b: Gender-specific  fatty acid ratios based on individual fatty acids (µmol/L) of serum  
                    phospholipids as mean (standard deviation) #. 
 
Fatty acid ratio  Total (n=1,024) Boys (n=475) Girls (n=549) p value* 
AA/LA 0.43 (0.11) 0.43 (0.11) 0.42 (0.12) ns 
(DHGLA+AA)/LA 0.56 (0.14) 0.57 (0.14) 0.55 (0.14) ns 
EPA/ALA 3.76 (2.80) 3.86 (2.70) 3.68 (2.89) ns 
DHA/EPA 7.11 (3.64) 6.67 (3.55) 7.49 (3.68) ns 
AA/EPA 27.5 (18.9) 27.1 (18.5) 27.8 (19.3) ns 
LA/ALA 199 (103) 202 (102) 197 (103) ns 
AA/(EPA+DHA) 3.31 (1.65) 3.49 (1.87) 3.15 (1.41) 0.022 
ω6/ω3 12.0 (4.9) 12.5 (5.4) 11.6 (4.5) 0.000 
P/S 0.79 (0.06) 0.79 (0.06) 0.79 (0.06) ns 
M/S 0.20 (0.03) 0.20 (0.03) 0.20 (0.03) ns 
 
   
*P values are based on independent t-test comparing boys and girls, ns:non significant. # rounded values 
  AA:Arachidonic acid, ALA:α-linolenic acid, DHA:Docosahexaenoic acid, DHGLA:Dihomo-γ-linolenic acid,     
  EPA:Eicosapentaenoic acid, LA:Linoleic acid, M:Monounsaturates, P:Polyunsaturates, S:Saturates, 
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Table 6.3c: Gender-specific  fatty  acid  ratios  based  on  individual  fatty acids  (area%) of  
     serum  phospholipids  as  mean  (standard deviation) #. 
 
Fatty acid ratio  Total (n=1,024) Boys (n=475) Girls (n=549) p value* 
AA/LA 0.45 (0.12) 0.45 (0.12) 0.44 (0.12) ns 
(DHGLA+AA)/LA 0.58 (0.14) 0.59 (0.14) 0.58 (0.14) 0.003 
EPA/ALA 4.01 (2.98) 4.12 (2.86) 3.92 (3.08) ns 
DHA/EPA 7.60 (3.84) 7.15 (3.74) 7.99 (3.89) ns 
AA/EPA 27.9 (19.2) 27.6 (18.9) 28.1 (19.4) ns 
LA/ALA 206 (105) 208 (106) 204 (105) ns 
AA/(EPA+DHA) 3.16 (1.63) 3.34 (1.87) 3.01 (1.38) 0.000 
ω6/ω3 9.1 (3.0) 9.3 (3.2) 8.9 (2.9) 0.008 
P/S 0.88 (0.06) 0.88 (0.06) 0.88 (0.06) ns 
M/S 0.33 (0.05) 0.33 (0.06) 0.32 (0.05) ns 
 
   
*P values are based on independent t-test comparing boys and girls, ns:non significant.  
 
 
Table 6.3d: Gender-specific comparisons of fatty acid ratios based on area% and conc% of  
      serum phospholipids as mean (standard deviation) #. 
 
Fatty acid ratio  Boys (n=475) Girls (n=549) 
 
area% conc% area% conc% 
AA/LA 0.45 (0.12) 0.43 (0.11)1 0.44 (0.12) 0.42 (0.11) 1 
(DHGLA+AA)/LA 0.58 (0.14) 0.57 (0.14) 1 0.58 (0.14) 0.55 (0.14) 1 
EPA/ALA 4.01 (2.98) 3.86 (2.70) 1 3.92 (3.08) 3.68 (2.89) 1 
DHA/EPA 7.60 (3.84) 6.67 (3.35) 7.99 (3.89) 7.49 (3.68) 
AA/EPA 27.9 (19.2) 27.1 (18.5) 28.1 (19.4) 27.8 (19.3) 
LA/ALA 206 (105) 202 (102) 1 204 (105) 197 (103) 1 
AA/(EPA+DHA) 3.16 (1.63) 3.49 (1.87) 3.01 (1.38) 3.15 (1.41) 
ω6/ω3 9.1 (3.0) 12.5 (5.4) 1 8.9 (2.9) 11.6 (4.5) 1 
P/S 0.88 (0.06) 0.79 (0.06) 1 0.88 (0.06) 0.79 (0.06) 1 
M/S 0.33 (0.05) 0.20 (0.03) 1 0.32 (0.05) 0.20 (0.03) 1 
 
   
1P values are based on paired t-test with p=0.000 between conc% and area% of boys or girls.  # rounded values 
 AA:Arachidonic acid, ALA:α-linolenic acid, DHA:Docosahexaenoic acid, DHGLA:Dihomo-γ-linolenic acid,   
 EPA:Eicosapentaenoic acid, LA:Linoleic acid, M:Monounsaturates, P:Polyunsaturates, S:Saturates, 
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Table 6.4a: Fatty  acid  ratios (based on conc%)  associated  to body mass index in  boys as 
         mean (standard deviation)#. 
 
 
*P values are based on the ANCOVA F-test including maturity, age, centre, body mass index, body fat, and   
  fat free mass as independent variables, with leptin and insulin as covariates. ns:non significant. 
  Bonferroni post hoc test: 1 p<0.05 compared to normal weight;2 p<0.01 compared to normal weight; 
     
                      
3
 p<0.05 compared to obesity. 
#
 rounded values 
  AA:Arachidonic acid, ALA:α-linolenic acid, DHA:Docosahexaenoic acid, DHGLA:Dihomo-γ-linolenic   
  acid, EPA:Eicosapentaenoic acid, LA:Linoleic acid, M:Monounsaturates, P:Polyunsaturates, S:Saturates, 
 
 
Boys  
Body mass index  Fatty acid ratio  
Underweight 
(n=25) 
Normal weight 
(n=332) 
Overweight 
(n=84) 
Obesity 
(n=34) p-value* 
AA/LA 0.39 (0.08) 0.42 (0.11) 0.45 (0.12) 0.48 (0.15) ns 
(DHGLA+AA)/LA 0.52 (0.10) 0.55 (0.13) 0.60 (0.15) 0.64 (0.18) ns 
EPA/ALA 3.12 (1.80) 3.75 (2.75) 4.48 (2.89) 3.97 (2.03) ns 
DHA/EPA 7.86 (3.96) 6.56 (3.49) 6.86 (3.81) 6.43 (3.11) ns 
AA/EPA 34.6 (26.4) 26.6 (18.5) 26.4 (16.4) 28.4 (15.2) ns 
LA/ALA 209 (93) 194 (101) 225 (108) 215 (103) ns 
AA/(EPA+DHA) 3.83 (2.12) 3.43 (1.61) 3.31 (1.08)3 2.94 (1.18) 0.029 
ω6/ω3 14.1 (6.1)2 12.4 (5.1) 11.8 (3.4) 14.3 (9.7) 0.017 
P/S 0.80 (0.07) 0.79 (0.06) 0.79 (0.06) 0.79 (0.05) ns 
M/S 0.19 (0.03) 0.20 (0.04) 0.20 (0.03) 0.20 (0.03) ns 
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Table 6.4b: Fatty  acid  ratios  (based on conc%)  associated  to  body  mass  index  in  girls  as  
      mean (standard deviation)#. 
 
Girls  
Body mass index  Fatty acid ratio  
Underweight 
(n=33) 
Normal weight 
(n=409) 
Overweight 
(n=87) 
Obesity 
(n=22) p-value* 
AA/LA 0.37 (0.11) 0.41 (0.11)3 0.48 (0.11) 0.51 (0.12) 0.001 
(DHGLA+AA)/LA 0.50 (0.12) 0.54 (0.13)2 0.62 (0.13) 0.65 (0.16) 0.031 
EPA/ALA 3.46 (2.38) 3.49 (2.34) 3.86 (3.59) 6.76 (6.28) ns 
DHA/EPA 7.13 (3.24) 7.63 (3.85) 7.34 (3.20) 6.04 (2.03) ns 
AA/EPA 25.1 (16.4) 28.2 (20.4) 28.1 (15.9) 24.0 (11.3) ns 
LA/ALA 186 (109) 197 (102) 193 (91) 244 (138) ns 
AA/(EPA+DHA) 2.94 (1.18) 3.09 (1.23) 3.45 (2.16) 3.31 (0.98) ns 
ω6/ω3 11.6 (4.3) 11.6 (4.2) 11.5 (5.8) 11.1 (4.0) ns 
P/S 0.77 (0.07) 0.80 (0.06) 0.80 (0.05) 0.77 (0.05) ns 
M/S 0.20 (0.04) 0.20 (0.03) 0.20 (0.03) 0.19 (0.04) ns 
 
      
 
*P values are based on the ANCOVA F-test including maturity, age, centre, body mass index, body fat, and fat   
  free mass as independent variables, with leptin and insulin as covariates. ns:non significant. 
  Bonferroni post hoc test: 1 p<0.05 compared to obesity;2 p<0.05 compared to overweight; 
     
                      
3
 p<0.001 compared to overweight. 
#
 rounded values 
  AA:Arachidonic acid, ALA:α-linolenic acid, DHA:Docosahexaenoic acid, DHGLA:Dihomo-γ-linolenic acid,  
  EPA:Eicosapentaenoic acid, LA:Linoleic acid, M:Monounsaturates, P:Polyunsaturates, S:Saturates, 
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Table 6.4d: Fatty  acid  ratios  (based on area%)  associated  to body mass index in  girls as  
      mean (standard deviation)#. 
 
Girls  
Body mass index  Fatty acid ratio  
Underweight 
(n=33) 
Normal weight 
(n=409) 
Overweight 
(n=87) 
Obesity 
(n=22) p-value* 
AA/LA 0.40 (0.12) 0.43 (0.12)1 0.50 (0.11) 0.53 (0.13) 0.000 
(DHGLA+AA)/LA 0.52 (0.13) 0.56 (0.13)2 0.65 (0.13) 0.68 (0.16) 0.025 
EPA/ALA 3.67 (2.50) 3.72 (2.48) 4.10 (3.87) 7.21 (6.69) ns 
DHA/EPA 7.65 (3.46) 8.14 (4.07)3 7.83 (3.43)3 6.46 (2.15) 0.021 
AA/EPA 25.3 (16.4) 28.5 (20.6)4 28.3 (16.0)4 24.2 (11.2) 0.004 
LA/ALA 191 (113) 203 (104) 198 (94) 253 (143) ns 
AA/(EPA+DHA) 2.81 (1.12) 2.95 (1.18) 3.30 (2.15) 3.16 (0.93) ns 
ω6/ω3 8.7 (3.0) 8.9 (2.9) 8.8 (2.6) 8.7 (2.9) ns 
P/S 0.85 (0.07) 0.88 (0.06) 0.88 (0.05) 0.85 (0.06) ns 
M/S 0.33 (0.06) 0.32 (0.05) 0.32 (0.05) 0.31 (0.07) 0.040 
 
      
 
#
 rounded values 
*P values are based on the ANCOVA F-test including maturity, age, centre, body mass index, body fat, and    
  fat free mass as independent variables, with leptin and insulin as covariates. ns:non significant. 
  Bonferroni post hoc test: 1 p<0.001 compared to overweight; 2 p<0.05 compared to overweight; 
     
                    
3
 p<0.05 compared to obesity; 4 p<0.01 compared to obesity. 
  AA:Arachidonic acid, ALA:α-linolenic acid, DHA:Docosahexaenoic acid, DHGLA:Dihomo-γ-linolenic   
  acid, EPA:Eicosapentaenoic acid, LA:Linoleic acid, M:Monounsaturates, P:Polyunsaturates, S:Saturates, 
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7 Individual serum phospholipid fatty acids and their association with 
lipid and lipoprotein concentrations in European adolescents 
 
 
Short Summary  
 
Background: The crucial role of lipids and lipoproteins in the development of CHD and 
atherosclerosis is well established and the origin of atherosclerosis is likely placed in 
childhood and adolescence. Fatty acids are proposed to have cholesterolemic effects on 
several blood lipids, suggesting SFA as hypercholesterolemic and PUFA as 
hypocholesterolemic compared to SFA. However, those studies are based on dietary FA 
intake data of adults and less is known about the association between serum FA 
concentrations measured in PL and blood lipid concentrations in healthy adolescents. 
Objective: To investigate the influence of individual serum FA (C16:0, C18:0, C18:1ω9c, 
LA, ALA, AA, EPA, and DHA) on blood lipid concentrations (i.e. TC, HDL, LDL, TG, 
Lp(a), apo A-1, and apo B) in healthy European adolescents. 
Results: The effect of individual FA (C16:0, C18:0, C18:1ω9c, LA, ALA, AA, EPA, and 
DHA) on several lipid and lipoprotein concentrations was investigated in 1,024 subjects (475 
boys and 549 girls). Multiple linear regression analysis has been used. As main cause of 
variance the independent variables age, maturity, BMI, and the lipids (TG, TC, HDL, LDL, 
Lp(a), apo A-1, and apo B) except the lipid parameter, which has been defined as dependent 
variable (e.g. TG), have been included. Additionally, one FA (i.e. C16:0, C18:0, C18:1ω9c, 
LA, ALA, AA, EPA, or DHA) has been included as predictor in the current model. When 
including FA in the regression model, TG were mainly influenced by C16:0 and C18:0 (R² 
change 0.07 in boys and 0.04 in girls). The influence of the selected FA on cholesterol-
containing lipoproteins can be neglected (R² change <0.004).  
Conclusion: The selected serum FA were associated to a minor degree with the lipid and 
lipoprotein concentrations of healthy European adolescents. Thus, it might be interesting to 
focus on other nutrients that accompany dietary fat intake (e.g. fat soluble vitamins, plant 
sterols, polyphenols) as well as other nutrients in the diet (e.g. dietary fibres, carbohydrates, 
proteins) to explain the effect of dietary FA observed in other studies. 
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Introduction 
 
Blood lipid (e.g. cholesterol) and lipoprotein (e.g. HDL, LDL) patterns play a qualitative and 
quantitative role in the development of atherosclerosis and CHD [1-5]. It is suggested that the 
beginning of atherosclerosis is placed in childhood and adolescence [6-8], where crucial 
metabolic changes (e.g. within lipid patterns) happen because of rapid growth and 
development. 
Current research suggests cholesterolemic effects of FA, more precisely, a cholesterol 
increase caused by higher dietary intakes of SFA, whereas dietary PUFA decrease the 
cholesterol content of several lipoproteins compared to SFA [9, 10].  
However, the cholesterolemic properties of dietary FA were investigated only in adults who 
were fed special diets focused on lipid-lowering effects [9, 10]. Beside that, study results, 
which found cholesterolemic effects of FA, are based only on dietary intake data. This data is 
critical for two reasons: (a) dietary intake data does not reflect the exact FA status of the body 
and (b) the data may be biased by the used assessment methods including questionnaires and 
food composition tables. These methods are still insufficient in assessing the exact dietary FA 
intake because of misreporting of the participants and lacking information about availability 
and content of individual FA in foods provided by the used food composition tables [11-13]. 
Furthermore, the intake of other dietary components may also lead to hypocholesterolemic 
effects and thus bias those mentioned findings, for instance the intake of dietary fibres [14, 
15] or plant sterols [16, 17].  
Consequently, it is important to investigate the association between serum FA and blood lipid 
concentrations to exclude those uncertainties.  
In the frame of the HELENA Study, the serum FA profile of PL in an adolescent group was 
assessed. Serum PL reflect the FA content of the diet for at least a few days [18, 19]. Further, 
absolute concentrations instead of relative proportions were used. This approach enables the 
use of FA, which are independent of other FA measurements of the same FA profile, like it is 
present in percentaged profiles. The aim of the chapter was to assess the variability caused by 
selected individual FA concentration of C16:0, C18:0, C18:1ω9c, LA, ALA, AA, EPA, and 
DHA on TG, TC, HDL, LDL, apo A-1, apo B, and Lp(a) concentrations.  
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Subjects and Methods  
 
A detailed description of study design, subject recruitment, medical examination, blood 
sampling, sample treatment, biochemical analysis, and evaluation procedures can be found in 
chapter 3 (General Methodology). 
 
Statistics  
All statistical analysis procedures were carried out gender-specific using Statistical Package 
for Social Sciences version 17.0 for Windows (SPSS Inc., Chicago, Illinois, USA). Blood 
analytes were skewed and logarithmically transformated before statistical analysis. Basic 
characteristics were compared using independent t-tests (metric variables) and chi square test 
(categorical variables). Correlations were made using Pearson product-moment correlations 
(r) with 2-tailed significance between lipids, lipoproteins, and the selected FA. The 
association of C16:0, C18:0, C18:1ω9c, LA, ALA, AA, EPA, and DHA with lipid parameters 
were analysed comparing two linear regression models. As main cause of variance, model 1 
included the independent variables age, maturity, BMI, and the lipid parameters of TG, TC, 
HDL, LDL, Lp(a), apo A-1, and apo B, except for the lipid parameter that was chosen as 
dependent variable in the current model. This model was compared with model 2 including 
the variables of model 1 additionally to one of the selected FA (predictors) of interest. The 
referring tables highlight the following indices to describe the results of the linear regression 
model. The adjusted coefficient of determination (R2) explains the proportion of the variance 
in a dependent variable at a significant level (through a significance test of R2) considering the 
complexity of the model. The standardized coefficient β is the average amount that the 
dependent variable increases when the independent variable increases one SD and other 
independent variables are held constant. The partial correlation measures the degree of 
association between the lipid variable and the selected FA when the other independent 
variables are removed. R² change was used to indicate the variability between the two models 
caused by the inclusion of the selected individual FA. Generally, p values <0.05 were 
considered as statistically significant. 
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Results 
 
Serum FA data was available for 1,024 adolescent subjects (475 boys and 549 girls) within 
the HELENA-CSS. Basic characteristics of the study population are presented in table 7.1. 
Fasting blood lipid concentrations were significantly higher in girls than in boys as well as 
most FA. Only oleic acid and EPA failed to reach statistical significance between genders.  
In table 7.2a, Pearsons correlations coefficients between FA and lipids/ lipoproteins in boys 
can be found. All FA correlated significantly with the listed lipids and lipoproteins except for 
Lp(a). Girls showed the same pattern as indicated in table 7.2b.  
Results of the multiple linear regression analyses are shown in table 7.3a for TG, in table 7.3b 
for TC, in table 7.3c for HDL, in table 7.3d for LDL, in table 7.3e for Lp(a), in table 7.3f for 
apo A-1, and in table 7.3g for apo B.  
For boys, the variables of model 1 (i.e. age, maturity, BMI, HDL, LDL, TC, Lp(a), apo A-1, 
and apo B) explained 44.7% of the variance of the TG concentrations. The strongest 
association, when including single FA in the model, was found between TG concentrations 
and C16:0 and C18:0. Palmitic acid, C18:0 as well as C18:1ω9c accounted for an additional 
change of 7.1%, 7.3%, and 3.5% of the adjusted R². The other FA (LA, ALA, EPA, DHA, and 
AA) led to a R² change of <2.3% (table 7.3a). With respect to TC, LDL, and HDL the 
adjusted R² of the models were 0.940, 0.878, and 0.937. The inclusion of FA in any of those 
models changed the results minimally. The selected FA were associated with changes of R² of 
approx. ≤0.3% of the TC, LDL, and HDL regression models (tables 7.3b-d). The inclusion of 
FA in the Lp(a) model failed to reach any statistical significance in boys. Further, age, 
maturity, BMI, HDL, LDL, TC, TG, apo A-1, and apo B accounted for 11.8% of the variance 
of Lp(a) concentrations (table 7.3e). The R² change of the apo regression models indicated an 
association of <0.5% by adding one FA (C16:0, C18:0, C18:1ω9c, LA, ALA, AA, EPA, or 
DHA) to the models. Generally, the adjusted R² of the models including age, maturity, BMI, 
HDL, LDL, TC, TG, Lp(a), and apo A-1 or apo B accounted for 77% and 88% of the variance 
of the apo A-1 and B concentrations (tables 7.3f and 7.3g). 
For girls, the adjusted R² of model 1 (i.e. age, maturity, BMI, HDL, LDL, TC, Lp(a), apo A-1, 
and apo B) accounted for 47.6% of the variance of the TG concentrations. The strongest 
association, when including single FA in the model, was found between TG concentrations 
and C16:0 and C18:0. Palmitic acid and C18:0 achieved a R² change of 4.7% and 4.1% in the 
second model. The other FA (LA, ALA, and C18:1ω9c) accounted for an additional increase 
of <2.5% of the adjusted R² (table 7.3a). The models with TC, LDL, and HDL as dependent 
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variables showed adjusted R² values of 0.945, 0.936, and 0.890. The inclusion of selected FA 
in any of these models had minor effects and showed a R² change of ≤0.4% (tables 7.3b-d). In 
contrast to boys, the Lp(a) regression model of girls showed significant results for C16:0, 
C18:1ω9c, and AA. The highest R² change of 1.7% was observed when adding AA to the 
model. The other independent variables age, maturity, BMI, HDL, LDL, TC, TG, apo A-1, 
and apo B accounted for 4.4% of the variance of Lp(a) concentrations (table 7.3e). 
Differences in the adjusted R² values of the regression models using apo A-1 and B as 
dependent variable showed a R² change of ≤1.0% for the selected FA (C16:0, C18:0, 
C18:1ω9c, LA, ALA, AA, EPA, or DHA). Generally, the model including age, maturity, 
BMI, HDL, LDL, TC, TG, Lp(a), and apo A-1 or apo B accounted for 78% and 89% of the 
variance of the apo A-1 and B concentrations (tables 7.3f and 7.3g). 
 
 
Discussion 
 
Studies, which investigated cholesterolemic effects of FA, focused on dietary data in 
adulthood [9, 10, 20-25]. Fatty acids assessed by dietary recalls may be inaccurate when 
investigating cholesterolemic properties on blood lipid concentrations, because the data may 
be biased by misreporting and insufficient assessment of the true content of FA in foods. 
Biomarkers like serum FA of the PL fraction may be better parameters for dietary intake [26] 
and endogenous modifications and thus a more reliable approach.  
A recently published study by Motoyama et al. [27] investigated the association of total 
serum ω6 and ω3 PUFA with lipids in three populations of men aged 40-49 years (whites 
n=261, Japanese n=285, and Japanese Americans n=212). Briefly, they made tertile groups of 
ω6 and ω3 PUFA for each population and compared age- and multivariable-adjusted tertile-
specific concentrations of lipids (TG, LDL and HDL). Serum ω6 and ω3 PUFA were 
significantly inversely associated with TG levels across all three populations. Further, ω6 
PUFA were significantly positively associated with HDL in whites and Japanese whereas 
EPA was significantly positively associated with HDL in whites. A significantly positive 
association of ω3 PUFA with HDL was found in Japanese. Both ω6 and ω3 PUFA were 
positively associated with LDL in Japanese but not in whites or Japanese Americans. 
However, whether these results are comparable with the current findings in European 
adolescents is questionable. Tertile groups were not applied in the HELENA Study, and 
whether the metabolism of adolescents follow similar metabolic patterns as observed in adults 
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is not clear. The few studies that found associations of serum FA and cholesterol levels in 
youth are solely based on the comparison of different TC cut-offs with FA compositions [28] 
or their correlations [29]. These studies do not allow a final evaluation of the cholesterolemic 
effects of serum FA and are not comparable with the present approach of a multiple linear 
regression analysis.  
Within the HELENA Study, the inclusion of C16:0 or C18:0 into the linear regression model 
of TG led to the highest R² change values in both genders (table 7.3a). It might be reasonable 
to conclude that these two FA as a main part of dietary SFA in TG are also reflected in the 
serum TG levels and thus account for the variability of the TG levels. The deviating 
associations between boys and girls of the analysed FA with the TG concentrations may 
reflect differences in the dietary intake and/ or gender-specific discrepancies in FA 
metabolism [30]. Beside that, approx. 50% of the TG levels were explained by the parameters 
used in the present regression model (i.e. age, maturation, BMI, HDL, LDL, TC, Lp(a), apo 
B, and apo A-1) in both sexes (table 7.3a). Therefore, it can be suggested that other 
parameters, which were not part of the regression model, have a more important impact on 
TG levels (e.g. dietary fat or other nutrients). 
The cholesterolemic effects of the selected FA (C16:0, C18:0, C18:1ω9c, LA, ALA, AA, 
EPA, and DHA) on TC, HDL, and LDL levels were minimal; the R² change value was <0.5% 
when adding one of those FA to the model. Due to the fact that apparently healthy adolescents 
were investigated, it may be possible that no cholesterolemic effects of those FA are 
observable. The HELENA participants showed acceptable lipid ranges and cholesterolemic 
effects of FA may possibly only be recognizable in adolescents with high lipid concentrations 
and/ or with higher FA concentrations. On the other hand, the serum FA proportion may be 
more important in regulating the cholesterol pool than individual FA concentrations.  
However, the literature suggests effects of individual dietary FA or FA classes [9, 10]. 
Cellular mechanisms of these cholesterolemic effects are not fully understood. Studies using 
cultured cell lines proposed modifications within the LDL receptor activity and altered acyl-
CoA:cholesterol acyltransferase enzyme activities caused by individual FA supplementation, 
although these studies show inconsistent results [31, 32].  
Lipoprotein(a) was hardly associated with FA in European boys and girls. The reason for the 
general low impact of FA on Lp(a) levels may be the strong link to apolipoprotein(a) 
genotypes and Kringle repeats, which mainly define Lp(a) variability [33]. Thus, Lp(a) 
concentrations are determined early in life, stay relatively constant over time, and are 
generally independent of other factors. This is supported by the fact that the variables of the 
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used regression models accounted solely for 12% and 5% of the variability of Lp(a) 
concentrations in boys and girls (table 7.3e).  
In general, the present basic regression models (model 1) explained quite sufficiently the 
variance of the different blood parameters without adding individual FA, except for Lp(a) and 
TG. These findings indicate an essential impact of age, maturation, and BMI as well as 
interaction effects of the lipids and lipoproteins on each other. However, one has to keep in 
mind that other factors may also be important in the regulation of lipid concentrations. For 
instance, hormones, genetic variations or lifestyle parameters (e.g. physical activity) could be 
of interest, but were not included in the model. Further, dietary fat intake itself was not 
available at the time of analysis. Moreover, dietary fat intake data may weaken the current 
results, based on reliable biomarkers, due to misreporting of the participants.  
Another important point is that prior study results are mainly obtained through substitutions 
of FA classes in the diet [10]. These sudden dietary changes in the FA profile lead to 
modifications of the serum FA composition, which may shift the serum cholesterol pattern of 
lipoproteins. Additionally, these serum FA changes may result in prompt inhibitions or 
activations of metabolic pathways as response of these sudden dietary changes, and thus 
influencing more factors than the FA content alone (e.g. altered gene expression due to FA 
interactions). This may also alter factors which are important for the regulation of the 
cholesterol metabolism. In the HELENA-CSS, no special diet was introduced and no dietary 
patterns were modified for the study purpose, thus shifted interactions between FA and 
metabolic pathways as a consequence of intended dietary changes were not expected. 
Accordingly, the expected influence of FA on the cholesterol pattern of lipoproteins may not 
be present as it may be observed in lipid profile of subjects with recently changed eating 
habits.  
Another reasonable explanation may be the intake of other dietary components affecting the 
serum lipid concentration [14-17, 34]. These dietary components may accompany dietary fat 
intake (e.g. fat soluble vitamins, plant sterols, polyphenols) and thus are ingested 
simultaneously. They have also lipid-lowering properties [16, 17, 34], but these effects could 
be covered or incorrectly associated to FA, because of the contemporary dietary intake. For 
instance, the simultaneously intake of plant sterols or tocopherols with dietary PUFA may 
enhance the distribution of cholesterol towards the enterohepatic cholesterol efflux. 
Moreover, dietary fibres, carbohydrates, proteins, or unknown components may affect lipid 
concentrations as well [14, 35]. 
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Conclusion  
 
In the present adolescent population, the associations between selected serum FA measured in 
PL and serum TG, TC, HDL, LDL, apo A-1, apo B, and Lp(a) parameters are minimal. 
Therefore, studies in adults, which found an association between dietary FA intake and blood 
lipids, may have another explanation. Moreover, the metabolism of adolescents may not 
follow in similar metabolic patterns as observed in adults. Furthermore, the lipid metabolism 
may be too strightly regulated to expect detectable changes due to one single FA. 
Additionally, investigations may focus on other nutrients that accompany dietary fat intake 
(e.g. fat soluble vitamins, plant sterols, polyphenols) as well as on other nutrients in the diet 
(e.g. dietary fibres, carbohydrates, proteins) to clarify their influence on lipid concentrations.  
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Table 7.1: Basic characteristics of the study population as mean (standard deviation). 
 
*p values (2-tailed) are based on an independent t-test; # based on Chi square test; ns:non significant 
1boys n=417, and girls n=494; 2boys n=461, and girls n=529;  
3boys n=469, and girls n=541; 4boys n=475, and girls n=547; 
5boys n= 462, and girls n=531. 
 
 HDL:High density lipoprotein cholesterol, LDL:Low density lipoprotein cholesterol. 
 
 Boys Girls p value* 
n 475 549  
Age (years) 14.84 (1.21) 14.90 (1.16) ns 
Height (cm) 169.8 (9.8) 161.8 (7.0) 0.000 
Weight (kg) 61.7 (13.7) 56.0 (10.2) 0.000 
Body mass index (kg/m²) 21.3 (3.8) 21.3 (3.4) ns 
Tanner stage1 3.9 (1.0) 4.0 (0.8) 0.007# 
Body fat (%)2 21.0 (10.5) 27.3 (7.6) 0.000 
Fat free mass (kg)3 51.8 (9.6) 41.8 (7.0) 0.000 
Triglycerides (mg/dL)4 64 (31) 73 (37) 0.000 
Total cholesterol (mg/dL)4 154 (26) 167 (28) 0.000 
HDL (mg/dL)4 53 (10) 57 (11) 0.000 
LDL (mg/dL)4 91 (25) 98 (25) 0.000 
Apolipoprotein A-1 (g/L)5 1.45 (0.21) 1.55 (0.23) 0.000 
Apolipoprotein B (g/L)5 0.62 (0.15) 0.68 (0.16) 0.000 
Lipoprotein(a) (mg/L)5 175 (219) 209 (258) 0.017 
C16:0 (µmol/L) 1,136 (191) 1,222 (221) 0.000 
C18:0 (µmol/L) 491 (99) 523 (97) 0.000 
C18:1ω9c (µmol/L) 255 (73) 263 (78) ns 
C18:3ω3c (µmol/L) 5 (3) 6 (4) 0.003 
C18:2ω6c (µmol/L) 814 (170) 880 (179) 0.000 
C20:4ω6c (µmol/L) 345 (89) 363 (97) 0.000 
C20:5ω3c (µmol/L) 18 (13) 19 (14) ns 
C22:6ω3c (µmol/L) 94 (38) 110 (40) 0.000 
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8 General Discussion 
 
The focus of this thesis is set on the lipid status of adolescents across Europe and their 
associations with several non-communicable (i.e. gender, age, and sexual maturity) and 
communicable (i.e. BMI, BF, and FFM) parameters. In the previous chapters lipids results 
(e.g. for cholesterol, TG, or FA) were described separately according to the association with 
those non-communicable and communicable factors. Within this chapter, the discussion will 
sum up the relationships between the non-communicable or communicable factors and the 
complete measured lipid profile of European adolescents. Further, the limitations and 
strengths of the HELENA Study, the different FA calculation methods, and the application of 
reference data will be discussed. 
The first non-communicable factor that will be discussed here is gender. In HELENA, gender 
differences within the lipid variables were the most striking results. Compared to boys, girls 
showed higher lipid levels measured in routine diagnostics (e.g. TC, HDL, LDL, or TG), as 
highlighted in table 4.1. Moreover, nearly all absolute FA concentrations, except for 
C15:1ω5c, C17:1ω7c, C18:1ω9c, C18:3ω6c, C20:3ω6c, and EPA, were higher in girls than in 
boys (table 5.3). This finding may be related to the higher levels of routine lipid parameters 
observed in girls, and may point to higher amounts of and/ or larger transport lipoproteins in 
females. However, differences in the percentaged FA profile (conc%) between boys and girls 
are less obvious (table 5.4). Girls showed higher proportions of C20:1ω9c, DHA, and total ω3 
FA, whereas total ω9 FA and in particular C18:1ω9c were decreased. The essential FA LA 
and ALA as well as EPA and AA did not differ between sexes. With respect to FA ratios, 
some gender-specific differences were found (i.e. [DHGLA+AA]/LA, AA/[EPA+DHA], and 
ω6/ω3) with higher ratios in boys, but these results were linked to the calculation method (for 
details see chapter 6). With regard to the lipid and lipoprotein ratios, only the mean TG/HDL 
ratio was significantly higher in girls compared to boys, whereas the other ratios (Apo B/Apo 
A-1, TC/HDL, LDL/HDL, Apo B/LDL, nonHDLC/HDL, and the AI) did not differ between 
genders. Generally, these findings show that gender differences exist, especially in the 
absolute values of blood lipids. Even though, these gender differences become less obvious in 
comparison with lipid and lipoprotein ratios, percentaged FA profiles, or FA ratios.  
The results of the routine diagnostic lipid parameters are in accordance with one study [1], but 
not with others [2, 3]. Discrepancies may be a consequence of different sub-group 
classifications. The separation of boys and girls into different age ranges leads to different
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group sizes, which may affect the study results. Further explanations may be the influence of 
country-specific eating patterns or genetic variability. Gender differences in FA profiles were 
not observed in other studies [4-7]. However, the present study population consists of a larger 
sample size and is more heterogeneous than the other study groups. Thus, it is likely that 
gender differences may be detected only in larger sample sizes or biased by the gender-
specific food and FA intake of the participating countries [8]. Furthermore, most studies, 
which investigated FA ratios in adolescents/ children, did not separate between boys and girls 
[9, 10] or did not find gender-specific differences in their study groups [4, 5]. 
Gender differences between the clinical lipid parameters may be explained by changes in the 
sex hormone levels, especially during adolescence. This assumption is supported by findings 
in other study populations [11-13]. Gender-specific sex hormone levels may also contribute to 
the different results found in the FA profiles, because sex hormone concentrations may affect 
enzyme activities of the FA metabolism [14]. However, the impact of sex hormones on the 
FA composition is less investigated in adolescents. In HELENA, the measurement of sex 
hormones was not feasible, thus this point cannot be judged sufficiently with the available 
data. Nonetheless, if was feasible to judge the state of puberty of the HELENA participants 
according to their physical signs, which will be discussed later on. Moreover, gender 
differences in serum FA may be related to gender-specific eating patterns including different 
food choices of the adolescents. Especially the essential FA of the ω6 and ω3 family have to 
be provided by the normal diet. For instance, the intake of long-chain ω3 FA, found in fatty 
fish and seafood, may be higher in female adolescents compared to male adolescents. Those 
FA have been proposed as dietary intake markers of such food groups [8, 15, 16].  
As a consequence of the gender-specific differences in the blood lipid concentrations, all 
other communicable and non-communicable determinants were discussed for boys and girls 
separately, which makes comparisons to other study results in some cases difficult. 
Age is a non-communicable factor, which is commonly used in the literature, to categorize 
children/ adolescents into several age groups for later comparisons. In HELENA, age was 
associated with shifted TG levels in boys (table 4.3a), and, as a consequence, with changes in 
the male TG/HDL ratio. Further, the present study found associations of age with several FA 
(conc%) namely C16:0, C18:0, PUFA, ω3 FA, and trans FA in female subjects. In boys, a 
relation between age and C14:1ω5c, C18:0, C18:3ω6c, C20:2ω6c, C23:0, and SFA was 
present (table 5.5). Moreover, the absolute FA composition of boys differed in C14:1ω5c and 
C20:1ω9c due to age, whereas in girls differences in C16:0, C17:1ω7c, C20:1ω9c, C22:1ω9c, 
C22:2ω6c, C24:0, C24:1ω9c, MUFA, ω9 and ω3 FA were observed. By contrast, FA ratios 
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with regard to age categories differed only in girls. Changes in the EPA/ALA, ω6/ω3, and/ or 
M/S ratio have been shown, depending on the calculation method.  
Higher TG levels with increasing age were also found in most [1, 17, 18] but not all [2] 
studies. Moreover, all mentioned studies found also age-dependent changes within the other 
lipid levels of boys and girls [1, 2, 17, 18]. By contrast, FA profiles were basically not 
analysed with a special focus on age [4, 5, 7, 9, 10, 19, 20], thus information concerning age 
and FA status is scarce. Only one known study used age groups to categorize their study 
population, but the study found no differences between the age groups 5-10 years, 10-15 
years, and 20-26 years. Significant changes were only observed when comparing 20-26 year-
olds with much younger age groups (i.e. 0-1 month or 1-12 months), for example in 
C18:1ω9c, AA, DHA and MUFA [6]. The association between FA ratios and age is even less 
investigated. 
It can be suggested that the main reason for alterations in the lipid profile of adolescents, 
observed due to age, is associated with changed eating pattern. Moreover, it is more likely 
that the age-associated findings in the studies mentioned before are related to maturity. Age 
describes mainly the chronological development of individuals and is not a reliable indicator 
of physiological/ biological development per se. Adolescents can be in different pubertal 
stages, but having the same age. Thus, in studies using age as a criteria instead of pubertal 
stages to group adolescents, significant physiological changes in the lipid profile are 
incorrectly referred to age, even though the age-associated observations are addressed to 
puberty [21]. Other researchers confirmed the link between puberty/ sexual hormones and 
changes in lipid profiles [11, 22-25]. Therefore, the HELENA Study assessed beside 
chronological age also the biological age expressed as Tanner stages. 
In the female HELENA population, there was an increase between Tanner stage IV and V for 
most lipid and lipoprotein ratios (Apo B/Apo A-1, TC/HDL, LDL/HDL, nonHDLC/HDL, and 
the AI), which was not apparent in males (table 4.4b). Further, boys showed associations 
between TC, HDL, and apo A-1 levels and maturity in a mostly inverse manner. Contrariwise, 
in girls, associations between TC, LDL, nonHDLC, and apo B levels and maturity were 
present, but without clear increase or decrease during maturity (table 4.4a). Relationships 
between maturity and the present FA composition were observed. In girls, FA values 
accounting for <1.0conc% of the FA profile, like C17:1ω7c, C20:0, C22:0, C23:0, and 
C24:1ω9c, differed during puberty. In boys, C17:1ω7c, ALA, C20:1ω9c, C20:2ω6c, EPA, 
C22:1ω9c, and ω9 FA were associated with sexual maturation (see table 5.6). Absolute FA 
values (ALA, EPA, and C20:1ω9c) decreased with progressing puberty in boys, whereas in 
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girls C20:0, C22:0, C22:1ω9c, C23:0, and C24:1ω9c decreased with higher Tanner stages. In 
boys, during maturity, the LA/ALA ratio based on conc% and area% calculations increased. 
Furthermore, the AA/EPA ratio estimated by FA in area% increased as well. The female FA 
profiles (conc% and area%) were not associated with maturity. 
Previous studies showed inconsistent findings concerning routine lipid parameters and their 
ratios, probably due to sample size, classification of maturity, and geographic differences 
based on different genetic backgrounds, eating patterns and lifestyle habits [13, 26-29]. In 
fact, a decrease of HDL is seen as a consequence of higher testosterone levels in boys, 
compared to girls, leading to a reduction of apolipoproteins associated with HDL [24]. 
Moreover, maturity proceeds gender-specifically and thus hormone concentrations are 
different between sexes and lead to different lipid levels, body fat content and/ or fat 
allocation. However, the measurement of sex hormones was not feasible, making precise 
conclusions impossible.  
None of the mentioned studies investigated the FA profile with respect to maturity; thus, no 
comparisons can be made [4, 5, 7, 9, 10, 19, 20]. In HELENA, the observations may be a 
consequence of increasing sex hormone concentrations during puberty and/ or altered dietary 
FA supply. Both possibilities could not be verified, because neither data on sex hormone 
status nor dietary FA intake data was available. 
Body mass index, percentage BF, and FFM were chosen as communicable factors within this 
thesis. The most striking finding was that female clinical routine lipid parameters were 
associated with BMI alone, whereas male serum routine lipid parameters were only related to 
BF content (table 4.5a). Additionally, higher lipid and lipoprotein ratios (Apo B/Apo A-1, 
TC/HDL, TG/HDL, LDL/HDL, nonHDLC/HDL, and the AI) were observed in boys with 
high percentage BF (≥25%), whereas in girls those ratios were increased with higher BMI 
status. In the male participants HDL values were not significantly altered with respect to BMI 
status. By contrast, lower HDL levels were observed in boys with higher percentage BF. In 
girls, HDL decreased with increasing BMI, but this decrease was not observed according to 
percentage BF in girls. The absolute FA composition of girls showed associations between 
LA, trans FA, C18:1ω9c, and C21:0 and BMI. Oleic acid and LA were lower in obese and 
overweight subjects compared to girls with normal BMI. In this study, changes in the absolute 
FA profile with respect to BMI were only apparent in girls, not in boys. In the percentaged 
FA profile (conc%) underweight and/ or normal weight girls had higher levels of C18:1ω9c, 
LA and lower levels of AA and LCPUFA (i.e. C20:3ω6c, AA, EPA, and DHA) than their 
overweight and/ or obese counterparts. Contrariwise, BF as grouping factor was only related 
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to changes in the male FA profile (absolute and conc%). In the percentaged FA profile 
(conc%), higher levels of C18:1ω9c, trans FA and lower levels of DHA and C24:1ω9c were 
associated with boys having a BF content of <25%. 
Generally, these findings indicate that higher fat/ weight status is associated with a more 
unfavourable lipid profile and an increased atherogenic risk. This was also observed in a 
Mexican study where the prevalence of different forms of dyslipidemia were significantly 
higher in obese and overweight than in normal weight boys and girls [3]. However, it is not 
clear why, with respect to body composition parameters, male lipid levels are associated with 
BF content only, whereas changes in female lipid parameters are related solely to BMI status. 
Differences may be obtained due to the assessment methods. Fat allocation shows gender-
specific differences, which may be reflected in the different skinfold measurements [30, 31]. 
It may also be possible that the sub-group classification (two BF sub-groups vs. four BMI 
sub-groups) with different group sizes results in altered findings as a consequence of specific 
eating patterns or genetic differences in those sub-groups. The majority of studies investigated 
the FA composition related to obesity and reported no sex differences within the individual 
FA, thus they analysed both sexes together [4, 5, 9]. In HELENA, boys and girls were 
analysed separately making direct comparisons difficult. The present findings of the absolute 
FA composition were not apparent in the study population of Gil-Campos et al., which may 
be a result of the mixed group design or the lower number of subjects in that study [32]. Fatty 
acid ratios are often implemented to detect differences in the FA content due to weight status 
[5, 9, 10]. Further, as estimates of desaturase activities, they may point to functional 
impairments of those enzymes in obesity [4, 33]. However, current research including the 
present findings are inconsistent [5, 9]. Those contrasting results may be a consequence of 
differences in the diet, genetics, FA analytics, and probably group sizes.  
 
The association between selected individual FA (i.e. C16:0, C18:0, C18:1ω9c, LA, ALA, AA, 
EPA, and DHA) and several blood lipid and lipoprotein concentrations was investigated using 
multiple linear regression analyses. Triglyceride levels were mainly associated with C16:0 
and C18:0 (R² change of 0.07 in boys and 0.04 in girls). The association between selected FA 
and the cholesterol-containing lipoproteins can be neglected (R² change <0.004). 
Previous study results are based on dietary data in adults and found cholesterolemic effects of 
FA [34-41], these studies cannot be compared with the HELENA results. The general 
problematic of dietary FA data consists of two points: (a) FA assessed by dietary recalls may 
be biased by misreporting leading to inaccurate evaluations and (b) food composition tables 
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cannot specify the true value of all possible FA in foods. Moreover, the investigation of the 
influence between dietary FA and blood lipids may not lead to correct conclusions, because 
that approach excludes the influence of physiologically important steps in FA metabolism 
(e.g. digestion, absorption, elongation, and desaturation of FA). These steps influence the 
amount and kind of FA in the body and thus any possible function of FA including the 
assumed cholesterolemic effects of FA on blood lipids. Therefore, biomarkers like serum FA 
of the PL fraction may be better parameters. These biomarkers consider dietary intake and 
endogenous modifications of the last days. A recently published study by Motoyama et al. 
[42] investigated the association of total serum ω6 and ω3 PUFA with lipids in three 
populations of men aged 40-49 years. Serum ω6 and ω3 PUFA were significantly inversely 
associated with TG levels across all three populations (whites, Japanese, Japanese 
Americans). Further, ω6 PUFA were significantly positively associated with HDL in whites 
and Japanese whereas EPA was significantly positively associated with HDL in whites. A 
significantly positive association of ω3 PUFA with HDL was found in Japanese. Both ω6 and 
ω3 PUFA were positively associated with LDL in Japanese but not in whites or Japanese 
Americans [42]. However, whether these results are transferable to European adolescents is 
questionable. Tertile groups were not applied in the HELENA Study, and whether the 
metabolism of adolescents follow similar metabolic patterns as observed in adults is not clear. 
The few studies that found associations between serum FA and cholesterol levels in youth are 
solely based on the comparison of different TC cut-offs with FA compositions [43] or their 
correlations [44]. These studies do not allow a final evaluation of the cholesterolemic effects 
of serum FA and are not comparable with the present study results.  
Nonetheless, the literature suggests cholesterolemic effects of individual dietary FA or FA 
classes [40, 41]. Possible cellular mechanisms of these cholesterolemic effects are not fully 
understood. Studies using cultured cell lines proposed modifications within the LDL receptor 
activity and altered acyl-CoA:cholesterol acyltransferase enzyme activities caused by 
individual FA supplementation, however, these studies show inconsistent results [45, 46]. 
Another reasonable explanation may be the intake of other dietary components affecting the 
serum lipid concentration [47-51]. These dietary components may accompany dietary fat 
intake (e.g. fat soluble vitamins, plant sterols, and polyphenols) and thus are ingested 
simultaneously. These components have also lipid-lowering properties [49-51], but because of 
the contemporary dietary intake, these effects could be covered or incorrectly associated to 
FA intake. For instance, the simultaneous intake of plant sterols or tocopherols with dietary 
PUFA may enhance the distribution of cholesterol towards the enterohepatic cholesterol 
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efflux. Moreover, dietary fibres, carbohydrates, proteins, or yet unknown components may 
affect lipid concentrations as well [47, 52]. 
 
A few limitations of the present study deserve comment. Because of the cross-sectional 
design, the temporal relationships are unknown; one cannot say anything about causality of 
the relationships. Furthermore, dietary FA intake was not taken into account. Dietary FA data 
based on questionnaires or interviews is mostly biased by misreporting and therefore become 
imprecise [53-56]. Additionally, available food composition tables and food data bases lack of 
sufficient information concerning amount and spectrum of individual FA to calculate the FA 
amount of certain foods separately. An alternative approach could be the correlation of serum 
FA patterns with foods and food groups, instead of calculating the content of single FA in 
particular foods. The FA pattern, like the percentage of SFA, MUFA, and PUFA, of foods and 
food groups, for instance, of butter, meat products, or plant oils are well known and would 
give some additional information concerning the association of dietary FA patterns and the 
serum FA composition. However, at the time of the analyses for the present thesis, this data 
was not available. A further critical fact of food composition tables is that newly developed 
food products are not included completely. Those food products are enriched with, for 
instance, ω3 FA, polyphenols, or dietary fibres to increase the nutritional value of the food 
products. These products are hardly assessed in the data bases, but may influence the lipid 
profiles in one or another way due to the fact that they are consumed by adolescents. These 
points indicate that FA measured in serum are more reliable parameters for the assessment of 
the FA status than dietary FA alone. Furthermore, it has to be mentioned that until the 
completion of this thesis is was not feasible to measure the sexual hormones of the 
participants, although, those measurements would help to specify relationships between 
different biomarkers and the state of maturity. However, it is intended to do hormone 
measurements in further analyses of remaining blood samples. 
Some strengths of the HELENA Study should also be stated here. The HELENA Study is the 
first European multicentre, cross-sectional study, realizing a standardized methodology, to 
cover and connect a wide range of different research fields, which deal with the health and 
fitness status of adolescents. This includes as main aspects: (a) dietary, nutrition and eating 
attitudes, (b) physical activity and fitness, (c) body composition, (d) haematology, nutrition 
physiology and immunonutrition, and (e) genetics. With this background, is is quite 
understandable that this thesis can only cover a small part of the HELENA Study. Further, the 
reliability of the data as well as the quality of the project are a consequence of harmonized 
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and standardized methods and materials, centralized sample recruitment, biochemical 
analyses, and database management, including a pilot study to assure an optimal study 
performance. 
 
Within this thesis different results were found with respect to the calculation method of the 
FA and their ratios. Due to the study design of the HELENA project, it was not possible to 
judge, which calculation method is the most reliable to interpret the results of FA profiles. 
However, the following points may highlight the main differences: first of all, FA and their 
ratios based on conc% may be more reliable than FA expressed as area%, because conc% 
calculations take into account the molecular mass of each FA detected and thus do not refer 
simply to a peak area. Nevertheless, the percentaged FA profiles of both methods are 
influenced by the number of FA included in the profile and the height of each FA peak. The 
dependency of FA within the percentaged FA profiles may obscure some important findings. 
The just mentioned problematic with percentaged FA profiles would be eliminated by using 
FA expressed as absolute concentrations, which are independent of other FA concentrations. 
Thus, changes in the concentration of one specific FA would not affect another FA of the 
same profile. Nonetheless, the most common method in the literature to express FA is the use 
of percentaged FA profiles, even though the absolute FA profile could give additional, 
important information. The reason could be the more sophisticated and more expensive 
measurements of absolute FA amounts. Nevertheless, it may be important to analyze the 
absolute FA profile to avoid falsified results because of percentaged weighting. For instance, 
shifted proportions of non-essential FA may easily alter the proportion of essential FA. As a 
consequence of the shifted proportion, the information value may be weaker or even incorrect 
[57, 58]. 
 
The discussion concerning reference values for a healthy adolescent population and its 
application for lipid screening and prevention strategies is ongoing and the question, which 
percentiles/ cut-offs should be used is not answered sufficiently yet. Moreover, it is still 
discussible how to develop reliable lipid reference values for adolescents. However, within 
the HELENA study design it was not realizable to create reference values per se. But the 
presented lipid concentrations and FA profiles (relative and absolute) are proposed to be used 
as physiological values of apparently healthy European adolescents. They may be applied as 
some kind of reference data for the comparison with other adolescent lipid concentrations, for 
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instance for the diagnosis of altered lipid and FA profiles of diseased subjects or the 
monitoring of therapeutic interventions.  
The NCEP published blood cholesterol cut-offs for children and adolescents (2-19 years) in 
1992, which will be the standard in clinical use [59]. These cut-offs for TC, LDL and TG 
levels are set at the 75th percentile for normal levels and at the 95th percentile for high levels, 
in the case of HDL at the 25th and 5th percentile. This approach has some limitations one has 
to keep in mind. First of all, the cut-offs are valid for the complete mentioned age range, 
neglecting possible physiological changes during adolescence. Further, the selected 
percentiles are completely arbitrary. Moreover, the lipid screening based on an American 
referent population, thus the cut-offs are addressed to the American population. The 
assessment was made in the early 1980s, but lifestyle and eating habits likely have changed 
during the last 30 years. However, more important is the fact that the reference values are 
based on data from children and adolescents from families with hypercholesterolemia or 
premature cardiovascular disease, and thus are not applicable to a healthy population. A more 
recent approach was made by Jolliffe and Janssen in 2008. They created age-specific lipid and 
lipoprotein thresholds for adolescents [60]. Data of 6,067 adolescents of NHANES (1988-
2002) was used to obtain percentile curves with the Lambda-Mu-Sigma method. They 
adapted the NCEP cut-offs for adults at age 20 and applied those particular percentiles to the 
age range of 12-20 year-old boys and girls. With this approach the percentile curves are more 
adapted to age-specific differences, which will be present in 12-20 year-olds. However, this 
approach is still discussible, because the risk factors of adults are not applicable to youth. 
Furthermore, age is not the main determinant associated with changes during that particular 
period of life. Maturity categorized into Tanner stages would be the best choice. Although, 
the selection of the already mentioned percentiles for lipid cut-offs by NCEP is arbitrary and 
not connected to any risk factor, those cut-offs are established and frequently used. Still, risk 
factors are difficult to determine in an apparently healthy adolescent population and the 
adoption of American data for the evaluation of European lipid profiles may not be 
appropriate.  
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9 Conclusions 
 
The HELENA results show that lipid research in the period of adolescence should be made 
separated for gender, because differences are present as reported for routine lipid parameters, 
lipoproteins, and most absolute FA concentrations. 
The use of chronological age in adolescence can lead to falsified assumptions with regard to 
growth and development. To avoid this bias, the use of biological age is recommended 
especially for the analysis of lipid parameters and lipoproteins (i.e. TC, HDL, LDL, TG, 
Lp(a), apo A-1, apo B).  
Higher adipose tissue content, expressed as BMI or BF, leads to a more unfavourable lipid 
pattern as seen in routine lipid and lipoprotein parameters and their ratios. However, this 
association was less clear between individual FA and parameters of body composition. The 
observations, that changes of the female lipid levels are more present due to BMI status, 
whereas changes in the male lipid levels are more often seen by BF categorization, need 
clarification. 
Although some FA ratios are associated with age, maturity, BMI, BF, and FFM in boys and 
girls, the results follow no clear pattern. The differences may be explained by and could be 
more related to different eating habits in the different sub-groups. Thus, it can be speculated 
that FA ratios are more likely modified by dietary factors such as amount of fat and dietary 
FA pattern. 
The association between the selected serum FA measured in PL and serum TG, TC, HDL, 
LDL, apo A-1, apo B, and Lp(a) parameters are minimal. Therefore, studies in adults, which 
found an association between dietary FA intake and blood lipids may not be correct. On the 
other hand, the metabolism of adolescents may not follow similar metabolic patterns as 
observed in adults. Moreover, investigations may focus on other nutrients that accompany 
dietary fat intake (e.g. fat soluble vitamins, plant sterols, polyphenols) as well as on other 
nutrients in the diet (e.g. dietary fibres, carbohydrates, proteins) to clarify their influence on 
lipid concentrations 
It has to be emphasized that the methodology of FA measurement and analysis differs 
between research groups and needs harmonization. Further effort in the establishment and use 
of absolute FA values must be undertaken, because differences between absolute and relative 
FA profiles do exist. 
Finally, the selected communicable and non-communicable factors should be taken into 
account when interpreting data of adolescent lipid profiles. 
  
 
Appendix 
 
 
A  Blood sampling questionaire 
 
 
 
Healthy Lifestyle in Europe by Nutrition in Adolescence in 13-16 years adolescents 
across Europe.  
Cross-sectional study (HELENA-CSS) and Pilot Study. 
 
BLOOD SAMPLING 
QUESTIONNAIRE 
 
  From UL2/Bonn November 2005 
 
Subject number:       H   2 
                                                          Number of centre        Number of school          Number of class   Number of subject 
 
Subjects initials:      
   first name/second name /family name 
Evaluation date:                 Day       Month           Year 
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Please ask the adolescent before taking the blood samples and tick the 
appropriate box to answer each question.  
 
1. Has the adolescent fasted for at least 10 hours? 
 
      Yes  (1)  No  (0) 
 
Please specify what time he had his last meal, snack or drink (other than water):  
 
     hh mm 
 
2. Did the adolescent come to school by motorised transport (car, bus, …)?  
      Yes  (1)  No  (0) 
 
Or walking?  
 
      Yes  (1)  No  (0) 
 
3. Did the adolescent have a common cold or other infectious disease during the 
last week? 
 
     Yes  (1)  No  (0) 
 
 If yes, please specify type of disease  
 
 
 (one letter per case) 
 
Answer will be coded (Coding instructions will be provided) by investigator before electronic data capture. 
  
 
 
If yes, please indicate for how long:    days  
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4. Did the adolescent have any symptoms of allergy during the last week?  
Examples of symptoms: Red itchy, watery eyes or sneezing/congestion/runny nose or 
urticaria or abdominal pain or asthma or other.  
 
     Yes  (1)  No  (0) 
 
 
If yes, please indicate for how long:    days  
 
 
If yes, please indicate which kind of allergy? 
    
   Pollen  
   Dust  
   Food allergens       
   Animals  
   Others:    
 
     for others, please specify : 
 
 
 
one letter per case 
 
Answer will be coded (Coding instructions will be provided) by investigator before electronic data capture 
 
 
 
 
5. Did the adolescent take any medication during the last month? 
 
     Yes (1)  No  (0) 
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If yes, please specify when, what was taken and doses (table): 
 
 
 Duration (days) Name of the medication Quantity per day 
 
1                                  
2                 
3    
4    
5    
 
 
 
6. Did the adolescent take any supplement (vitamin/minerals) during the last 
month? 
 
     Yes (1)  No  (0) 
 
If yes, please specify when, what was taken and doses (table): 
 
 
 Duration (days) Name of the supplement Dose per day 
1                                  
2                 
3    
4    
5    
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7. Has the adolescent been vaccinated during the last two weeks? 
 
     Yes (1)  No  (0) 
 
 
 
If yes, please specify when and what vaccine: 
 
 
 
Date of vaccination:    
                                               dd            mm                      year 
 
 
Type:  
 
 
 
one letter per case 
 
Answer will be coded (Coding instructions will be provided) by investigator before electronic data capture
  
 
 
 
 
. (Only for girls) Is the girl menstruating at the moment?  
 
     Yes   (1)  No  (0) 
 
 
Please specify first day of last menstruation: 
 
 
 
Date:    
                                               dd             mm                     year 
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9. Has there been any complications during the blood extraction? 
 
     Yes (1)  No  (0) 
 
If yes, specify the problem: 
 
 
one letter per case 
 
Answer will be coded (Coding instructions will be provided) by investigator before electronic data capture
  
 
And fill an adverse event form in the Case Report Form !!!! 
 
 
 
END OF THE BSQ 
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B Case report form 
 
 
 
 
Healthy Lifestyle in Europe by Nutrition in Adolescence in 13-16 years adolescents 
across Europe.  
Cross-sectional study (HELENA-CSS) and Pilot Study. 
 
 
CASE REPORT FORM 
 
 
 
 
 
 Subject number :   H2         
                                                                      
 
Subjects initials :      
   first name/second name /family name 
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GENERAL INSTRUCTIONS FOR THE INVESTIGATOR 
 
General Instructions for the Investigator (see SOP of the CRF) 
 
When completing this CRF, please 
- Use a ballpoint, fine-tip pen (permanent ink), black or blue. 
- Make sure that all entries are clear and legible, preferably in block letters. 
- Use English and specific medical terminology. 
- Make corrections by drawing a single line through the incorrect item, which must remain legible, and write 
the correct data next to it. 
- Do not use correction fluids or any other method of erasure! 
- Date and initial for all corrections and changes. 
- Tick closed boxes and circles  
 
Do not use 
- abbreviations and acronyms 
 
Subject Initials : first name-middle-family/last name (ex) 
Jean    Marcel     DUPONT                   J     M     D 
- If, there is no second name, put a “-“ 
- Subject initials must remain consistent throughout the CRF.  
-  
Enrolment Code 
- Subjects will be assigned an enrolment code number at inclusion : study code Helena CSS – H1 - city 
number (see Appendix) -number of study inclusion  
                Subject number:     H2          
                                                 Number of centre   Number of school   Number of the class   Number of subject 
 
   Exemple                          H2    0      4                 0      1          0       5           1      0 
 
Missing Data 
- If some information has been impossible to obtain, please strike out the field/box and explain briefly next to 
the field/box why the information is missing. 
 
Historical dates 
- If a historical date, or part of a historical date, has been impossible to obtain, please fill in as much as is 
known and strike out the remaining field(s) 
 
Sic  
- Indicate data which are unusual or unexpected but still correct by noting ‘Sic’ next to that data. Sic can be 
understood as ‘so is correct.’ 
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SELECTION OF SUBJECTS 
Inclusion Criteria 
          Yes  No 
Male and female subjects aged 13 – 16 ± 2 years       
 
Schooling in one of the participating cities         
 
Informed consent form signed by the parents and/or       
the legal representative. 
 
Exclusion Criteria 
Subject participating simultaneously in another research trial     
 
 
Subject number  :  
 
 
Date of consent :                                    2   0   0 
                day           month                          year 
 
 
Visit Date :                                                                                   2   0   0                                                           
                                                                       day           month                         year                 
 
 
Name and signature of the investigator : 
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PHYSICAL EXAMINATION 
 
 
1) Date of Birth :             1   9 
                 day           month                        year 
  
   
2)   Sex :   Male (1)   Female  (2) 
 
3) Medical personal history  (including traumatic accidents): 
 
None  (0) 
 
Or Medical diagnosis (see coding annex): (1) 
 Year of diagnosis /or 
intervention 
Past medical or surgical history 
(coding) 
1               /    
2               /    
3               /    
4               /    
5               /    
6               /    
7               /    
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4) Current treatment (medication or supplements) 
Has the subject taken any treatment for more than 7 days during the last 30 days ? 
 
Yes (1)  No  (0) 
 
If yes, please specify when and what was taken): 
During of medication  
Start date  
(dd/mm/year)    
End date 
(dd/mm/year)    
On 
going 
What 
Medication 
(INNs) 
CODE (see 
appendix IV) 
1 
  /  /      /  /        /   
2 
  /  /     /  /         /   
3 
  /  /     /  /         /   
4 
  /  /     /  /         /   
5 
  /  /     /  /         /   
6 
  /  /     /  /         /   
7 
  /  /     /  /         /   
8 
  /  /     /  /         /   
     
Has the subject taken any treatment in the last 24 hours? (except when on going 
is ticked) 
Yes (1)  No  (0) 
 
Fever (>38°C) during the last 24 hours Yes  (1)  No  (0) 
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5) Allergy  
Has patient any allergy?    Yes  (1)  No  (0) 
 
If yes, please indicate which type of allergen? 
  
   
   Pollen  
   Dust  
   Food  
  Animal  
   Other:   
 
If Other, please specify  
 
 
 (one letter per case) 
 
 
Which is/are the clinical signs? 
 
Atopic dermatitis 
Urticaria 
Allergic rhinitis 
Asthma 
Other  
 
If Other, please specify  
 
 
 (one capital  letter per case) 
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6) Clinical examination of following items and tick the appropriate box : 
Normal  Abnormal  If abnormal findings, specify 
 
a) General condition   (1)   (0) …………………………… 
 
b) Abdominal palpation  (1)  (0) …………………………… 
 
c) Pulmonary auscultation (1)  (0) …………………………... 
 
d) Cardiac auscultation  (1)  (0) …………………………... 
 
e) Other abnormalities if detected  
 
 
(one capital  letter per case) 
7) Pubertal status (see appendix I) 
Girls 
                  a)              breast              b)                 pilosity 
1                                                 2 3 4 5 1 2 3 4 5 
          
Boys 
                 a)              gonade                 b)             pilosity 
1                                                 2 3 4 5 1 2 3 4 5 
          
 
Only for girls, if adaptable 
 
Have you already your menses?     
Yes  (1)  No  (0) 
 
Age of menarchy:  
                                                                                                                Months                                   Year 
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Date of last menstruation:    
               dd            mm               Year 
 
Daily oral contraception?              Yes (1)  No  (0) 
Or 
Patch contraception?     Yes (1)  No  (0) 
 
 
CLINICAL PARAMETERS 
 
8) Anthropometry 
 
a)  Height :                                   cm  
 
b) Weight :                                   kg 
 
 9) Bio-impedancemetry : 
 
 measurement 
 
 
Resistance 
 
 
 
Reactance 
 
 
 
o % of Body Density by Bop Pod (optional): 
measurement 
 
 
 
 
, 
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10) SKIN FOLD THICKNESS 
 1st 
measurement 
2nd 
measurement 
3nd 
measurement 
a) Bicipital (mm)    
b) Tricipital (mm)                
c) Sub-scapular (mm)    
d) Suprailiac (mm)    
e) Thigh (mm)    
f) Calf (mm)    
 
11) CIRCUMFERENCES 
 1st 
measurement 
2nd 
measurement 
3nd 
measurement 
a) Arm (mm)  
 
 
 
 
b) Biceps (mm)  
 
  
c) Waist (mm)    
d) Hip (mm)  
 
  
e) Proximal thigh (mm)    
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12) VITAL SIGNS 
a) Blood pressure (mmHg) :  
                          
      
Systolic 1                        Diastolic 1 
 
 
Systolic 2                                Diastolic 2 
 
 
                     
 
 
                        
 
                                 
b) Heart Rate ( beats/min) :    
 
13) Do the subject participate to accelerometry assessment ?Yes (1)      No   
 
BLOOD  SAMPLES 
 
Laboratory Assessments, blood 
          Yes  No 
Subject allocated to a blood samples class ?        
          Yes  No 
Blood samples have been collected (including specific questionnary ?)    
 
Sample Date                             /                 /                           
dd                            mm                                    Year       
           
                                                                     Yes               No 
Did the adolescent have fever/cold the day of blood samples?                       
 
Please fill the appropriate Laboratory request form HELENA-CSS 
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SPECIFIC QUESTIONNAIRES FOR HELENA-CSS   
 
 Tick when done     Date   Yes                 No 
 
General Questionnary for Adolescents Self European Socio-economic Status 
  /  /                  
                                                                                                                       
Nutrition Knowledge (NKT-C)    /  /                          
Eating Behaviour (EWI-C)     /  /                          
YANA-C       /  /      first   
      /  /      second         
Food choice and preference    /  /                          
Determinants of Healthy Eating (HE) Determinants of physical activity (PA) 
      /  /                         
Physical Activity (PAQ)        /  /                         
Questionnaire for Parents (QP)    /  /                         
     
Blood sample questionnary     /  /                              
Accelerometer                                                /  /                              
Physical fitness tests                                      /  /                              
Sedentary questionnary                                /  /                              
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ADVERSE EVENTS (see Appendix 4 for definitions) 
 
DESCRIBE THE ADVERSE EVENTS BELOW: 
1st event : 
It is a serious adverse event?        YES  NO 
Description of the event including date and hour of occurrence, duration, and hour of 
resolution, and consequences for the subject. 
________________________________________________________________________________________________ 
________________________________________________________________________________________________
________________________________________________________________________________________________ 
________________________________________________________________________________________________ 
________________________________________________________________________________________________ 
________________________________________________________________________________________________ 
2nd event : 
It is a serious undesirable event?  YES  NO 
Description of the event including the date and the hour of beginning, the duration, and hour to end, 
and the consequences for the subject. 
________________________________________________________________________________________________ 
________________________________________________________________________________________________
________________________________________________________________________________________________ 
________________________________________________________________________________________________ 
________________________________________________________________________________________________ 
________________________________________________________________________________________________ 
 
3rd event : 
It is a serious undesirable event?  YES  NO 
Description of the event including the date and the hour of beginning, the duration, and 
hour to end, and the consequences for the subject. 
________________________________________________________________________________________________ 
________________________________________________________________________________________________
________________________________________________________________________________________________ 
________________________________________________________________________________________________ 
________________________________________________________________________________________________ 
 
CAUTION: IF A SERIOUS ADVERSE EVENT OCURRED, YOU MUST MAKE A 
STATEMENT ON SPECIFIC FORM (SEE NEXT PAGE!) FOR YOUR LOCAL 
REGULATORY AGENCY. 
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SERIOUS ADVERSE EVENT (SAE)  REPORT 
 
SUBJECT IDENTIFICATION OF SAE                            
 
 
 
SAE date                                                             /                      /                   
                                                     dd                mm                   Year 
 
 Awareness of SAE by the Investigator                                      /                         / 
                                                                                             dd              mm                      Year 
Death            
           
Hospitalisation     
 
Life threatening    persistent or significant disability/Incapacity  
 
If death 
Probable cause of death………………………………………………………………………………………… 
                                                                                                                                                                      
Date of death                            /                   /                                   Autopsy performed : Yes    No  
                                      dd                 mm                      Year 
 
If hospitalized 
Date of hospitalization                         /                    /                                                                           
                                                     dd                 mm                      Year 
 
Date of discharge                                   /                  / 
            
           dd                mm                  Year 
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Symptoms, course………………………………………………………………………………………………… 
………………………………………………………………………………………………………………………. 
Diagnostic investigations results 
…………………………………………………………………………………………………... 
 
Treatment of AE…………………………………………………………………………………………………… 
 
Other comments…………………………………………………………………………………………………... 
 
 
 
Investigator’s initials   ……………….. 
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STUDY TERMINATION 
 
Has the subject completed all exams and questionnaires of the study?     
 
Yes       No   
 
If no, please specify: 
 
Essential for each subject: 
                                                                                                Yes                   No 
1.    Inclusion criteria                                                             
 
2.    Weight and height                                                           
                      
3.    Informed consent signed                                                 
 
Optional (each subject must complete at least 75% of the following, 
i.e. 12 measurements) 
 
1.    Clinical examination (validity assessed by the Medical Doctor) 
      Yes             No 
          
2.    Anthropometric measurements (all the measurements)  
       Yes            No 
          
3.    BIA 
      Yes             No 
          
4.    General Questionnary for adolescents Self European Socio-economic 
Status      (not fully blank) 
      Yes             No 
          
5.    Nutrition Knowledge (NKT-C)(75% of the questions responded) 
       Yes            No 
          
6.    Eating Behaviour (EWI-C) (75% of the questions responded) 
       Yes            No 
          
7.   YANA-C (2 days) 
      Yes              No 
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 8.  Food choice and preference (75% of the questions responded) 
       Yes            No 
          
 
 9.  Determinants of Healthy Eating (HE) + Determinants of physical activity 
(PA)  
  Yes            No 
          
 
      10. Physical Activity (PAQ) 
   Yes  No 
                       
 
11. Questionnary for parents (QP) (75% of the questions responded) 
     Yes              No 
        
 
12. Blood Sampling (including questionnaire)  
     Yes              No 
          
   
13. Accelerometry assessment (minimum criteria defined into the protocol) 
     Yes              No 
        
 
14. Physical fitness tests  
     Yes              No 
        
 
 
 
 
 
 
 
 
 
 
Appendix B 
  
Main reason (only one) for premature discontinuation 
 
Withdrawal of the subject     
 
Adverse event                                       
Please make sure that AE form is completely filled 
 
Subject lost of follow-up           
 
Other                                
Please specify...................................... 
 
 
 
 
 
Name and signature of the person checking the CRF 
 
Date and signature 
 
                /                   /   
 
 
 
Name of the investigator:    ………………………………… 
Date and signature                
 
               /                    /  
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